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Focusing medicine to disease locations is a needed ability to treat a variety of 
pathologies. During chemotherapy, for example, typically less than 0.1% of the drugs 
are taken up by tumor cells, with the remaining 99.9% going into healthy tissue. 
Physicians often select the dosage by how much a patient can physically withstand 
rather than by how much is needed to kill all the tumor cells. The ability to actively 
position medicine, to physically direct and focus it to specific locations in the body, 
would allow better treatment of not only cancer but many other diseases. 
 
Magnetic drug targeting (MDT) harnesses therapeutics attached to magnetizable 
particles, directing them to disease locations using magnetic fields. Particles injected 
into the vasculature will circulate throughout the body as the applied magnetic field is 
 
used to attempt confinement at target locations. The goal is to use the reservoir of 
particles in the general circulation and target a specific location by pulling the 
nanoparticles using magnetic forces. 
 
This dissertation adds three main advancements to development of magnetic drug 
targeting. Chapter 2 develops a comprehensive ferrofluid transport model within any 
blood vessel and surrounding tissue under an applied magnetic field. Chapter 3 
creates a ferrofluid mobility model to predict ferrofluid and drug concentrations 
within physiologically relevant tissue architectures established from human autopsy 
samples. Chapter 4 optimizes the applied magnetic fields within the particle mobility 
models to predict the best treatment scenarios for two classes of chemotherapies for 
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Chapter 1: Introduction 
1.1 Overview 
1.1.1 Introduction to Magnetic Drug Targeting 
A need exists to be able to focus medicine to disease locations. During chemotherapy, for 
example, typically less than 0.1 to 1% of the drugs are taken up by tumor cells, with the 
remaining 99% going into healthy tissue [1], [2]. Chemotherapy encompasses treating 
patients with a diverse collection of drugs that attempt to preferentially destroy cancer 
cells either by inhibiting cellular division (which kills fast growing cancers, but also bone 
marrow, hair, skin, gut, and immune system cells) or by interrupting essential cell 
signaling pathways [3]–[8]. Physicians often combine drugs into chemotherapy cocktails 
that can compound side effects, and the dosage is usually selected by how much a patient 
can physically withstand rather than by how much is needed to kill all the tumor cells [3], 
[9], [10]. The ability to actively position medicine, to physically direct and focus it to 
specific locations in the body, would allow better treatment of not only cancer but other 
diseases [11]–[14]. 
 
Magnetic drug targeting (MDT) refers to the attachment of therapeutics to magnetizable 
particles, and then applying magnetic fields to concentrate them to disease locations such 
as to solid tumors, regions of infection, or blood clots [14]–[20]. Even though in some 
specialized cases the magnetizable particles can be introduced into the body outside the 
blood flow, e.g. as in magnetic treatment of the inner-ear where a small gel containing 
nanoparticles is placed on the round window membrane [21], [22] or intranasally [23], 
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[24], usually ferromagnetic particles are directly injected into the circulation by a vein or 
artery [11], [14], [25]–[32]. Particles so injected will circulate throughout the vasculature 
as the applied magnetic field is used to attempt confinement at target locations. 
Depending on the vessel into which the particles were injected (vein or artery), MDT will 
occur before the particles pass through the liver (first pass method [32]–[34]) or after the 
particles pass through the liver, lung and heart [14], [26], [35], [36]. The latter is more 
common, but reduces the drug amount available that can be targeted since a large portion 
of the drug is filtered by the liver and kidneys [11], [37], [38]. The goal of magnetic drug 
targeting is to use the reservoir of particles in the general circulation and target a specific 
location by pulling the particle and drug complexes using magnetic forces. 
 
There are several other targeting techniques capable of directing therapy to desired 
locations. These include the use of magnetic fields [11], [12], ultrasound [39], [40], 
electric fields [41], [42], photodynamic therapy [29], [43], environment reactive targeting 
[44], and antigen recognition [45]–[49]. While this thesis focuses on magnetic drug 
targeting, it is important to note that there are synergies between these targeting 
techniques. Multifunctional particles capable of exploiting the benefits from each 
technique can be used to increase targeting ability. For example, transport of particles 
across the blood brain barrier using magnetic fields was assisted by first damaging the 
blood brain barrier using ultrasound [50]. Magnetic drug targeting could add specificity 




Magnetic fields – more so than light, electric fields, and ultrasound [39]–[43] – are 
desirable for directing therapeutics inside patients because they can penetrate deep into 
the body, are routinely applied through the body in magnetic resonance imaging (MRI), 
and are considered safe even up to very high strengths (8 Tesla in adults, 4 T in children) 
[51]–[54]. Magnetic fields can both sense and actuate magnetic particles, although 
achieving both at once is an engineering challenge [55]–[57]. In contrast, light and 
ultrasound have limited tissue penetration depths [43], [58], [59], while strong electric 





Figure 1: Overview of contributions presented. The ultimate goal of magnetic drug targeting is to 
direct therapeutics to disease locations deep within the body. The current state of the art still 
relies upon static magnets that are only capable of pulling magnetic nanoparticles to surface 
locations [14]. The three main contributions presented within this dissertation are the 1) modeling 
of ferrofluid transport within blood vessels, 2) within tissues, and the 3) optimization of a 




1.1.2 Applications of Magnetic Drug Targeting 
Therapeutic magnetic elements have been created by the attachment of chemotherapy [3], 
[10] or gene therapy [62]–[64] to ferromagnetic particles [12], [13], [65]–[71], by filling 
polymer capsules or micelles (capsules that self-assemble from lipid molecules [72]) with 
both drugs and magnetic materials [71], [73], or by growing cells in a cell-culture 
medium with magnetic nanoparticles to let the cells ingest the particles and thereby 
become magnetic [74], [75]. A bare iron oxide nanoparticle is the simplest example of a 
magnetic carrier [76]. Magnetic particles can also consist of magnetite (Fe3O4) or 
maghemite (Fe2O3) nano-crystals embedded in a polymer core, and are usually coated 
with a layer of molecules (often starch or polyethylene glycol (PEG) molecules) to make 
the particles more biocompatible [68], [71], [73]. In more sophisticated particles, this 
coating is optimized to better hide the particles from the human immune system, so that 
the particles have a longer circulation time in the body before they are removed to the 
liver, kidneys, and spleen [71], [77]. Particle sizes can be controlled by various 
fabrication processes [68], [71], [78] and are made from nanometer to micrometer sizes.  
 
They are usually injected into an animal or a patient as a ferrofluid, which is an emulsion 
of magnetic particles in water. Such magnetic nanoparticles have been tested in animals 
[12], [13], [26], [28], [31], [32], [34], [36], [50], [77], [79]–[107] and humans [16], 
[108]–[110]. Other entities besides particles – such as polymer capsules [111], flexible 
rods [96], lipid micelles [44], [112], [113], and live cells (such as stem cells) [74], [75], 
[114] – can also be loaded with magnetic materials and thus made magnetic. Stem cells 
are being magnetized so that they can be directed to regions of cardiovascular disease, 
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such as hardened blood vessels in diabetic patients, to help restore tissue function [75], 
[114]–[116], or to the retina for ocular regeneration [117]. All of these magnetized 
carriers, from nanoparticles to cells, can then be manipulated inside the body by 
externally applied magnetic fields. It takes a lot of development to ensure that magnetic 
carriers are safe, effective, and therapeutic [71]. Due to stringent regulatory approval 
requirements, so far only a few magnetic particles have been commercialized and 
approved for human use, and not yet as therapeutic carriers but only as imaging agents 
[118]–[121]. While magnetic particles have been used in clinical trials, the field of 
magnetic drug targeting is still new, and important information about the particles’ 
biodistribution, especially while being targeted, is still unknown. 
 
During magnetic drug targeting, magnetic carriers must be safely and effectively 
controlled inside the human body. The body consists of a heterogeneous and complex 
environment, which varies widely from person to person, and is not well understood. 
Many relevant and significant issues for effective control of particles remain unanswered, 
including uncertainty about the mechanisms of ferrofluid transport within the body, how 
nanoparticles can or cannot cross blood vessel walls, and how much force is required to 
direct them from blood into tissue. Similarly, there is a lack of knowledge of basic 
internal body parameters. The location of most blood vessels, the blood flow velocities in 
each vessel, the resistance of different tissue types to particle motion, and many other 
biological parameters are not known in general or for the case of each specific patient. 
Yet, even though the situation is highly uncertain, prior magnetic drug delivery has 
already been shown to effectively focus therapy to some desired locations in animals and 
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humans. For example, in the Lübbe 1996 phase I human clinical trials, a single 
permanent magnet was able to concentrate chemotherapy to inoperable but shallow 
(≤ 5 cm below skin depth) head, neck, and breast cancer tumors [14], [31], [122]. 
 
Since the success of the Lübbe trials [14], many groups have extended magnetic drug 
targeting for other applications. Pankhurst et al. has been targeting magnetically loaded 
mesenchymal stem cells to sites of vascular injury [114]. Häfeli et al. have used 
implanted magnets located behind the cornea to collect stem cells for retina regeneration 
[117]. Magnetic nanoparticles have been able to deliver therapeutics across the blood 
brain barrier when combined with ultrasound, which mechanically disrupts the blood 
brain barrier [50]. Due to the magnetic response characteristics of super paramagnetic 
iron oxide nanoparticles (SPIONs), there is a growing interest in using SPIONs for 
delivering thermal energy to tissue [16], [17], [84], [123]–[130]. This thermal application 
has been used to create targeted hyperthermia in prostate cancers [16], [110]. 
 
1.1.3 Challenges with Magnetic Drug Targeting 
The depth, precision, and utility of magnetic targeting has been limited by particle 
material and surface properties [68], [71], by an insufficient understanding of particle 
transport in the human body [131]–[134], by the strength and design of magnets [51], 
[135]–[137], by a lack of deep-body real-time nanoparticle sensing capabilities [79], and 
by control algorithm development and implementation [138]–[140]. Magnetic 
nanoparticle fabrication and the resulting material and surface properties have been 
surveyed [12], [68]–[71], [141]. Essentially, material magnetization properties, , set the 
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strength of the magnetic forces for a given particle size and applied magnetic field [76], 
[96], [142]–[144], whereas surface coatings, particle size, and particle shape regulate 
biocompatibility and particle circulation times [12], [68], [71]. Understanding how 
various particle parameters impact ferrofluid transport is key, however, visualization 
techniques are currently limited. Real-time and sensitive measurement of nanoparticle 
distributions in vivo is challenging [16], [25], [68], even in small animals where depth of 
imaging is less of an issue [107], [128], [145], and has made it difficult to collect 
sufficient data to adequately validate models of ferrofluid transport. 
 
Impossibility of a Stable Magnetic Trap 
If it would be possible, the easiest, robust, and simplest way to implement magnetic drug 
targeting would be to create a magnetic trap. This would consist of some arrangement of 
magnets, either spatial or temporal, that pushes ferrofluid to one small concentrated 
region. Therefore, the patient would only have to be positioned properly underneath this 
magnetic trap to target a specific region within the body. Then over time, without the aid 
of a visualization technique, the ferrofluid would concentrate at a single site thereby 
increasing the drug concentration. This optimal scheme is unfortunately impossible for a 
collection of magnets and ferromagnetic/paramagnetic particles as shown by Samuel 
Earnshaw in 1839 [146]. 
 
Samuel Earnshaw’s result on “the nature of molecular forces which regulate the 
constitution of the luminiferous ether” was read to the Cambridge Philosophical Society 
in March 1839, but was not printed until 1842 [146]. The result considers particles 
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attracted to each other by an inverse square law, and proves that “instability cannot be 
removed by arrangement (of the particles); for though the values of , ,  
depend upon the arrangement of the particles, the fact that one at least must be positive 
and one negative depends only upon the equation , which is true 
for every arrangement. And consequently, whether the particles be arranged in cubical 
forms, or in any other manner, there will always exist a direction of instability.” 
Earnshaw’s function  is the potential energy of a single particle being attracted by many 
others. The proof proceeds by showing that the equation for  is “that of an hyperboloid” 
(a saddle), with the result that the sum of its three second derivatives must equal zero. 
Even if two derivatives are negative (corresponding to particle stability in a plane), the 
third derivative must then be positive (instability along a line). 
 
Earnshaw’s result equally applies to nanoparticles in a magnetic field. Although 
nanoparticles do not attract each other strongly, the potential energy created by an 
imposed magnetic field is also, at best, an energy saddle. It is not possible to create an 
energy well between magnets, no matter how they are arranged.  
 
This result has implications for magnetic drug delivery; no arrangement of magnets can 
create an energy well between them to focus ferromagnetic particles to an interior target. 
Diamagnetic particles could be focused, in principle, but diamagnetism is six orders of 
magnitude weaker than ferromagnetism (  instead of +20) and the forces 
created would be too tiny to move particles against tissue or blood resistance. Even if 
sufficient forces could be created on diamagnetic particles, the susceptibility of human 
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tissue is similar to that of diamagnetic materials in particles ( ) [11] but 
its volume is far greater; thus the tissue would experience orders of magnitude greater 
forces than diamagnetic nanoparticles, which would harm patients. Thus Earnshaw’s 
1839 theorem, which shows that no static magnetic field can focus ferromagnetic 
particles to an interior target, remains a key and fundamental limitation for magnetic drug 
targeting. The solution is to bypass the assumptions of the theorem, for example, by 
introducing feedback control and varying the magnetic fields in time and space to control 
ferrofluid dynamics. 
 
1.2 Physics of Magnetic Drug Targeting 
1.2.1 Magnetic Fields and Forces Acting upon a Particle 
Magnetic nanoparticles are small and experience small forces even under strong magnetic 
fields. In prior magnetic drug delivery experiments, magnet strengths have ranged from 
70 milli-Tesla [142] to 2.2 Tesla [147], and corresponding magnetic gradients have 
varied from 0.03 T/m [148] to 100 T/m [86], a range that reflects magnet cost, 
complexity, safety, and ease-of-use versus desired (or possible) depth of targeting. For 
comparison, modern neodymium-iron-boron (Nd12Fe14B) permanent magnets can be 
purchased in strengths of up to 1.48 Tesla [149], [150] and the electromagnets used in 
magnetic resonance imaging systems create fields of 1 - 4.7 T, with some commercially-
available MRI systems going as high as 9.4 T [51], [79]. In the 1996 human trials, 0.2 -
 0.8 T permanent magnets were used to target 100 nm diameter particles to 5 cm depths 
[14], [31]. Targeting depths of up to 12 cm have been reported in animal experiments 
using larger 500 nm to 5 µm diameter particles and a 0.5 T permanent magnet [32]. Both 
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permanent and electromagnet designs can be optimized to extend magnetic fields and 
gradients further out, to increase the depth of magnetic forces. 
 
1.2.2 Directing Magnetic Particles 
Precision magnetic control of a single object has been demonstrated in animals and 
humans. Gentle magnetic manipulation of a rigid implanted permanent magnet through 
the brain, with a view to scan and burn out brain tumors by subsequently heating the 
magnet using RF (radio-frequency) magnetic fields, has been presented [151], [152] and 
tested in dogs [153]. Based on market opportunities, the focus of this effort changed to 
magnetically assisted cardiovascular surgical procedures and led to the founding of 
Stereotaxis (www.stereotaxis.com). This company now uses magnetic control to guide 
catheters, endoscopes, and other surgical tools with magnetic tips for precision treatment 
of cardiac arrhythmias and other cardiovascular procedures [154]–[156]. To date, 
Stereotaxis has carried out over 40,000 successful patient procedures in nearly 200 
facilities around the world. Systems to magnetically steer implantable devices and 
microrobots, for gut, eye, cardiac, endovasculature, and lung surgery [157]–[164] have 
been tested in pigs and chicken embryos [165]–[168]. Conventional MRI machines have 
also been used as the control system to manipulate microscale particles [98], [158], 
[169]–[172], as well as magnetotactic bacteria [140], [173] or magnetized cells [116], 
[174]–[176], in pigs and mice [170], [174]. While MRIs are attractive due to their 
magnetic strength and clinical availability, the difficulty is that MRIs are designed to 
create a strong uniform magnetic field, but spatially varying magnetic fields are required 
to create forces on particles. Unless the MRIs are substantially modified [177]–[179], 
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they do not create sufficient magnetic spatial gradients to effectively manipulate 
nanoscopic particles. The control algorithms used in the above single-object manipulation 
systems have ranged from PID [158], [167] to point-wise optimization [151], [152], least-
squares inversion [180], robust nonlinearization with backstepping [172], [181], a 
generalized predictive controller [171], and model predictive control [182]. 
 
Precise manipulation of a fluid of nanoparticles is more difficult than control of a single 
object. In prior ferrofluid trials, a magnet held outside the body drew in and concentrated 
particles to shallow breast, head and neck, and brain tumors [14], [17], [26], [31], [34]–
[36], [50], [68], [80], [85], [94], [99], [100], [102], [105], [106], [109], [183], [184] 
(Figure 1b). There was no dynamic magnet control and the magnets accumulated the 
particles to targets beneath the skin or skull. Implantation of magnets or magnetic 
material into patients, such as within blood vessel walls, has been suggested as a way of 
reaching deeper tissue [87], [91], [97], [185]–[193]. The implanted materials serve to 
locally increase magnetic field gradients, and thus forces, when an external magnetic 
field is applied. Such a treatment envisions bringing magnetized endothelial cells to 
blood vessel walls and could also be appropriate for treating tumors that cannot be 
surgically removed but when magnetizable implants can be inserted into or near the 
tumor [87], [97], [185]–[187]. Overall, although the field of magnetic drug targeting is 
advancing towards commercial particles approved for human use [16], [115], [118]–
[121], it remains open for significant improvements in modeling, design, and control, 
especially for non-invasive methods to effectively target deeper tissue. This dissertation 
takes the next step in developing the basics for magnetic drug targeting: 1) how can 
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magnetic drug targeting be properly modeled and designed for any situation; 2) how can 
magnetic drug targeting be correctly modeled and designed for the specific treatment of 
hepatic metastatic breast cancer. 
 
1.3 Prior Work 
1.3.1 Prior Modeling 
Particle Targeting Models 
The current state of magnetic drug targeting modeling has typically been limited to 
individual particle dynamics within the blood or to fluid dynamics within a single 
impermeable vessel. Rosensweig began the theory of magnetic drug targeting by 
investigating the forces acting upon a single magnetic entity (either a particle or magnetic 
bolus) [194]. This was further investigated and extended to capture efficiency in various 
vessels for a single object [36], [106], [131], [195]. The basis of these modeling schemes 
rely on comparing magnetic force to blood drag forces. All of these models lack 
modeling extravasation or membrane-tissue dynamics in addition to ignoring diffusion 
characteristics. They only model the magnetic and blood forces and not the movement of 
particles through vessel walls or membranes. This, however, is a major component in 
drug targeting since the particles must leave the vessels and enter tissue, to deliver 




Particle Mobility Models 
The partial differential equations for the time dynamics of nanoparticle concentration are 
stated in Section 3.4, and there the particle movement for any condition is described. 
However, the specific movement that occurs in a given organ or biological environment 
is completely dependent upon the parameters of that biological space. Chief among these 
biological parameters is the diffusion coefficient of the tissue and how it depends upon 
size. The following is the Brownian diffusion equation 
(1)    
   
    
that relates the diffusive flux to the concentration gradient of the particles [37], [38], 
[131], [196]. Here  is the Boltzmann constant,  is the absolute temperature,  is the 
fluid viscosity, and  is the particle radius. While equation (1) does describe the diffusion 
coefficient as a function of particle size, it is only relevant for fluids and not tissues 
where the interstitial spaces can further inhibit particle diffusion and potentially mobility. 
In addition, the size dependence of the diffusion of particles through tissues is not a 
simple inverse relationship but instead exhibits behavior consistent with cut-off 
thresholds [37], [38]. This change in passive diffusion of a particle as it traverses between 
blood and tissue is described by an effective diffusion coefficient, which is the ratio of 
diffusion within the tissue to that within blood. This effective diffusion coefficient can 
then extend to approximate the relationship between the mobility of the particles as they 
traverse through tissue (see equation (7)). There have been many models to describe the 
decrease in the particle diffusion coefficient including the Renkin pore model [37], [38], 




small molecules (less than 100 nm) and do not accurately describe large particle 
diffusion. 
 
The two classical models to approximate particle diffusion through tissues that will be 
described next are: 1) the Renkin reduced coefficient model [197]; and 2) the fiber matrix 
model [198]. These models examine nanoparticle movement through tissues or 
membranes, but they do not deal with the how the particles arrived within the tissue 
space. If the particles are within the circulatory system, then they must be able to 
extravasate and enter the tissue before these models are applicable. If the vessels within 
the target tissue do not have pores or there is no active transport, then the mobility 
through tissues is not applicable. While they have limitations, they still provide valuable 
insight into nanoparticle behavior when within tissues. 
 
Renkin Reduced Diffusion Coefficient Model 
(2)   
(3) 
The Renkin equation (equation (2), where  is the effective diffusion coefficient, and 
 is the pore radius) approximates the apparent diffusion of a molecule attempting to 
travel through a membrane with a specific pore size. It was derived from a theoretical 
model [197] and only depends upon the particle radius and the average pore size of the 
membrane. Equation (3) rewrites the Renkin equation for simplicity. Equation (3) has 
two components. The first term,  (first component on the right hand side), is a 
measure of how much the size of a pore ‘excludes’ a particle from entering. If the particle 
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or solute is already within the membrane, then . The second term on the right 
hand side, , is a measure of the movement once the particle is within a membrane’s 
pore and accounts for the increase in hydrodynamic drag as the particle moves through 
the membrane. 
 
These equations are consistent with measurements made by Beck and Schultz [199] who 
constructed membrane sheets with well-defined pore sizes and near unity tortuosity. 
These membranes allowed for careful measurements of the diffusion through the 
membranes for various solutes ranging from 0.52 nm to 4.3 nm. While the results 
supported the Renkin equation, they were not able to investigate larger pore sized 
membranes that would be consistent with some biological membranes and structures (i.e. 
the glomerulus of the kidney) [199]. 
 
For the considered treatment case of the liver, pore sizes of the fenestrated capillaries 
found in the livers of humans have been measured on the order of 120 nm in diameter 
([200]) to several microns ([38]). Assuming the smallest pore size is similar to the spaces 
within the extracellular matrix and a 100 nm diameter particle, the effective diffusion 
coefficient within the liver would be on the order of , an order of magnitude 
lower than that in blood. 
 
There have been several further extensions on the Renkin equation. Deen et al. extended 
the equation to include tortuosity and for larger particles. The reduced diffusion 




where  is the pore surface area,  is the total membrane surface area,  is the 
tortuosity, and  is known as the porosity or the void volume fraction of the membrane 
[37], [201]. The tortuosity term is defined as the diffusion path length divided by 
membrane thickness [37], [38], [199]. It is a measure of the amount of additional 
movement a particle has to travel once inside a tissue or membrane to reach the opposing 
end. If the tortuosity term is large, then the particle has to traverse pores that are long 
winding channels. If the term is near unity, than the channels instead are straight 
passageways through the membrane or tissue.  
 
Equation (4) shows another method of calculating the effective diffusion coefficient for a 
given tissue and particle type. However, it requires knowledge of three crucial tissue 
parameters: 1) the porosity of the tissue; 2) the tortuosity; and the 3) tissue pore size. The 
later has been estimated for several types of tissues a measure of the extracellular spaces 
of the tissue. However, the first two are not known for tissues that are not engineered 
with specific characteristics, limiting its usage. 
 
Fiber Matrix Model 
Another method of describing the diffusion of a solute through a tissue is the fiber matrix 
model. This model (developed in [198]), extends upon a model by Ogston [202]. It 
assumes that the tissue space contains a given concentration of long cylindrical fibers 




where  is the specific volume of the fibers, and  is the fiber concentration, and  is 
the volume fraction. Since this model starts with the assumption of long cylindrical fibers 
comprising the tissue architecture, it has the potential to better approximate the tissue 
properties. 
 
The parameters in equation (5) can be estimated based upon collagen content in various 
tissues. Most tissues have a discretized preferred fibril diameter at  11 nm increments (11, 
22, 33, 44, 55, etc. [203], [204]) and the collagen content and function are intertwined. 
For example the cornea has approximately a fiber diameter of ~ 20 nm with a very 
organized structure ensuring opacity, compared with the larger fiber bundles in tendons 
of ~ 500 nm providing structural support [203]. Continuing with the treatment case of 
liver, volume fractions have been measured in human livers to be on the order of 0.7 
[205] with measured fibril diameters between 0.2 to 5 µm [206]. Considering a 100 nm 
diameter nanoparticle, the worst case effective diffusion coefficient would be , 
approximately an order of magnitude less than the diffusion coefficient in blood. This 
value for the effective diffusion coefficient is similar in magnitude to what is predicted 
from the Renkin pore model. 
 
Limitations of Mobility Models 
These two theoretical models have been compared to experimental measurements of 
small molecule diffusion. Nugent et al. [207] compared these two models with measured 
diffusivities of small molecule solutes in normal and tumor tissue. However, the main 
 19 
 
limitation in utilizing these or other models predicting particle movement is the size 
choice of the solutes tested. Most experimental studies have only examined solutes below 
10 nm [37], [197], [199], [207], [208]. As magnetic nanoparticles can be orders of 
magnitude larger than this, it is invaluable to know specifically how these larger particles 
will move through tissue. 
 
Another more subtle limitation of these and previous models of particle motion is the 
assumption made linking the decrease in diffusion coefficient to the decrease in the 
magnetic drift coefficient. The magnetic velocity (described more fully later in equation 
(14)) is 
(6) , 
where the magnetic drift coefficient, , describes the mobility of the magnetic 
nanoparticle under an applied magnetic field, , in a certain fluid. Einstein’s relation 
suggests that any physical barriers, such as membrane pores, that impact particle 
diffusion will also equivalently impact particle mobility [37], [38]. This would be 
represented by the following equation: 
(7) 
where  is the effective magnetic drift coefficient. However, this analogy considers only 
passive motion of the particles. It does not include the ability to exert an external force 
upon the magnetic nanoparticles and thus deforming the surrounding tissue space. While 
the tissue architecture might create barriers to particle motion, it is conceivable that the 
magnetic forces could pull the particles through a weakly formed extracellular matrix. 
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This would negate the assumption described in equation (7) as the effective magnetic 
drift coefficient could be much greater than approximated. 
 
There are limitations and caveats to the above two models, however, absent relevant 
experimental measurements, they are the best current methods to approximate 
nanoparticle movement through tissues.  
 
1.3.2 Animal and Clinical Trials 
While magnetic nanoparticles have been approved for use in patients for MR imaging 
agents [118]–[121], there have been a limited number of clinical trials involving 
magnetic drug targeting. Most notably, Lübbe et. al have performed simplistic targeting 
with magnetic nanoparticles (from Chemicell GmBH) conjugated with doxyrubicin in 
clinical trials involving several patients with inoperable facial tumors [14]. There have 
been only a few patient trials since that have either involved using the magnetic field 
outside of an MRI to target nanoparticles [109], [209], or using nanoparticles as 
thermotherapy [16]. 
 
There are, however, a multitude of MDT experiments performed in vivo in animals. 
These range from dogs [28], hamsters [91], [95], mice [84], [86], [89], [104], rabbits [26], 
[80]–[83], [98], [103], [105], rats [31], [36], [50], [85], [87], [90], [94], [97], [99], [100], 
[106], sheep [102], to swine [32], [34]. These have progressed the development of MDT, 
however, they still rely on static magnetic fields to concentrate particles at a desired 
'surface' location. This introduces targeting limitations and reduces the potential benefit 
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of MDT. By applying a closed-loop feedback strategy, the particles can be specifically 
targeted at a designated region deeper within the body able reach sites greater than 5 cm 
depth (the current limitation in human trials [14]). 
 
1.4 Contributions Presented 
This dissertation adds three main advancements to the magnetic drug targeting field. 1) 
The creation of a comprehensive ferrofluid transport model within any vessel, membrane 
and tissue space under an applied magnetic field verified by available published works. 2) 
A ferrofluid mobility model used to predict ferrofluid and drug concentrations within 
physiologically relevant histological samples from human autopsies. 3) An optimization 
of applied magnetic fields using the particle mobility models to predict the best treatment 
scenarios for two classes of chemotherapeutic drugs. 
 
1.4.1 Blood Vessel Simulations 
There are two categories of forces acting upon magnetic particles as they traverse 
throughout the body: those that are induced; and those that are a consequence of the 
environment. In the first, the magnetic force generated by an external magnetic field pulls 
particles towards the magnet creating a resultant drag force resisting this motion [194], 
[210]. In the second, the biological system transports particles through the blood and 
scatters particles as they interact with red blood cells [131]. Starting with physical first 
principles, Chapter 2 predicts the possible ferrofluid behaviors that can occur within any 
given blood vessel with any surrounding tissue space. Very few assumptions of 
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nanoparticle characteristics were made and the developed model encompassed the entire 
space of what is experimentally and biologically feasible (see Table 1).  
 
By accurately describing the forces acting upon a magnetic nanoparticle and starting with 
physical first principles, the transient concentration of nanoparticles is described within a 
blood vessel including the surrounding tissue by a set of equations. Using these equations 
and custom finite element solver built in collaboration with California Institute of 
Technology, the entire realistic parameter space is exhaustively surveyed uncovering 
three fundamental magnetic nanoparticle behaviors: magnetic dominated; velocity 
dominated; and boundary layer formation. The behavior of a ferrofluid within a blood 
vessel and tissue was determined to be governed by only three non-dimensional 
parameters. These behaviors remain even as the constraints upon the simulation are 
relaxed. Therefore, an experiment can be correctly designed to create a desired magnetic 
nanoparticle behavior. 
 
1.4.2 Tissue Simulations 
While an open loop trap cannot exist (see section 1.1.3 where Earnshaw’s theorem is 
discussed), open loop control still can be used for specific treatment scenarios. Metastatic 
breast cancer often results in hundreds of micro-tumors in a patients’ liver. Contrary to 
primary tumors, these metastases often have low blood perfusion and chemotherapy often 
cannot accumulate to therapeutic levels within these micro-tumors [211]. These untreated 
tumors lead to cancer reoccurrence. Chapter 3 introduces a new method by which to 
equalize chemotherapies throughout the liver parenchyma (the functional tissue of the 
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liver). This method, coined dynamic magnetic shift (DMS), uses external magnetic fields 
to pull chemotherapy loaded magnetic nanoparticles throughout the liver. 
 
Our collaborators at the National Cancer Institute started with histological patient data 
from NIH autopsy studies of terminal breast cancer patients. They then stained and 
marked the liver sections for blood vessels and cell nuclei. Using these histological 
sections, we took blood vessel density measurements to characterize the blood vessel 
population of either normal or tumor tissue. These measurements confirmed the existence 
of small micro-tumors containing fewer blood vessels compared to the surrounding 
normal tissue. It is these micro-tumors that are problematic for treating with 
chemotherapeutic agents. Therefore the treatment target for DMS was aimed at 
improving the drug concentrations throughout these micro-tumors. 
 
To understand and quantify how DMS will improve the drug concentration within these 
micro-tumors, we created a ferrofluid transport model through tissue architectures. This 
model utilized the blood vessel distribution from actual autopsy sections and focused the 
treatment target on the problematic micro-tumors. By comparing the ferrofluid 
distribution that would occur naturally due from diffusion to the distribution from 
applying shifting magnetic fields, the potential therapeutic increase in ferrofluid 
concentration was determined. By using magnetic shift, the concentration of ferrofluid 





1.4.3 Optimization of Dynamic Magnetic Shift 
Chapter 3 introduced the idea of DMS and quantified the potential impact that the 
treatment scenario could have on the micro-environment of metastatic breast cancer 
within the liver. However, while the benefit was significant in Chapter 3 (  
improvement over diffusion), the question remains if we can improve it. What 
combination of transient magnetic fields would be the best to pull the ferrofluid 
throughout the liver to achieve therapeutic treatment goals? 
 
Chapter 4 examines the optimal parameters necessary to deliver the ferrofluid throughout 
the liver architecture. The therapeutic treatment goals were defined for two classes of 
chemotherapeutic agents: 1) those drugs that only act during a specific phase of the cell 
cycle and must therefore be available for the cells as long as possible; and 2) those drugs 
that are insensitive the current phase of the cell cycle. These two goals led to the 
development of two distinct metrics to quantify the benefit a specific treatment scheme 
has upon the tissue architecture. 
 
Using these two metrics as a way to compare the treatment scenarios, the optimal 
treatment was determined for shifting in two-directions by exhaustively simulating the 
various treatment scenarios. Not only was the optimal treatment searched over the 
direction of magnetic movement, but 140 micro-tumor cases were examined from 16 
patients. Lastly, the robustness of these optimal treatment schemes was tested as the 
mobility parameters of the ferrofluid were relaxed. The robustness experiments examined 
the method by which the optimal treatment schemes change as the particles decrease in 
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tissue mobility. This optimal control scheme can then be used as a technique for treating 
metastatic breast cancer present within the liver for future patients.  
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Chapter 2: Modeling Magnetic Nanoparticle Transport through a Blood 
Vessel under an Applied Magnetic Field 
This work originally appeared in [212] and [213]. 
This work was done in collaboration with Catherine Beni and Oscar Bruno from the 
California Institute of Technology. They developed the finite element solver, termed the 
vessel-membrane-tissue (VMT) solver, used to solve the model. I created the VMT 
model, and identified and investigated the treatment space. Lastly, I used prior 
experimental studies to validate the model. 
 
2.1 Introduction 
Magnetic drug targeting refers to the attachment of therapeutics to magnetizable particles, 
and then applying magnetic fields to concentrate them to disease locations such as to 
solid tumors, regions of infection, or blood clots [11], [12], [18], [25], [108], [134], [142], 
[214].  In some cases, however, the magnetizable particles can be introduced into the 
body outside the blood flow, e.g. as in magnetic treatment of the inner-ear where a small 
gel containing nanoparticles is placed on the round window membrane [21], [22], [215], 
usually ferromagnetic particles are injected into a vein or artery [11], [108], [25], [26], 
[80], [28]–[31], [14], [125], [216], [192], [102], [109], [106]. Particles so injected will 
circulate throughout the vasculature as the applied magnetic field is used to attempt 
confinement at target locations. Two main considerations arise from the in vivo use of 
these particles. First, the particles must be small enough to make it out from the blood 
vessels into surrounding tissue (they should be no larger than approximately 400 – 600 
nm to extravasate out from even 'leaky' tumor vessels [11], [37], [38], [133], [216], 
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[217]), and, more subtly and crucially, they must be small enough to have sufficiently 
long in vivo residence times (larger particles are removed faster by the mononuclear 
phagocyte system; in human clinical trials [30], [108] Chemicell’s 100 nm particles were 
shown to have 30 min plasma residence times).  Second, the magnetic force on these 
small particles is minimal. Magnetic force scales with particle volume [194], decreasing 
the size of a particle by a factor of 10 decreases the magnetic force on it by 1000. Even 
with strong magnetic fields ( > 1 Tesla) and high magnetic gradients (≈ 0.5 T/cm), the 
forces on ferro-magnetic nanoparticles remain extremely small, in the range of pico-
Newtons [194], [218], [219].  
 
 
Figure 2: Verification of magnetic drug delivery from the body to the cellular scale in animal and 
human clinical trials.  a) Magnetic resonance (MR) image for a cancer patient, magnetic 
nanoparticle (ferrofluid) accumulation can be seen as lighter regions at the arrow tips (due to the 
MR extinction phenomena [53]) [14], [30], [31], [108], [209].  b) Rat studies: concentrated 
ferrofluid is visible under the skin [31], [220].  c) Ferrofluid concentrated in rabbit tumor micro-
vessels (white arrow) [26], [35].  d) Magnetic nanoparticles at the membrane of mouse epithelial 
cells (e.g. black arrow) [221]. 
 
Thus a key issue in magnetic drug delivery is whether the applied magnetic forces can 
compete with convective blood (drag) forces that tend to wash particles away. The 
questions are: can particles be confined to target regions against blood flow? In which 
blood vessels and where do they concentrate? How deep within the body can targeting 
occur?  Past animal experiments [21], [26], [28], [31], [32], [34], [36], [50], [80]–[87], 
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[89]–[92], [94], [95], [97]–[106], [222] and phase I human clinical trials [14], [31], [109], 
[209] have observed the accumulation of magnetic nanoparticles by visual inspection, 
magnetic resonance imaging, and histology studies.  These have shown that magnetic 
forces can concentrate micro- and nanoparticles in vivo near magnets, but the details of 
that concentration cannot be seen experimentally. MRI and visual inspection do not have 
the resolution to show in which vessels magnetic forces have exceeded blood drag forces, 
and they certainly cannot show where in the vessel accumulation is occurring. Equally, 
histology studies are carried out after the animal has been sacrificed and blood flow 
stopped; they speak only partially to where in the blood vessels the particles might have 
been. Thus, in this chapter, we address this issue via simulations. We map the parameter 
space and characterize what should happen in an idealized blood vessel in terms of 
applied magnetic force strength and blood flow velocity. Our goal is to forecast and 
characterize the type of behaviors that will occur. 
 
We note that the usual back-of-the-envelope analysis is not sufficient; it does not predict 
what is observed experimentally. Consider the rat experiments shown in Figure 2b. Here 
our collaborators (Lübbe and Bergemann) used a 0.5 Tesla, 5 cm long, 5 mm wide 
permanent magnet to focus 250 nm diameter iron-oxide nanoparticles. Even for a particle 
at a distance of just 1 mm away from the magnet (just below skin depth), the magnetic 
force on this particle (see equation (11) and [194], [218]), including the effect of particle 
magnetic saturation and using an exact solution [223] for the magnetic field around the 
magnet, is only about  N.  By comparison, the Stokes blood drag force [224] 
on the same particle, for the slowest measured 0.1 mm/s blood-flow velocities in rat 
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capillaries [225]–[227], is  N, a factor of  greater.  This simple 
comparison suggests that the field gradient near the magnet cannot capture a 250 nm 
particle against even the weakest blood flow in a rat. Yet in Figure 2b the dark spots 
where the particles have been focused can be clearly seen. This focusing was carried out 
while the rats were alive and their blood was flowing, and it has been repeated even with 
100 nm diameter particles where the magnetic forces are 2.5
3
 = 15.625 times smaller. 
Clearly, a crude comparison of magnetic forces per particle to Stokes drag is insufficient 
to match in vivo behavior. This mismatch is also apparent in the literature both for in 
vitro and in vivo experiments. In in-vitro studies (eg. [106], [228]), particles were focused 
even when centerline stokes drag forces exceeded magnetic forces. In the in vivo cases 
(eg. [26], [36], [95]), Stokes drag due to the slowest blood flow in the animals/humans 
exceeded maximum magnetic forces yet particle focusing was still observed. 
 
The rough calculation above is deficient for two main potential reasons. 1) The blood 
flow drag forces on the particle vary with its position in the blood vessel. A particle at the 
vessel center-line will experience a higher blood velocity and hence a higher drag force, 
but a particle near the blood vessel wall will be surrounded by a near zero blood velocity. 
This decrease in velocity is due to the flow resistance provided by the vessel wall, the 
'no-slip' boundary condition [38], [229], [230]. Thus a particle near the vessel wall will 
experience a much smaller drag force and can potentially be held by a much smaller 
magnetic force (see Figure 3, this effect is also noted in [219] for micro-channels).  
Alternatively 2) the particles might agglomerate to some degree even though they are 
typically engineered to minimize agglomeration [11], [12], [216]. This will increase the 
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magnetic force, which grows with volume, much faster than the Stokes drag, which 
grows with diameter, thus increasing trapping. In this chapter, we will focus on 
examining the first issue in detail, as it is the next crucial question. Item 2) is addressed 
approximately by considering an agglomerated clump as simply a larger ‘super-particle’ 
(see Section 2.15.5). Consideration of agglomeration thus folds into our non-dimensional 
numbers for size and force (discussed in Section 2.8.1). A more sophisticated, analysis of 
agglomeration will be carried out in future work.    
 
This chapter focuses on systematically characterizing the behaviors of ferromagnetic 
nanoparticles in a single idealized blood vessel under the action of an applied magnetic 
force, blood drag, diffusion within the blood, and transport of particles from blood to 
surrounding tissue (modeled simply as diffusion, as in [37], [38]).  It includes an ability 
to predict what happens in shallow and deep, small and large blood vessels, and it 
resolves the mismatch between experiments and the usual, but simplistic, back-of-the-
envelope centerline Stokes drag versus magnetic force calculation described above. It is 
organized from the simplest scenario to cases that include added features such as spatially 
varying magnetic forces, blood pulsatility, curved vessel geometry, and skin boundary 
conditions. These added features do not qualitatively change the three types of 
nanoparticle behaviors observed: blood velocity dominated, magnetic force dominated, 
and boundary layer formation regimes. In addition, we do not consider cases where the 
concentration of ferromagnetic nanoparticles is sufficiently high to obstruct the flow 
within a blood vessel. We find that the observed nanoparticle concentration behavior in 
in-vitro and in vivo studies is correctly predicted by a single three-parameter non-
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dimensional map (Figure 9 and Figure 11) that delineates the blood velocity dominated, 
magnetic force dominated, and boundary layer formation behaviors. Our summary result 
is simple to use and will enable a more systematic design of future magnetic in vivo drug 
delivery systems. 
 
Simulating ferrofluid behavior, even in a single straight vessel, is challenging. We 
created an in-house vessel-tissue-membrane (VMT) numerical solver based on the 
Alternating Directions Implicit (ADI) method [231]–[234]. The VMT solver was both 
more accurate and 500 times faster than COMSOL (a general-purpose commercially 
available partial differential equation solver often used in the magnetic drug delivery 
literature, e.g. [228], [235]), and it was able to solve cases that COMSOL could not (see 
Section 2.8). Using VMT we were able to solve all cases, though the most challenging 
cases still took a long time (the case of mass Péclet number equal to 1  10
8
 in Section 
4.3 took 48 hours). There are ways to further improve VMT to make these cases run 
much faster and this will be reported in future publications as part of our effort to create a 
general-purpose fast and accurate simulation environment for magnetic drug delivery. 
 
The current study is essential to better forecast what happens in vivo in shallow and deep 
blood vessels under varying circumstances. Our modeling is the next needed major step: 
it goes beyond a naive back-of-the-envelope calculation but is still tightly focused on the 
issue of blood convection versus magnetic forces. It necessarily cannot include all the 
complex details of magnetic particle phenomena in vivo, because much of that behavior is 
still not well understood at a physiological and physical level and therefore cannot yet be 
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quantified mathematically. For example, extravasation [11], [37], [38], [133], [216], 
[236]–[238] is an active research field in its own right and the mechanisms that drive it 
are not yet fully known or characterized. Since extravasation cannot be included in detail 
at our level of modeling, we represent it here by a diffusion term (from blood to tissue) 
that is folded into the effective diffusion coefficient (as is done in [37]). Even with this 
limitation, our model still provides accurate and effective results that are hard to attain 
any other way. It is necessary for our larger effort to design controllers that will achieve 
deep tissue magnetic drug targeting [218], [239]–[241], and its ability to simply but 
accurately predict in vivo behavior will aid the research efforts of the broader magnetic 
drug delivery community. 
 
2.2 The Three Parameters 
We consider the scenario of a single blood vessel with an inflow of blood and ferro-
magnetic nanoparticles that are actuated by an externally applied magnetic force. We find 
that the nanoparticles exhibit three distinct and specific behavioral patterns: either 
velocity dominated (they are washed out of the back of the blood vessel), magnetic force 
dominated (magnetic forces overcome the blood vessel membrane and surrounding tissue 
barriers), or they form a boundary layer at the blood/tissue interface. Three non-
dimensional numbers are required to determine which behavior is occurring. These three 
numbers are: 
 
The Non-Dimensional Magnetic Force Strength (the Magnetic-Richardson 
Number):  This number quantifies the ratio between the applied magnetic force and the 
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blood Stokes drag at the vessel centerline. When this number is greater than unity then 
the magnetic force is larger than the blood Stokes drag force at the vessel centerline. 
 
The Renkin Reduced Diffusion Coefficient:  This quantifies the ratio between diffusion 
in the blood vessel membrane and diffusion in the blood. If this number is smaller than 
unity then particles in the blood vessel membrane diffuse much slower than the same 
particles in blood. 
 
The Mass Péclet Number:  This number quantifies the ratio between the maximum 
centerline blood flow velocity times the average blood vessel width to the total particle 
diffusion coefficient. When this number is much greater than unity then particle 
convection occurs much faster than diffusion across the blood vessel width. 
 
2.3 Domain Geometry 
Figure 3 shows the model geometry: an idealized straight blood vessel contained by an 
endothelial layer next to an underlying tissue layer. This geometry is a simplified version 
of the Krogh tissue cylinder [37]. Similar to the Krogh cylinder model, the tissue space is 
a region between adjacent vessels and the model only applies to capillaries because it 
does not incorporate a vascular muscle layer. This restriction, however, can be relaxed by 
substantially lowering the diffusion coefficient of the membrane layer (see section 
2.15.1) thus better approximating non-capillary vasculature. The vessel has an inlet at the 
left-hand side and an outlet at the right-hand side. Blood and a constant concentration of 
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ferro-magnetic nanoparticles enter from the left. A magnet is held below the blood vessel 
and creates a downwards magnetic force. 
 
 
Figure 3: The simulated blood vessel geometry. The blood vessel is idealized as a straight 
channel. Blood and a constant concentration of magnetic nanoparticles enter from the left. The 
magnetic particles (black circles) within the blood vessel experience diffusion, migration under 
blood flow, and magnetic forces. Magnetic particles in the surrounding endothelial and tissue 
layer experience diffusion and magnetic drift but no blood flow forces. The magnet can be a long 
distance from the blood vessel (deep targeting) and here this is denoted by the break in the length 
bar on the right of the figure. Inset: The simulated domain around a blood vessel in deep tissue. 
 
2.4 Governing Forces 
We consider the three main forces acting upon the ferro-magnetic nanoparticles. These 
include blood advection forces induced by blood plasma convection [37], [196], [224], 
magnetic drift induced by the applied magnetic field [210], [242], [243], and diffusion 
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forces induced both by Brownian diffusion [196] and the scattering effect that colliding 
and shearing red blood cells have on the nanoparticles [131]. 
 
2.4.1 Maxwell’s Equations for the Magnetic Field 
Electromagnetic fields are classically described by Maxwell’s equations [244]. We 
specialize to the case of magneto-static equations that are appropriate for stationary, or 




Here  is the magnetic field [T],  is the magnetic intensity [A/m],  is the current 
density [A/m
2
],  is the material magnetization [A/m],  is the magnetic susceptibility, 
and  is the permeability of a vacuum [  N/A
2
]These equations hold true in 
vacuum and in materials, for permanent magnets (magnetization ), and for 
electromagnets (current ) [194], [210], [245]. Through the human body, magnetic 
fields propagate essentially unchanged because the magnetic susceptibility of tissue is 




 [246], [247]). In contrast, the magnetite cores (e.g. Fe3O4) 
of ferro-magnetic particles have magnetic susceptibilities 5 to 7 orders of magnitude 
higher than that of tissue ( ), therefore these particles are strongly influenced by 




2.4.2 Magnetic Forces on a Particle 
A single ferro-magnetic particle in a magnetic field will experience a force that depends 
upon the magnetic field and field gradient around it [87], [185], [210], [239]. 
(11) . 
Here  is the radius of a nanoparticle [m] and  is the gradient operator [with units 1/m]. 
For simplicity, the hydrodynamic radius is considered to be the same size as the magnetic 
core radius (the case where they differ is discussed in Section 2.15.8). The first relation is 
more familiar and clearly shows that a spatially varying magnetic field ( ) is 
required to create a magnetic force. The second equivalent relation states that the 
magnetic force on a ferro-magnetic particle is always from low to high magnetic fields 
and proportional to the gradient of the magnetic field intensity squared. The two relations 
are equal by the chain rule and it is evident that the magnetic force is also proportional to 
the particle volume.  
 
If the applied magnetic field is sufficient to saturate the nanoparticle, then  in 
equation (11) is modified to  where  is the saturated magnetization of 
the particle. Since  lines up with , this does not change the direction of the force, 
only its size. Thus, this case is considered within our framework simply by modifying the 
size of the magnetic force used. 
 
As shown in Figure 4, when the magnet is held at a long distance compared to the blood 
vessel width, we can assume that the magnetic force is constant in space throughout the 
blood vessel width and length. This negates the need to solve the magneto-static 
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equations; it is true to within a few percent even for wide blood vessels near magnets, and 
it does not qualitatively change the resulting nanoparticle behaviors (Section 2.15.3 
analyses the case where the magnetic force does vary in space according to the magneto-
static equations).  
 
 
Figure 4: Magnetic forces are usually constant within the tissue-vessel system. Here even though 
a magnet is held close to the blood vessel (at a distance that is less than its length) the resulting 
magnetic force within the blood vessel is still essentially constant: the maximum error of |Fconst-
Fexact|/|Fexact| < 10 %.  
 
For the rat experiment shown in Figure 2b, the force acting upon a single iron oxide 125 
nm radius particle at a 1 mm depth is given by equation (11) to be  pN. (Here 
the 0.5 T permanent magnet produces a magnetic field intensity of  A/m and a 
magnetic spatial gradient of  A/m
2
 at a distance of 1 mm, the particles had a 




2.4.3 Magnetic Forces on a Concentration of Particles (on a Ferrofluid) 
A ferrofluid is composed of many magnetizable nanoparticles and is essentially super-
paramagnetic. Ferrofluids are strongly magnetized in the presence of an external field and 
then lose their magnetization once the external field is removed due to rapid random 
particle reorientation [194], [210], [245]. Neglecting particle-to-particle interactions, 
which are small due to particle reorientations and anti-agglomeration coatings [11], the 
magnetic force on each elemental volume of ferrofluid is given by [38], [196] 
(12)  




2.4.4 Magnetic Drift Velocity: Magnetic Forces versus Stokes Drag 
When the magnetic force of equation (11) is applied to a particle, it will accelerate the 
particle in the direction of this force until it reaches an equilibrium velocity  relative to 
the surrounding blood (or surrounding tissue). The opposing Stokes drag force on a 
spherical particle is given by [38], [196] 
(13) 
were  is the dynamic viscosity of blood [kg m/s]. When the Stokes drag force first 
equals the applied magnetic force, then the particle has reached its equilibrium relative 
velocity (magnetic velocity) 
(14)  
where  is the magnetic drift coefficient. This relative velocity adds 
to the fluid velocity (equation (15) below) and together they give the net convection plus 
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magnetic drift velocity. (Equation (13) does not include wall effects that modify the drag 
force on a particle within a few particle diameters of an external obstruction [248], [249]. 
Equation (14) also does not include magnetic particle-to-particle interaction forces. For 
an initial discussion of the effects of agglomeration see Section 2.15.5 or [250]–[252].) 
 
Within the membrane and tissue layers, Stokes drag is not the only limitation to the 
maximum velocity induced by magnetic forces. There are many obstacles in the form of 
cells and extracellular matrix components that inhibit particle movement [37], [38], 
[237], [253]. These obstacles lead to an analogous magnetic drift coefficient for the 
membrane and tissue layers. Einstein's relation assumes that these obstacles also inhibit 
diffusion in a similar manner [37], [38]. Therefore the analogous magnetic drift 
coefficient for the membrane and tissue layer is generated by scaling  by the Renkin 
Reduced diffusion coefficient described in Section 2.8.4 [37]. 
 
Using the same rat example as before (Figure 2b) and a blood viscosity of 0.003 Pa s, the 
magnetic drift velocity of the 250 nm diameter iron oxide particles in blood is then  ≈ 
1.4 x 10
-5
 m/s, i.e. it is 14 μm/s.  
 
2.4.5 Advection Forces 
The fluid velocity profile in a channel is curved - it is highest at the centerline and is zero 
at the walls due to the no-slip boundary condition. For Newtonian fluids in straight 
channels at steady state, this curved profile is parabolic [196], [254].  Blood, however, is 
a non-Newtonian fluid due to the presence of the clotting protein fibrinogen, which 
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causes red blood cells to aggregate at low shear rates. This creates a blunted flow profile 
known as plug flow [37].  Such a profile can be fit empirically by [255] 
(15)   
where  is the velocity in [m/s],  is the maximum centerline velocity [m/s],  is 
the radial location [m],  is the radius of the vessel [m], and  is a constant for a 
particular profile. A value of  is usually chosen to fit experimental data of the 
cardiac cycle [255]. This equation removes the need to solve the Navier-Stokes equations 
for the blood flow profile. In rat vessels the smallest centerline blood velocity is on the 
order of 0.1 mm/s [225]–[227], in humans it is 0.5 mm/s [37]. 
 
2.4.6 Diffusion Forces   
There are two main types of particle diffusion that occur within a blood vessel: Brownian 
thermal motion and particle scattering due to collisions with blood cells.  
 
Brownian Diffusion 
Brownian motion refers to the random motion of particles under the action of thermal 
fluctuations and is quantified by a diffusion coefficient [37], [196] 
(16) 
that relates the diffusive flux to the concentration gradient of the particles. Here  is the 
Boltzmann constant and  is the absolute temperature. For 250 nm diameter particles in 
blood at body temperature (37
o











Diffusion from Blood Cell Scattering 
Collision of blood cells with nanoparticles causes the particles to scatter and can be 
modeled as additional diffusion [131]. The scattering diffusion coefficient is on the order 






/s and can therefore be greater than the diffusion due to thermal 
motion. The total particle diffusion is the sum of thermal and scattering diffusion hence 
. 
 
2.4.7 Additional Forces not Considered within the Model 
Several additional forces are neglected for simplicity. These include additional forces that 
occur when particles concentrate near the blood vessel boundary. If the particles 
concentrate to significant levels at the vessel boundary, the resultant concentration can 
extend into the vessel where blood velocity forces are high. It is possible for the 
collection of particles to then impact the blood flow and change the blood velocity flow 
profile. This effect is neglected within this model. 
 
In addition, the effect of objects within the blood flow imparting an additional force as 
they collide with the particles is not considered. These objects include red blood cells, 
white blood cells, or platelets. While this is approximated for red blood cell interactions 
with the addition of a scattering diffusion coefficient, it does not completely describe the 
scenario for all vessel types or objects. One such un-described scenario is within 
capillaries or other small vessels where red blood cells encompass the entire vessel lumen 




2.5 Summary of Governing Equations and Boundary Conditions 
The concentration of ferrofluid at each location is a function of time: it increases when 
the flux of particles to that location is positive and decreases when it is negative [196], 
[248]. The flux is the summation of the three effects discussed above: diffusion, 
convection by blood flow, and magnetic drift. Thus 
(17) 
where  is the blood flow velocity. Considering a constant magnetic force acting only in 
the negative -direction and the specific blunted blood flow profile of equation (8), the 
concentration can then be described by the partial differential equation 
(18)  
stated in two spatial dimensions, in  and . The concentration inside the tissue is defined 
more simply by the equation  
(19) . 
Boundary conditions are required to complete the model. At the blood flow inlet, a 
constant concentration of magnetic particles is imposed (see also Figure 3). At all 
external boundaries of the tissue-vessel system, the normal diffusive flux is set to zero 
( ) enforcing the requirement that the total flux at those boundaries is exactly 
the convective flux (so that ferrofluid correctly convects out of the vessel outlet with the 
blood flow). The interior boundaries between the vessel and endothelial layer, and the 
endothelial layer and tissue, satisfy two conditions: the ferrofluid concentration is 
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continuous across each interface (no concentration discontinuities), and the ferrofluid that 
leaves one domain enters another (no ferrofluid is lost or created). 
 
Since in magnetic drug delivery a magnet is often held outside the skin, and nanoparticles 
then concentrate closest to it but do not leave the body, it can be desirable to include a 
'skin' boundary condition that prevents nanoparticles from leaving the tissue (this would 
be placed at the bottom of the tissue layer in Figure 3). We do not consider this added 
feature for the majority of the chapter because we are interested in ferrofluid behavior in, 
immediately around, and between blood vessels. Therefore we permit the nanoparticles to 
leave this focused inspection domain. Skin introduces a new complication, the pile-up of 
nanoparticles in the tissue next to it, and it can distort the behavior around blood vessels 
in a way that depends on tissue thickness. It necessitates a 4
th
 non-dimensional number 
thus requiring a 4-dimensional visualization of the prototypical behavior of ferrofluids. A 
skin boundary condition is included in Section 2.15.6 and correctly causes ferrofluid to 
pile-up near the magnet. 
 
2.6   Range of Physical Parameters 
2.6.1 Magnetic Parameters 
Magnetic nanoparticles are usually defined as a moiety between 1 nm and 1 μm that 
contain a magnetic core [11]. The magnetic core is usually composed of magnetite or 
maghemite [11], [80], [102], [104], [106], [108], [228], [256], [257] but other exotic 
materials can be used including cementite [32], [34]. For in vivo studies the size of 
particles used ranges from ≈ 10 nm (small carriers) [102] to 5 μm (large carriers) [32], 
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[34]. Smaller particles (size < 25 nm) usually exhibit superparamagnetic behavior that 
helps reduce agglomeration when the magnetic fields are removed [11]. Larger particles 
(size > 60 nm) benefit from not passing through normal fenestrated capillaries where the 
pore cut-off size is approximately 60 nm [11], [216]. 
 
The magnetic fields generated by external magnets in in-vitro studies have ranged 
anywhere from  mT [142] to  1.5 T [214], [228]. Animal trials have had ranges 
between 0.1 T and 1.5 T [31], [36], [80], [102], [109]. While the FDA has approved 
magnetic strengths up to 8 T for use with humans [11] and human clinical trials have 
utilized 0.2 to 0.8 T magnet field strengths [14], [30], [31], [108]. Most often permanent 
magnets have been used with sizes ranging from tens of millimeters to tens of centimeters 
[32], [34], [80], [108], [142], [228]. Occasionally electromagnets were utilized [214], 
[257]. The distance of particles from magnets has ranged from ≈ 1 mm to ≈ 12 cm in the 
literature [14], [32], [36], [106], but we consider up to 30 cm distances to examine the 
possibility of deep tissue magnetic targeting [218], [239], [241]. 
 
2.6.2 Advection Parameters 
In humans, typical centerline blood velocities range from 0.5 mm/s in capillaries to the 
largest value of 40 cm/s in the aorta [37], [38], [131]. Average vessel diameters vary 




2.6.3 Diffusion Parameters 
Particle size and vessel radii impact the diffusion of nanoparticles. The largest diffusion 
coefficients occur in large vessels (arterioles and arteries) where cell scattering effects are 
high and with small particles where Brownian diffusion is large. The smallest diffusion 
coefficients occur in small vessels (capillaries) where scattering effect are negligible and 
with large particles where Brownian diffusion is small. The typical range in humans of 
total particle diffusion coefficients is between  to  m
2
/s [37], [131].  
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Table 1: Human physical parameters encountered in magnetic drug delivery. (Essential quantities 
needed for the sub-sequent non-dimensionalization are bolded.) 
Parameter Symbol Parameter Range 
Particle Radius 1 nm – 5 µm 
Distance from Magnet 1 mm – 30 cm 
Magnetic Field Strength 
(or Magnetic Intensity) 
0.1 – 1.5 T 
8  104 – 1.2  106 A/m 
Magnet Length 1 - 30 cm 
Magnetic Drift Velocity 9  10-15 m/s – 3.8  10-4 m/s 
Magnetic Force on a Particle 5  10-25 – 1.1  10-11 N 
Maximum Centerline Blood Velocity 0.5 mm/s – 40 cm/s 
Vessel Diameter 7 μm – 3 cm 
Blood Viscosity 0.003 Pa s 
Centerline Stokes Drag on a Particle 3  10-14 – 1.1  10-7 N 
Temperature 310 K (body temperature) 
Brownian Diffusion Coefficient 
Scattering Diffusion Coefficient 
1  10-14  - 1  10-12 m2/s 
3.5  10-12  - 6  10-10 m2/s 
Total Diffusion Coefficient (in blood) 1  10-14 – 6  10-10 m2/s 
Diffusion Coefficient (in membrane) 0 (particles > pores) - 1.5  10-12 
Diffusion Coefficient (in tissue)  0 (particles > interstitial spaces) - 1.2  10-14 
 
2.7 Non-dimensionalization of Governing Equations 
In a model with dimensional parameters, like equation (17), the numerical parameter 
values used depend on the chosen units (meters versus millimeters), there are typically 
multiple parameters associated with each phenomena (with diffusion, convection, and 
magnetic drift), and their effects are coupled together (for example, changing the particle 
radius changes both the diffusion coefficient  and the magnetic drift coefficient ). 
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Non-dimensionalizing (i.e. normalizing) the model reduces the number of parameters to 
those that are actually independent [248].  The resulting non-dimensional numbers 
capture the ratio between competing physical effects; they remain the same even if a 
different system of units is chosen; and they are uncoupled in the sense that each non-
dimensional number is the ratio between two competing effects and is independent from 
parameters that make up any third effect (e.g. the Renkin number is a ratio of diffusion in 
tissue versus in blood and does not depend on particle size).  
 
As described in section 2.2, for our idealized blood vessel system, nanoparticle behavior 
is uniquely determined by three non-dimensional numbers: the magnetic-Richardson 
number, the Renkin reduced diffusion coefficient, and the mass Péclet number. If we 
consider two situations A and B in which the blood vessel width, particle size, and 
magnetic field strength differ dramatically, but these two situations share the same three 
non-dimensional Richardson, Renkin, and Péclet numbers, then these two different 
situations will exhibit identical behavior because they will both have exactly the same 
balance of magnetic, diffusion, and convection phenomena. 
 
We now formally derive the non-dimensional form of our model (upcoming equations 
(24), (25), and (26)) from the dimensional form. Repeating equation (17) for clarity 
(20)  
let , , , , and  so each non-
dimensional variable (hatted) is the dimensional variable divided by a characteristic 
quantity. Here , , and  are the characteristic length (the width of the blood 
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vessel), characteristic concentration (the inlet magnetic particle concentration), and the 
characteristic velocity (the maximum centerline velocity in the blood vessel). Using these 
three characteristic quantities, it is further possible to consistently define all other needed 
non-dimensional variables and derivative operators as ,  
and . 
 
Table 2 summarizes the non-dimensional transformations for all variables. The five 
essential dimensional variables (those variables that are bolded in Table 1) reduce down 
to just two non-dimensional numbers, as predicted by the classical theorem of non-
dimensional analysis: the Buckingham Pi Theorem [248]. These two non-dimensional 
numbers are the magnetic-Richardson number and the mass Péclet number. The third 
non-dimensional number considered in the chapter, the Renkin reduced diffusion 
coefficient of the endothelial membrane or the tissue, is required because diffusion in the 















 the average width of the blood 
vessel, e.g.  = 0.03 mm for an 
arteriole  
X Length [m] 
Y Length [m] 
Velocity [m/s] 
 the maximum centerline blood 
velocity, e.g.  cm/s for an 
arteriole 
Concentration [mol/m3] 
 the inlet concentration, e.g.  
to  mol/m3 
Time [s] 
Non-dimensionalized by the 




Non-dimensionalized by the 
composite quantity  
 
Substituting the non-dimensional variable (or derivative operator) multiplied by the 
constant characteristic quantity for each dimensional variable (or operator) rewrites 
equation (20) as  
(21)    
 . 
Multiplying both sides by  
(22) . 
Canceling and grouping terms, and recalling that  is defined to be  gives 
(23) . 
Defining the mass Péclet number to be  and the magnetic Richardson 




equation (24) (where the sub-script B has been added to denote nanoparticles in blood 
and the hats have been dropped). Equations for the membrane and tissue are derived in 
exactly the same way.  
 
2.8 Simulation Development 
2.8.1 Non-Dimensional Governing Equations: The 3 Key Numbers 
Non-dimensionalization of the mathematical model is crucial for mapping out ferrofluid 
behaviors; it reduces the number of parameters from the 16 in Table 1 to three key 
independent numbers and it prevents repeatedly solving self-similar cases that have 
differing dimensional parameters but share the same behavior [248]. Non-dimensional 
numbers achieve this saving by capturing the ratios between competing physical effects 
thus illustrating which effects win when and by how much.  
 
As done previously in section 2.7, we non-dimensionalize equation (17) by choosing a 
characteristic length scale (the width of the blood vessel ), a characteristic velocity (the 
maximum centerline velocity in the blood vessel ), and a characteristic 
concentration (the nanoparticle concentration at the blood vessel inlet ), and then 
normalize each variable with respect to these three characteristic quantities. Section 2.7 
defines all the resulting non-dimensional variables and provides a detailed derivation of 




now where  is the non-dimensional concentration of nanoparticles in the blood and  
is the non-dimensional blood velocity. Equations (25) and (26) are the non-dimensional 
analogs for transport of magnetic particles in the endothelial membrane and in tissue 
respectively 
(25)  
(26)   
This normalized model is completely parameterized by 4 non-dimensional numbers: the 
magnetic-Richardson number , the mass Péclet number , the Renkin reduced 
diffusion coefficient   for endothelial membrane diffusivity compared to blood, and the 
Renkin reduced diffusion coefficient    for the diffusivity of tissue compared to that of 
blood. The thin endothelial membrane either effectively acts as a barrier to nanoparticles 
or not, thus it suffices to vary either   (when the membrane limits transport) or    (if 
tissue limits transport). Since there is little need to vary both, 3 non-dimensional numbers 
are sufficient to completely characterize nanoparticle behavior.  
 
2.8.2 Magnetic-Richardson Number 
Based on the Richardson number [196], [258], we define a magnetic-Richardson number 
as the ratio of the magnetic force to the Stokes drag force that would act upon a single 
stationary particle at the centerline of a blood vessel. The magnetic-Richardson number is 




As the magnetic-Richardson number increases to a value greater than unity, the magnetic 
forces experienced by a particle are much higher than the drag forces created by the 
blood velocity. As the number decreases below unity, the blood velocity forces dominate. 
 
For the smallest rat blood vessels, the magnetic force upon an iron oxide 250 nm 
diameter particle at 1 mm depth was 0.1 pN. The Stokes drag force on that same particle 
in a rat blood vessel with a centerline velocity of 0.1 mm/s is 0.7 pN. Therefore the 
magnetic-Richardson number in this case is . 
 
2.8.3 Mass Péclet Number 
Here the mass Péclet number [37], [196], [254] is defined as the ratio of the blood vessel 
width multiplied by the maximum centerline blood velocity to the total diffusion 
coefficient of the nanoparticles within the vessel. At large Péclet values, the blood 
advection of nanoparticles far exceeds their diffusion. 
(28) 
 lood  essel idth Maximum  lood  elocity
Total  iffusion Coefficient of Particles
 
Continuing with our rat example, with a centerline velocity of 0.1 mm/s (the slowest 
measured in a rat capillary), a vessel diameter of  ≈ 6 μm, and a nanoparticle in blood 








2.8.4 The Renkin Reduced Diffusion Coefficient 
The behavior of semi-permeable membranes, such as the blood vessel wall, can be 
modeled by the Renkin reduced diffusion coefficient [37], [38]. This coefficient is the 
ratio of the diffusion coefficient in the membrane to the diffusion coefficient in the blood. 
(29)  
 iffusion Coefficient in Membrane
Total  iffusion Coefficient in  lood
 
As this ratio decreases towards zero, the ferrofluid increasingly remains within the blood 
vessel. As the ratio increases towards unity, the ferrofluid begins to leave the vessel and 
enters the membrane. When this ratio is one, the ferrofluid behaves as if the vessel wall 
did not exist. With this number the permeability of the endothelial membrane can be 
varied in a simple manner. 
 
If pore diameters of a membrane are known, the following equations can be used to 
estimate the ratio of blood to tissue diffusion coefficients 
(30) ,   
where  is the average radius of the pores in a membrane [37], [38], [197]. For normal 
endothelial pores of size  nm in rat capillaries [225]–[227],  , while in 
leaky blood vessels where   nm,  .  
 
Not only is the ratio of membrane to blood diffusion coefficients important, but the ratio 
of tissue to blood diffusion coefficients impacts particle behavior. Similar to the semi-
permeable vessel wall, tissue diffusivity is highly dependent upon particle size and the 
extra-cellular spacing. Therefore it is necessary to vary this number as well, and this is 
accomplished in Section 2.15.7. 
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(31)   
 iffusion Coefficient in Tissue
Total  iffusion Coefficient in  lood
 
Tissue diffusivity is usually greater than the membrane diffusivity but is typically less 
than the total blood diffusivity. In the rat example, for a tumor extracellular space of 
1 µm,    
[37]. 
 
2.9   Numerical Implementation 
Magnetic particle behavior was simulated by using both the commercial multi-physics 
package COMSOL (www.comsol.com) and by an algorithm designed specially to meet 
the significant challenges posed by the  essel-Membrane-Tissue (VMT) convection 
diffusion problem. The second method is based on a combination of: 1) a graded mesh to 
adequately resolve thin boundary layers; 2) the Alternating Directions Implicit (ADI) 
method [234]; 3) an on-and-off fluid-freezing methodology that allows for efficient 
treatment of the multiple-time scales that exist in the problem; and 4) a change of 
unknowns that enables evaluation of steady states in tissue and membrane layers through 
a highly accelerated time-stepping procedure [231]–[234]. The resulting linear-time 
unconditionally-stable numerical methodology, called the VMT solver, is both 
significantly more accurate and up to four orders of magnitude faster than the COMSOL 
simulation, in addition to being capable of resolving thin boundary layers for cases where 
COMSOL fails. For example, considering the case of , ,  , 
  , on a Intel Xenon quad core 3.1 GHz processor with 80 GB of available 
memory, COMSOL obtained a solution within 48 hours while our VMT solver obtained a 
steady state solution with 5 digits of accuracy in only 5 minutes and using 32.7 MB of 
memory. For another, much more difficult case using , , 
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 ,   , our VMT solver obtained a steady state solution with 5 digits of 
accuracy in under 8 minutes and using just 98.3 MB of memory while COMSOL was 
unable to provide a solution.  
 
Full details of the numerical methodology (with additional accuracy and computing 
improvements resulting from use of the novel Fourier Continuation-Alternating 
Directions method [259]) used in the VMT solver will be presented in a forthcoming 
contribution [260].  
 
Below we provide details of both the COMSOL and VMT numerical implementations, 
then a comparison of the two to show that they give the same answer (up to the poorer 
solution accuracy possible with COMSOL is shown in section 2.11). 
2.9.1 COMSOL Implementation 
Software Implementation 
For implementing the model, the software package COMSOL Multiphysics version 3.4 
was chosen initially. This package allowed the geometry specified in Figure 3 to be 
constructed. Equations (24), (25), and (26) were solved for the entire control volume 
using the prescribed blood velocity and magnetic velocity (equations (15) and (14)). 
Simulation times ranged from 15 minutes for the easy cases with , up to 36 
hours for , and were unsolvable for  even when using a high-end 
quad-core 32 GB RAM computer (a typical 2009 desktop PC or laptop has only 4 GB of 





COMSOL computes the solution by using the finite element method; that is by meshing 
the region and numerically integrating the approximate solution of the PDE at all mesh 
points until converged [261]. The mesh sizing must be sufficiently small to capture any 
physics being modeled in the domain. In systems with both advection and diffusion, the 
cell Péclet number sets the mesh sizing dependence on the modeled physical phenomena 
to ensure numerical stability. The cell Péclet number is defined as  
(32)  
where  is the mesh size in any primary coordinate direction. When , the 
solution is guaranteed to be numerically stable [262]. This requirement for stability 
demands small mesh elements due to small diffusion coefficients (for a  
simulation, this requirement translated into  required mesh points and 80 GB of 
available memory, either random access or virtual memory).  The COMSOL simulations 
were solved using a computer that contained a quad-core processor. Using COMSOL and 
this high-end computer we were able to solve cases up to  but higher Péclet 
number cases remained unsolvable (a  would have required  mesh 
points to ensure numerical stability corresponding to a 2000 Terabytes  
Gigabytes of required memory, an infeasible amount). 
 
2.9.2 Vessel-Membrane-Tissue (VMT) Solver 
The VMT solver provided far more capabilities than COMSOL and was both over 500 
times faster than COMSOL and able to solve cases that COMSOL could not. Using the 
VMT solver we were able to resolve all the needed cases to sufficient accuracy to 
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accurately and unambiguously locate the delineations between our 3 observed behaviors. 
The VMT solver is comprised of four distinct components used in combination: 1) a 
graded mesh to adequately resolve thin boundary layers; 2) a change of unknowns that 
enabled evaluation of steady states in tissue and membrane layers through a highly 
accelerated time-stepping procedure [231]–[234]; 3) an on-and-off fluid-freezing 
methodology that allowed for efficient treatment of the multiple-time scales that exist in 
the problem; and 4) the Alternating Directions Implicit (ADI) method for solving PDEs 
[234].  
 
To resolve the thin boundary layer that can form at the interface between the vessel and 
the endothelial layer, a typical Cartesian mesh was not adequate. Instead, the VMT 
method used a graded mesh implemented through an exponential change of unknowns of 
the form  
(33) ,  and 
(34) ,    ,    . 
To numerically resolve advection in the vessel, we began by using a small time step, 
. This presented a problem, however, because diffusion in the membrane and 
tissue can be small. Therefore using this time step required a long simulation time in 
order for the concentration to reach steady state. If the time step was taken to be much 
larger, we risked being unable to resolve ferrofluid advection in the vessel. To overcome 
this difficulty, we periodically ‘froze’ and ‘un-froze’ the concentration in the blood 
vessel. Freezing occurred once the concentration in the blood vessel approached steady 
state allowing for only the concentration in the membrane and tissue to be evolved. 
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Evolution of the concentration in only the membrane and tissue continued until the 
freezing approximation was no longer accurate, at which time we unfroze the 
concentration in the blood, and evolved the entire system at a significantly reduced time-
step until freezing could be performed again. The process was repeated until steady-state 
in the complete system was reached.  
 
In order to quickly obtain steady states in the membrane and tissue regions for each 
frozen vessel concentration, we performed a transformation that allowed us to take 
advantage of a fast steady-state solver based on selection of adequately chosen, very large 
time-steps. The required transformation was a change of unknowns 
(35)  
that eliminated the magnetic term in the PDE for the membrane and tissue, converting the 





We then selected time-steps in a form described in [263], that is (36) 
(37)  
where 
(38) ,     
 is the step size in the -direction in the membrane, and  is the iteration number. This 





An essential element of the overall VMT solver was the Alternating Directions Implicit 
(ADI) methodology first introduced in [231]–[234]. Based on reducing a given PDE into 
separate ODEs through the factorization of terms associated with a particular variable, 
ADI methods require line-by-line solutions of small sets of simultaneous equations. The 
key feature of these methods is their unconditional stability, thus permitting our VMT 
solver to avoid the extremely small time-steps imposed for stability by explicit schemes 
in the presence of small diffusion coefficients and allowing the use of the efficient time-
stepping scheme described earlier. The ODEs generated from this method can be solved 
by using a variety of methods. Because of the rectangular geometry being considered for 
the VMT solver, a standard Finite Difference approach was used. For general (e.g. 
curved) domains, another approach is required. The only available methodology that 
gives rise to unconditionally stable numerics for the Alternating Directions method in 
general non-rectangular domains is the Fourier Continuation-Alternating Directions (FC-
AD) approach introduced in [259]. By solving the ODEs generated in the ADI algorithm 
through the use of Fourier Continuation methods [264], the FC-AD algorithm has the 
ability to yield high-order accurate, unconditionally stable solutions in essentially linear 
time. The FCA  algorithm is currently being implemented for future simulations of flow 
through more complex vasculature geometries and will be presented in a forthcoming 
chapter, [260]. 
 
2.10 Determination of Experimental Domains 
In vivo experiments often contain a wide range of physical variables that fold into the 
development of the three non-dimensional numbers. These numbers are dictated by the 
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biology of the system studied and include items such as varying blood vessel widths, 
blood vessel velocities, and diffusion coefficients within various tissues, membranes, and 
blood vessels. Typically, information is not known about the exact physical variables 
experienced by every nanoparticle within the animal or human at any specific time. Some 
particles can be within liver regions, while others are floating within skin tissue. 
Therefore, the analysis of the entire biological system must include educated estimates 
for the expected range of all the key non-dimensional numbers. Our three non-
dimensional numbers are written again below with the biologically varying parameters 
marked by a double underline: 
(39) 
Magnetic Force at Centerline
Sto es  rag Force at Centerline
 
(40) 
 lood  essel idth   Maximum  lood  elocity
Total  iffusion Coefficient of Particles
 
(41)  
Minimum  iffusion Coefficient in Membrane or Tissue
Total  iffusion Coefficient in  lood
 
 
2.10.1 Magnetic-Richardson Number Range 
As shown in equation (39), the magnetic-Richardson number is only dependent upon one 
biological variable: the centerline blood velocity. Therefore the range of the magnetic-
Richardson number is as follows 
(42)  





denote the maximum and minimum of this velocity across physiological conditions, at 




2.10.2 Renkin Reduced Diffusion Coefficient Range 
Equation (41) illustrates the fact that the Renkin reduced diffusion coefficient is 
dependent upon the diffusion in the membrane, the diffusion in the tissue, and the 
scattering diffusion coefficient due to blood vessel size and velocity. The tissue and 
membrane diffusion coefficients are properties of the tissue and can range from a lower 
bound of ‘zero’ when the particle is larger than the membrane pores or tissue interstitial 
spaces, to an upper bound equal to the diffusion coefficient within the blood. The 
scattering diffusion coefficient can be estimated by using the following formula [131] 
(43)  
where the dimensionless coefficient is , the red blood cell radius is 
 m, and  is the shear rate at the vessel wall. Therefore the range for 





2.10.3 Mass Péclet Number Range 
The mass Péclet number varies with more complexity than the other two numbers as is 
evident from equation (40). The numerator varies not only with the centerline velocity of 
a vessel but also with the diameter of that vessel. Physiologically the velocity is also 
dependent upon the diameter of the vessel and the exact shape of this dependency is not 
linear. In addition the denominator is also dictated by the scattering diffusion coefficient 
that is governed by the vessel diameter. From equations (39) and (41), the needed 











To understand the shape of the mass Péclet curve, the relationship between the vessel 
diameter and centerline blood velocities must be known or estimated. For some 
organisms, i.e. humans, this relationship is well known [265] and appropriate bounds for 
these data points can be determined. For other organisms, i.e. rats, the relationship is not 
well known and bounds must be estimated more roughly to allow all possibilities. Figure 
5 shows the relationship within humans for the vessel diameter to the vessel velocity 
[265] with our two chosen bounding curves for the data shown.  
 
 
Figure 5: Relationship between vessel diameter and blood vessel velocity within humans [265]. 
Our chosen upper and lower limits to bound the data are shown. 
Upper Limit 
 y = 0.108x1.328 
Lower Limit 




























The combination of these ranges for the non-dimensional numbers generates the shape of 
the experimental domains seen in Figure 15 of the main text. These domains are simple 
(conservative) rectangles when only general physiological information is known 
(Bergemann, Widder), they are tighter curved domains for the situation in humans 
(Lübbe) where more specific physiological information is available.  
 
2.11 Comparison of COMSOL versus VMT 
Up to the accuracy possible in COMSOL, the two numerical methods provide the same 
answers. Below we show two side-by-side comparisons: one easy case in which the 
COMSOL solution accuracy is sufficient (here there is a very good match between 
COMSOL and VMT) and one medium-difficulty case where COMSOL was able to find 
a solution but the accuracy of VMT is better. For hard (high Péclet number) cases, 
COMSOL cannot provide a solution and VMT is the only option.  
 
 
Figure 6: Easy case at a , ,  . Cross-sectional magnetic nanoparticle 
concentration for steady state for both COMSOL and the VMT method. The percent error is 





Figure 7: Medium case at a , ,  . Cross-sectional magnetic 
nanoparticle concentration for steady state for both COMSOL and the VMT method. The percent 
error is calculated by (CComsol – CVMT)/CVMT. 
 
2.12 The Three Prototypical Behaviors 
Each simulation of equations (24), (25) and (26) calculated the time sequence and ending 
equilibrium concentration of ferromagnetic nanoparticles as a function of location in 
blood and tissue. From this concentration data, cross-sectional plots spanning the 
diameter of the tissue-vessel system were generated. By varying the three non-
dimensional numbers, three distinct particle behaviors were observed. These behaviors 
were then delineated on a plot of Renkin reduced diffusion coefficient versus magnetic-
Richardson number for a given mass Péclet number (Figure 9). Péclet number 
dependence is subsequently shown in Figure 10 and Figure 11.  
 
The three prototypical behaviors are shown below with an early, intermediate and steady 





Figure 8: The three prototypical behaviors: A) magnetic force dominated case ( ,  ), 
B) velocity dominated case ( ,  ), and C) boundary layer formation ( , 
 ). (A) The magnetic force dominated case shows a cross-sectional concentration of the 
magnetic nanoparticles for three times at  seconds (early), 0.3 seconds (middle), and at 
equilibrium, at . Particles are pulled towards the magnet and out through the bottom of 
the tissue resulting in a constant concentration equal to the blood inlet concentration. Here the 
tissue diffusion is set to equal the diffusion in the endothelial membrane. (B) Velocity dominated 
shows a cross-sectional concentration of the magnetic nanoparticles for three times at  
seconds (early), 18 seconds (middle), and at equilibrium, at . Particles are washed out 
before they generate a significant boundary layer along the vessel wall. At long times diffusion 
equilibrates the concentration between tissue and blood. Here the tissue Renkin number is set at 
   , which means it is ten times as easy for particles to diffuse through tissue than through 
the endothelial membrane. (C) Boundary layer formation shows a cross-sectional magnetic 
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nanoparticle concentration for three times at  seconds (early), 30 seconds (middle), and at 
equilibrium, at . (i) The steady state profile for . Here the particle 
concentration is shown on the same linear scale as in other time snap shots. (ii) The steady state 
profile for a higher magnetic-Richardson number, for . Here both the particle 
concentration and the cross-sectional plot are shown on a log scale. In both boundary layer cases 
(  and ) the particles build-up along the vessel membrane on both the vessel side 
and within the membrane. The boundary layer forms very rapidly. In (ii) the membrane particle 
concentration is sufficiently high to cause a concentration in the tissue greater than the vessel 
inlet concentration. In both (i) and (ii) the tissue Renkin number is set at      which means 
it is ten times as easy for particles to diffuse through tissue than through the endothelial 
membrane. 
 
2.12.1 Magnetic Force Dominated Behavior 
In this regime the applied magnetic forces dictate particle behavior. Here the magnetic 
forces control the transport of the particles irrespective of the blood drag forces. It turns 
out that when the magnetic force is dominant and is constant, the equilibrium 
concentration will approach a constant value throughout the tissue-vessel system being 
considered. The constant downward magnetic force pulls the nanoparticles from the 
blood vessel inlet downwards into the tissue and out the bottom, and any transient 
concentration gradients are smoothed out by diffusion. Here the maximum concentration 
never exceeds the inlet concentration, as shown in Figure 8(A). This is a reasonable result 
since we are assuming the blood vessel sees a constantly replenished supply of 
nanoparticles (from the rest of the body). The applied (approximately constant) magnetic 
force and diffusion then serve to distribute that concentration of nanoparticles equally 
throughout the region of tissue below the blood vessel and above the magnet. Here the 





2.12.2 Velocity Dominated Behavior 
In velocity or Stokes drag dominated behavior the blood drag force on a stationary 
particle far exceeds the magnetic and diffusion forces. Here the blood velocity washes the 
particles out the back of the vessel before magnetic forces have had a chance to affect 
them, as shown in Figure 8(B). Since the inlet of the vessel is always refreshing the fluid 
flow with the inlet concentration, the overall concentration in the blood remains near that 
of the inlet concentration. Particle concentration in the tissue is much lower even for long 
times but eventually, by diffusion, reaches a steady state where the concentration in the 
tissue is equal to that in the blood vessel. This case acts as if there is no magnet at all 
since blood forces far exceed its effect. Due to the speed of each effect, different time 
scales for the ‘early’ and ‘middle’ frames were chosen in Figure 8 so that the middle 
panels could illustrate the intermediate concentrations of each behavior.  
 
2.12.3 Boundary Layer Formation 
The boundary layer regime occurs when the magnetic and blood drag forces are 
comparable; it is the most interesting case. Figure 8(C) illustrates this case. In this 
regime, the nanoparticles build-up near the vessel wall, either inside the vessel where the 
blood velocity is near zero and/or in the membrane next to the vessel build-up (by 
diffusion). The concentration elsewhere in the blood essentially remains at the set inlet 
concentration. In this case the concentration of nanoparticles near the vessel wall can 
exceed the inlet concentration by double or higher. Compared to the previous velocity 
dominated behavior, which also exhibits a slight build-up of particles along the vessel 
wall, we define the ferrofluid behavior as forming a boundary layer when 
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(47) .  
In addition, it is this case which has the potential to increase the nanoparticle 
concentration within the tissue to above the unit (blood inlet) concentration, Figure 
8(C(ii)). It is this boundary layer regime that illustrates how a focusing of nanoparticles is 
possible even if the magnetic force is substantially smaller than the centerline drag force 
(as in the rat example of Figure 2b). 
 
While this behavior is desired for magnetic drug targeting, there are important 
considerations when a large concentration build-up occurs within the vessel membrane. If 
the particles carry a therapeutic compound, it is possible that undesired treatment of the 
vessel membrane will occur. This potential side effect is important to evaluate while 
developing a magnetic drug targeting treatment. 
 
2.12.4 Mapping the Behavioral Space 
Summary of Behaviors under Non-dimensional Number Variations 
For ferro-magnetic nanoparticles under the action of diffusion, blood convection, and a 
magnetic force in a straight idealized blood vessel surrounded by tissue, we find three 
behavior regimes: magnetic dominated, blood velocity dominated, and a boundary layer 
formation regime.  Only in the boundary layer case is the ferrofluid concentrated by the 
applied magnetic field (Figure 8(C)). In the magnetic and velocity dominated cases it 
escapes, either out the bottom of the tissue or through the blood vessel outlet. In these 
two cases it is only the constant re-supply of ferrofluid at the vessel inlet that provides the 





Figure 9: Magnetic nanoparticle behaviors as a function of the magnetic-Richardson and Renkin 
reduced diffusion coefficient non-dimensional numbers. The mass Péclet number was held 
constant. Three regions are shown: the magnetic dominated region at the top (the thin solid blue 
region); the velocity (Stokes drag) dominated region on the left (dashed lines region); and the 
boundary layer formation region on the right (wavy lines region). Notice that boundary layer 
build-up behavior is still possible even if the magnetic force is just 0.01% of the Stokes drag force 
at the vessel centerline, i.e. at . The boundary between the velocity and boundary 
layer build-up regions is diffuse as shown schematically by the thickness of the fuzzy gray line 
separating them.  
 
For the simulation results below, the behavior of any case is grouped into one of these 3 
regimes by analyzing the equilibrium concentration profile across the vessel cross-
section. If the steady state cross-sectional concentration is uniformly equal to the inlet 
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concentration then the behavior is classed as magnetic dominated; if the steady state 
vessel wall concentration build-up is less than + 1% of the inlet concentration then it is 
classed as velocity dominated; and if the cross-sectional concentration exhibits high 
vessel wall concentration build-up then it is classed as boundary layer formation. In all 
cases, this classification exactly matches the qualitative classification based on transient 
and equilibrium behavior shown in Figure 8.  
 
According to the range of dimensional parameters given in Table 1, the three key non-
dimensional numbers were correspondingly varied between 10
-8
 and 30 for the magnetic-
Richardson number, between  and 1 for the Renkin reduced diffusion coefficient, 
and between 30 and  for the mass Péclet number. To examine the behaviors at a 
constant mass Péclet number, simulations were conducted over a logarithmically-spaced 
grid of 7 magnetic-Richardson and 5 Renkin numbers. Then, to determine the 
dependence on the Péclet number, the Péclet number was varied over 7 values while the 
Renkin number was held constant and the Richardson number was varied. This provided 
a general understanding of the non-dimensional number space. To precisely identify the 
locations of delineations between the 3 behavioral domains, simulations were completed 
over two fine grids. First, a fine grid of 10 magnetic-Richardson, 1 Renkin, and 9 Péclet 
numbers was used. Then, a grid of 13 Renkin, 6 magnetic-Richardson, and 7 Péclet 
numbers was used. In total, this yielded 720 cases that were simulated and analyzed. 
Figure 9 and Figure 11 below summarize the results and show the behavior delineations. 





Figure 10: Behavioral dependence upon mass Péclet number. As the mass Péclet number 
decreases, the delineation between behavior types shifts to the right (to larger magnetic-
Richardson numbers). In addition, at lower mass Péclet numbers, the magnetic dominated region 
increases in size towards lower Renkin reduced diffusion coefficients. 
 
Figure 9 illustrates the behavior trends at a mass Péclet number of 333 (i.e. the 
convection of the nanoparticles is 333 times faster than their diffusion through the blood 
vessel width). It shows the regions in which the three behavior types occur. The velocity 
dominated region occurs at low magnetic-Richardson numbers where the Stokes drag 
forces are much larger than the magnetic forces. Meaning, there is a cutoff value at which 
the Stokes drag forces are able to overcome the magnetic forces sufficiently so that 
concentration build-up within the vessel is negligible. In contrast, at moderate and higher 
magnetic-Richardson numbers, the Stokes drag forces are not as effective and a highly 
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concentrated boundary layer develops. However, as the Renkin reduced diffusion 
coefficient is increased, this ferrofluid boundary layer region occurs less readily, because 
any build-up of particle concentration in the endothelium can more easily diffuse out into 
the vessel and be swept away by blood convection. Thus the velocity dominated behavior 
will also occur in circumstances where the membrane provides a weaker barrier to 
particle movement described by a larger Renkin reduced diffusion coefficient. This is 
shown by the curving gray line in Figure 9. But, at near unity Renkin reduced diffusion 
coefficients, the diffusion coefficients in the blood, endothelial membrane, and tissue are 
approximately the same and the particles see no difference between these three media 
leading to magnetically dominated behavior where magnetic forces pull particles 
downwards through the membrane and tissue towards the magnet. 
 
Figure 10  illustrates the shift in behavior regimes with changing mass Péclet number. 
The changing Péclet number moves the behavior regimes on the magnetic-Richardson 
and Renkin axes. As the mass Péclet number decreases, i.e. as particle diffusion increases 
compared to their convection, the boundary between the velocity dominated and the 
boundary layer region shifts towards larger magnetic-Richardson numbers where larger 
magnetic forces are required to overcome the Stokes drag forces. As the particles are able 
to move more freely due to higher diffusion effects, they do not easily concentrate within 
the vessel and require larger magnetic forces to retain them near the vessel wall. In 
addition, it can be seen that at low mass Péclet numbers ( ), the magnetic dominated 





Figure 11: The delineation of the boundary between the velocity dominated and boundary layer 
formation regimes is denoted by  (left panel, it is measured along the magnetic-Richardson axis 
at a Renkin coefficient of ) and it depends on the mass Péclet number (right panel). The 
stated equation provides a convenient fit of  versus  for the curve shown in red.  
 
The shift in the velocity-dominated/boundary formation behavior delineation, , due to a 
mass Péclet number change can be approximated by a power law fit 
 that has an  value of 0.99998 (Figure 11). As the mass Péclet number 
increases, the delineation shifts to smaller magnetic-Richardson numbers. At a mass 
Péclet number of ,  and the characteristic behavior will be boundary 
layer formation. This suggests that at very large mass Péclet numbers (at very high blood 
velocities in big vessels) the nanoparticles will build-up along the blood vessel even with 
very small applied magnetic forces. This is because we assume that the particles continue 
to be supplied at a constant concentration at the inlet of the blood vessel (Figure 3) from 
the rest of the body. As they flow quickly to the right, the downward magnetic force 
brings them to the blood vessel wall predicting a sharp boundary layer due to the now, in 
comparison, small effect of diffusion. In practice when there are very large blood 
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velocities, only few nanoparticles immediately near the blood vessel wall will be 
captured during the short time that the nanoparticles remain within the vessel before they 
flow out the back. This leads to a very thin boundary layer formation of only a few 
particles at high mass Péclet numbers.  
 
 
Figure 12: Concentration at the blood vessel wall ( ) versus magnetic-Richardson 
number for a given mass Péclet number. Curves associated with each constant mass Péclet 
number are shown in blue. The red line illustrates a concentration cutoff requirement of  
for boundary build-up behavior. Any magnetic-Richardson number larger than the intercept 
between the red line and blue curve for a given Péclet number (shown by a downwards purple 
triangle) will exhibit a boundary build-up behavior. The dotted orange line shows cutoffs for a 
higher vessel wall concentration requirement of . 
 
Figure 12 can be used to determine the blood vessel concentration ( ) for a 
given magnetic-Richardson number and mass Péclet number. The blue curves correspond 
to constant mass Péclet numbers and illustrate the blood vessel wall concentration's 
dependence upon magnetic-Richardson number. The concentration cutoff requirement of 
 (equation (47)) is depicted by a red line, while an alternate equally-valid cutoff 
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requirement of  is depicted by a dotted orange line. While equation (47) was used 
to define the behavior boundary delineation, a larger blood vessel wall concentration 
could easily be chosen and determined by Figure 12. 
 
Figure 9, Figure 10, Figure 11, and Figure 12 can be used to quickly look up the expected 
behavior of any magnetic drug focusing experiment. For an in vivo setting, from a 
knowledge or expectation of the experimental parameters, the magnetic field strength, the 
magnetic field gradient, particle size, considered blood vessel depth, width, blood 
centerline velocity, and membrane pore size, the designer should compute or estimate the 
magnetic-Richardson number (equation (27)), the Renkin reduced diffusion coefficient 
(use the smaller of the two Renkin numbers between the endothelial membrane (29), and 
the tissue (31)), and the Péclet number (equation (28)). Then look up the resulting 
expected behavior in Figure 9 or Figure 10. (Use the  fit equation of Figure 11 to find the 
location of the boundary between the velocity and boundary layer formation cases if your 
Péclet number is not one of those shown in Figure 10.) 
 
The analysis above predicts experimental results in the literature extremely well, for both 
in-vitro and in vivo cases (see the next section). However, it still treats an idealized case. 
Additional model features, such as pulsatile blood flow, curved blood vessels, particle 
agglomeration, and skin boundary conditions are included in Section 2.15. Except for the 
effect of skin, which can significantly distort the ferrofluid concentration profile for 
blood vessels very near it, we find that none of these effects make a substantial difference 
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– the behavior is still magnetic dominated, velocity dominated, or forms a boundary layer 
essentially as outlined in Figure 9 and Figure 11.  
 
2.13 Comparison with Experiments 
Several experimental studies currently published ranging from in-vitro glass vessels to in 
vivo animal targeting have been studied and compared to our predicted behavior. Each 
experiment can be compared against Figure 9, Figure 10, Figure 11, and Figure 12. We 
find excellent agreement between prior published experimental observations and our 
predictions – in fact, there are multiple cases where we can now explain behavior that 
was not previously understood.  
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Table 3: Parameters for experimental studies reviewed in Sections 2.13.1 to 2.13.5. Bolded items 
are quantities used to determine our three characteristic non-dimensional numbers. Here 'cp' and 
‘M’ are used to denote capillary and major blood vessel properties respectively. ‘Sm’ and ‘Lg’ 
denote small and large ranges. ‘N/A’ denotes inapplicable variables because the experiments 
were completed within glass tubes. ‘--’ denotes un nown variables that are not needed because 
the magnetic forces were either supplied or could be otherwise be calculated.  
Parameter Ganguly Xu Widder Bergemann Lübbe 
Particle Radius   5 nm 10 nm 7 nma |0.5 µmb 125 nm 50 nm 
Distance to 
Magnet 
  1 mm -- 5 mm 1 mm 0.5 cm 






1 x 106 A/m 
-- 
0.55 T 
4.3 x 105 A/m 
0.5 T 
3.9 x 105 A/m 
0.8 T 
6.3 x 105 A/m 
Magnet Length   6 cm -- -- 5 cm 3 cm 
Magnetic Force   4 x 10
-5
 pN 2.6 x 10
-5








5.3 mm/s * ≈ 0.1 mm/s ≈ 0.1 mm/s ≈ 0.5 mm/s 
M 100 mm/s ** ≈ 20 cm/s ≈ 20 cm/s ≈ 10 cm/s# 
Vessel Diameter  
cp 10 mm 
(3effective) 
2 mm 
 6 μm  6 μm  7 μm 
M  1 mm  1 mm  5 mm 
Fluid Viscosity   0.001 Pa s 0.001 Pa s 0.003 Pa s 0.003 Pa s 0.003 Pa s 
Stokes Drag Force  
cp 
0.5 pN 
1 pN * 3 pN 0.7 pN 1.4 pN 
M 20 pN ** 6 nN 1.4 nN 0.28 nN 






0 0 0 






0 0 0 
Lg 1x10-13 m2/s 6x10-13 m2/s 6x10-13 m2/s 
Tissue Diff. Coef.  
Sm 
N/A N/A 
0 0 0 













































9 x 10-5 
2.5 x 10-5 * 0.04 0.14 0.025 





3.6 x 105 
5.3 x 105 4 x 103 1 x 103 3.5 x 103 







 0  0  0 





1.6 x 10-6 
1 x 10-6 2.2  x 10-5 5 x 10-5 2.4 x 10-5 
M 7.2 x 10-8 2.2 x 10-6 2.2 x 10-6 4.4 x 10-7 
(*) 100% retention of particles; (**) 15% retention of particles; (
#
) ignores vena cava and 
aorta velocities; (
a
) radius of magnetite particle; (
b




2.13.1 Analyzing Ferrofluid Transport for Magnetic Drug Targeting [228] 
Ganguly et al. attempted to capture ferrofluid particles within a glass tube containing a 
moving fluid by using a permanent magnet located beneath the tube. The set-up is 
analogous to the one presented in this chapter allowing for an easy comparison. Table 3 
shows the parameters used in this experiment and the corresponding values of our three 
non-dimensional numbers.   
It is important to note that in this experiment, the particles are injected into the bottom 
1/16
th
 section of the glass pipe. They continue axially along this radial location until they 
encounter the magnet. Therefore, although the maximum velocity of the fluid within the 
pipe is 2.5 cm/s, the maximum fluid velocity experienced by the particles is 4.8 mm/s 
(assuming a parabolic velocity profile). This produces the , , and   non-dimensional 
numbers noted in the ‘Ganguly’ column of Table 3. 
 
Here the Renkin reduced diffusion coefficient is not applicable because there is only a 
single vessel domain. Thus, the behavior of the particle concentration is dependent solely 
upon the magnetic-Richardson and mass Péclet numbers. The mass Péclet number leads 
to the estimation of the velocity/ boundary layer delineation position . By comparing 
this value to the magnetic-Richardson number, the behavior type can be determined. 
Since  this places the predicted behavior squarely within 
the boundary layer formation regime (even though the centerline Stokes drag far exceeds 
the maximal applied magnetic force, ). We thus correctly predict the 
experimentally observed boundary-layer formation region where the usual Stokes drag 




2.13.2 Site-directed Research of Magnetic Nanoparticles in Magnetic Drug 
Targeting [106] 
Similar to the experiment described above, Xu et al. captured moving nanoparticles 
within a glass tube using a permanent magnet. Xu's experiment, in contrast to Ganguly, 
includes a magnet located farther away and a spherical capturing chamber is used (the 
glass tube spreads out into a spherical bulb and then goes back to a straight tube). The 
bulk fluid velocity was adjusted, and the retention percentage within the capturing 
chamber was quantified for various speeds. The authors noted that the retention was 
100% at a 5.3 mm/s and ≈ 15% at 100 mm/s. The parameter values for these cases are 
shown in Table 3 under 'Xu'. 
 
Similar to Ganguly’s experiment, due to a single vessel domain the Ren in reduced 
diffusion coefficient is not applicable. As above, the delineating boundary position  and 
the magnetic-Richardson number  are compared for the two cases Xu et al. considered. 
When the fluid velocity is 5.3 mm/s, the magnetic-Richardson number is x 25 larger than 
the behavior delineation . This comparison implies behavior well within the boundary 
layer regime. However, to correlate this behavior to the measured capture percentage 
requires determination of the boundary thickness that develops before the capture region. 
Since nanoparticles were not pre-mixed with the fluid but instead injected into the flow, 
the particles retain their initial injection position within the flow section. If the particles 
are assumed to be in the lower quarter of the flow near the magnet (a reasonable 
assumption if the particles were injected with minimal velocity), then the boundary layer 




flowing at 5.3 mm/s then the capture percentage predicted by a simulation of this case 
was ≈ 100% which matches the measured 100% retention by Xu et al. When Xu set their 
velocity to the higher 100 mm/s value, only 15% of the particles were captured in their 
experiment. In this case the delineating boundary position  is a little closer to the 
magnetic-Richardson number (  is  greater then ). The percentage captured 
predicted by a simulation of this case was 13%, which closely matches the 15% retention 
measured by Xu et al. 
 
Xu et al. commented that the standard force comparison (capture force requirements 
versus magnetic forces) did not predict the occurrence of their observed behavior. They 
suggested that the particles agglomerated to generate large magnetic forces. While 
agglomeration may increase magnetic force upon the concentration of particles (see 
Section 2.15.5), our more subtle comparison of magnetic forces versus Stokes drag forces 
away from the channel centerline is sufficient to correctly predict Xu’s results.   
 
2.13.3 Tumor Remission in Yoshida Sarcoma-Bearing Rats by Selective 
Targeting of Magnetic Albumin Microspheres Containing Doxorubicin [36], 
[266] 
Widder et al. conducted in vivo experiments on rats to target tumors located on the tail 
using magnetically responsive microspheres and an external magnet. These microspheres 
are composed of a coat of albumin surrounding magnetic material (magnetite 
nanoparticles with 10-20 nm diameters) and a chemotherapy agent (doxorubicin).  
Magnetic material composition within microspheres has a wide range but is typically 
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between 20% to 50% by weight (w/w) [195]. Knowing the density of the albumin shell 
(1.36 g/ml [267]), the number of particles within a 1-micron sized microsphere can be 
approximated (≈ 6000 for 20% w/w). They injected the ventral caudal artery near the rat 
tail tumors with these magnetically responsive albumin microspheres. The permanent 
bipolar adjustable gap magnet was positioned around the tumor and held for 30 minutes. 
For cases in which the magnet was applied, the rats saw decreased tumor size over the 
length of the experiment. Without a magnet, the rats usually had an increased tumor size 
and eventually died during the experiment. These data suggests that the magnetic 
particles were concentrated by the magnet at the tumor location. 
 
Table 3 shows the numbers for this experiment. There is a range of appropriate magnetic-
Richardson numbers here, from  (for small capillaries) to  (for 
major vessels). Likewise, the Péclet number varies from  to . Finally, the 
Renkin diffusion coefficient, determined from Equation (30), ranges between   
when in sinusoidal capillaries (liver, spleen and bone marrow) and essentially zero when 
in continuous capillaries and fenestrated capillaries. For tumors with leaky vessels that 
have an average membrane pore size of 600 nm, the maximum Renkin number is 
 . Based on this, we predict that the behavior delineation position will be 
 for capillaries and  in large vessels. Since the delineation 
position is well to the left of the magnetic-Richardson number, the behavior will 
primarily be boundary layer formation. We thus predict, except for situations where the 
Renkin number approaches unity (for damaged or sinusoidal vessels), that the particles 
can be accumulated to higher concentrations due to a boundary layer formation in the tail 
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for all physiological conditions – for small and large vessels, with fast and slow blood 
vessel velocities. Since the rat tumors decreased in size due to magnetic forces, it is 
reasonable to conclude that the magnetic particles were targeted into and around the 
tumor location. This matches our theoretical predictions above.  
 
2.13.4 Preclinical Trials Experiences with Magnetic Drug Targeting [31], [220]  
The rat experiments of Figure 2b are used as an example throughout this chapter. The 
non-dimensional numbers for these experiments are summarized in Table 2 under 
‘ ergemann’. Here, for a 1 mm focusing depth, the magnetic-Richardson number  
varies from 0.14 in capillaries to  in large vessels and the Péclet number varies 
similarly from 1000 to . The Renkin reduced diffusion coefficient is effectively 
zero for continuous and fenestrated capillaries. In sinusoidal capillaries, the Renkin value 
is approximately   and within lea y vessels with an average pore size of ≈ 600 
nm the Renkin value is  . From these values, the behavior delineation position is 





Figure 13: Predicted ferrofluid concentrations for 1 mm deep magnetic targeting in the rat 
experiments of Figure 2b. An initial, intermediate, and final (steady-state) time are shown for 
capillary (slowest blood flow, mm/s) and a major blood vessel (fastest blood flow, 
 cm/s). Contrary to the crude estimate in the introduction, magnetic focusing is 
predicted even in the major blood vessels.  
 
Since  far exceeds , both capillaries and large vessels at  1 mm depth will experience 
a boundary layer formation behavior, except for situations where the Renkin number 
closely approaches unity (for damaged vessels) then velocity dominated behavior occurs. 
Figure 13 shows the predicted transient and equilibrium ferrofluid concentration for a 
capillary and major blood vessel at 1 mm depth near the magnet. Ferrofluid focusing is 
seen near the blood vessel wall for both the slowest (capillary) and the fastest (major 




2.13.5 Clinical Experiences with Magnetic Drug Targeting [14] 
Lübbe has performed phase I human clinical trials for the treatment of head, neck and 
breast cancer shallow (near the skin) tumors (last column in Table 3 under ‘Lübbe’). At 
the surface of the tumor (at a 0.5 cm distance from the magnet) the magnetic-Richardson 
number varies from 0.025 in capillaries to  in large vessels and the Péclet 
number varies similarly from 3500 to . The Renkin reduced diffusion coefficient 
is effectively zero for continuous capillaries. In fenestrated capillaries and sinusoidal 
capillaries the Renkin value is respectively   and  . Within leaky vessels 
with an average pore size of ≈ 600 nm the Ren in value is  . From these values, 
the boundary position delineation is predicted to be  in capillaries and 
 in large vessels. 
 
We find that the magnetic-Richardson number  is several orders of magnitude larger 
than the behavior delineation position value  at the surface of the tumors. Therefore, a 
boundary layer formation behavior is predicted at tumor surfaces. A boundary behavior, 
however, will still occur at some distance within the tissue as long as the magnetic force 
upon those deeper particles keeps the magnetic-Richardson number within the boundary 
layer formation regime. The depth of boundary layer formation can be determined within 
a given force field for physiological blood velocities (capillaries and large vessels) as 
shown in Figure 14. Up to a depth of 5 cm and 7.9 cm for large vessels and capillaries 
respectively, the particles will exhibit a boundary layer behavior. After these cutoff 
distances, the nanoparticles will exhibit a velocity dominated behavior and will be 
washed away by blood flow in major and minor blood vessels respectively. Between a 
 85 
 
distance of 5 cm and 7.9 cm, the particles will transition from a complete boundary layer 
behavior to a velocity dominated behavior getting washed away first in larger vessels that 
exhibit a higher blood velocity.  
 
 
Figure 14: Focusing depth for the Lübbe 0.8 Tesla human clinical trials experiments. The magnet 
is positioned a distance of 0.5 cm from the skin. The predicted depth of the boundary layer 
formation, transition, and velocity dominated regions is shown. For particles deeper inside the 
body, the magnet is unable to exert a sufficient magnetic force (shown on the right) to generate a 
ferrofluid boundary layer behavior. Focusing of magnetic nanoparticles is predicted to be possible 
in major vessels up to a 5 cm depth, and in capillaries to a greater 7.9 cm depth.  
 
During Lübbe’s clinical trials, nanoparticles were observed to be targeted approximately 
within 5 cm [268] of the magnet located at the tumor site by magnetic resonance imaging 
immediately after treatment (Figure 2a), a finding that is consistent with our predictions 
here [31]. If the same sized particles with a stronger and larger magnet were used, such as 
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a 2 Tesla (MRI strength) electromagnet with a 25 cm diameter, 20 cm length and 5 cm air 
core, then we predict that targeting would be possible to a depth of 20 cm in large vessels 
and to a depth of 30 cm in capillaries. 
 
2.14 Summary of Cases 
Figure 15 shows a graphical representation of all the experimental cases considered in 
this chapter and compares them to our predicted behavior. For the human clinical trials 
(Lübbe), the experimental domain is represented more accurately as being curved 
because the magnetic-Richardson number and the mass Péclet number both vary together 
across human physiological conditions: blood velocity is higher in bigger blood vessels 
[265]. This affects both the Richardson and Péclet numbers (see equations (27) and (28)). 
It was possible to quantify the upper and lower bound curves for human experiments 
(Lübbe), but not for animal experiments (Widder and Bergemann), because more 
published physiological data is available for humans. A detailed analysis and derivation 






Figure 15: Summary of experimental studies. The firmly shaded regions in green and blue denote 
the magnetic and velocity behavior domains. The boxed or curved boxed regions show the values 
spanned by each experiment. The dark shading (dark yellow in B, purple in C, and dark red in D) 
shows the region of the corresponding experiment that exists in the velocity dominated region. 
The light shading (light yellow in B, light purple in C, and pink in D) shows the region of the 
experiments where the concentration created in the tissue is greater than the vessel inlet 
concentration. The in-vitro experiments (A) exist entirely in the boundary layer regime. Widder 
(B) and Bergemann (C) have small portions in the velocity dominated region, only at small 
magnetic-Richardson numbers and high Renkin coefficients. Lübbe (D) extends into the velocity 
behavior domain when mass Péclet numbers and magnetic-Richardson numbers are small, and 
this extent increases as the Renkin coefficient increases.  
 
Figure 15 also shows where the magnet creates a concentration in the tissue that is greater 
than the systemic injected concentration. In the boundary layer domain, even though 
particles accumulate at the blood/membrane interface, there are some cases where that 
accumulation is high enough to create a  in the surrounding tissue, and others 
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where the accumulated amount is insufficient. The cases where more tissue accumulation 
occurs are influenced by the endothelium thickness to blood vessel diameter ratio, and 
this additional geometric consideration adds a further non-dimensional number that can 
be varied. In Figure 15, the lightly shaded regions (light yellow in B, light purple in C, 
and light pink in D) show the extent of the experimental domains that are predicted to 
have a tissue concentration greater than unity. Here we assumed a representative 
endothelium thickness to vessel diameter ratio, a ratio that corresponds to a typical 
arteriole. 
 
2.15 Relaxing Simulation Parameters 
Additional features can be added to relax simulation idealizations. These features 
sometimes make a quantitative difference to the nanoparticle concentration profiles but, 
with the exception of the skin boundary condition, they do not make a qualitative 
difference. The three behavioral forms still occur though their delineations can shift 
moderately depending upon the features added. 
 
2.15.1 No Extravasation through Blood Vessel Membrane 
First, there is a trivial case to consider when the blood vessel will not allow any particles 
to pass through the membrane into the surrounding tissue: i.e. no extravasation. This case 
can be modeled by forcing the flux normal to the blood vessel membrane surface to be 
equal to zero. Figure 16 shows how the two characteristic behaviors (velocity dominated 
and boundary layer formation) remain in effect in this case. The magnetic dominated 
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behavior, however, which requires particles to move from the blood into the tissue, is no 
longer possible.  
 
 
Figure 16: No extravasation through the blood vessel membrane. The characteristic behaviors still 
exhibit their defining characteristics within the blood vessel. The magnetic dominated case is no 
longer possible. Instead, when there is no extravasation (e.g. for particles bigger than blood vessel 
fenestrations) magnetic dominated behavior is replaced by a boundary layer type behavior. 
 
2.15.2 Pulsatile Blood Flows 
Flow in blood vessels is pulsatile [255], [269]–[272], its forward velocity increases and 
decreases as the heart pumps (see Figure 5(a) in [269] of an archetypal peak velocity 
waveform complied from 3560 cardiac cycles). We now include this blood velocity 
oscillation and show that it does not qualitatively change the 3 types of behavior we see – 
we still find a magnetic dominated, velocity dominated, and boundary layer regime.  
 
The waveform associated with high pulsatile cardiac blood flow was used to set the blood 
velocity in time. A choice of three heart rates was used (a resting heart rate of 1 Hz, 
1.5 Hz, and a rat heart rate of 6.75 Hz) and applied to three cases that produce the three 
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characteristic behaviors. Since magnetic drug targeting localizes particles to a region by 
use of a magnet held locally for minutes, e.g. [108], but blood pulsation occurs once 
every second, it is appropriate to consider the averaged effect that the pulsating blood 
flow will have on particle concentration. Figure 17 shows the time averaged concentration 
profiles taken for three heartbeats after a treatment window of one hour for the 9 chosen 
cases. 
 
In comparison to [273], we do not consider a significant ferrofluid inlet concentration 
where the ferrofluid can then become an obstacle to the incoming flow and therefore we 
do not expect recirculation regions to be created. This phenomenon can make the average 
of the pulsatile case differ from the steady inlet flow case. Based on the range of 
biological parameters, the relevant non-dimensional numbers possible range between 
0.01 (in capillaries) and 27 (in the largest vessels) for the Womersly number and the 
Reynolds number varies between 0.001 (in capillaries) and 3900 (in the largest vessels 





Figure 17: Pulsatile blood flow concentration profiles for the three characteristic behaviors 
experiencing three different heart rates (HR). For each pulsatile case, the concentration profile 
consists of the time average for three heartbeats after a treatment window of one hour. This 
concentration can be compared to the prior steady state concentrations when blood flow 
pulsatility is not considered. The three behaviors are qualitatively the same and further are also 
similar quantitatively. (For this 333 Péclet number case, the Womersley and Reynold numbers 
can vary between 0.01 to 0.19 and 0.001 to 2.6 respectively for physiological and practical 
engineering conditions, according to the parameters in Table 1.) 
 
Figure 17 shows that blood pulsatility under a uniform magnetic force field does not 
impact behavior delineation: the time-averaged concentration profiles remain in the 
magnetic dominated, velocity dominated, or boundary layer regime as they were in the 
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constant blood flow case. This result has allowed for the simplification of the 
physiological model to the cycle-averaged blood velocity experienced within that vessel, 
a simplification we have used throughout the chapter.  
 
2.15.3 Non-Uniform Magnetic Force Fields 
Previously, we treated the magnetic force as constant (see Figure 4). Here the exact 
magnetic field and the spatial variation in the resulting magnetic force on the magnetic 
particles is used. The magnetic force increases as the particles move closer to the magnet. 
Various parameters for a particular experiment will adjust how much the magnetic force 
increases in the blood vessel and surrounding tissue. These parameters include the size of 
the magnet, the size of the considered tissue-vessel system, and the distance of the tissue-
vessel system from the magnet. In this section we exactly solve the magneto-static 
equations (8) to (10) and plug the computed magnetic field  into equation (17) to 
state and solve the PDE for particle transport (previously the magnetic force  was 
assumed to be a constant pointing downwards). To quantify the deviation from a uniform 
magnetic force, we use the metric RM = FM,max  /FM,centerline where FM,centerline is the 
magnetic force along the blood vessel centerline and FM,max is the maximum magnetic 
force within the considered vessel-tissue domain (it occurs at the bottom of the domain 
nearest the magnet corners where the magnetic field gradients are the highest). To 
examine how non-uniform magnetic force fields affect the three prototypical behaviors, 
three case studies were simulated for a varying magnetic force ratio of RM = 2 and 10. 
Rm was varied by increasing the size of the magnet and reducing the distance between the 





Figure 18: Concentration profiles for various magnetic force ratios. Three cases were chosen that 
illustrated the prototypical behaviors (magnetic dominated, velocity dominated, and boundary 
layer formation behavior) and the magnetic force ratio was changed from RM = 1 to 2 and 10 by 
increasing the size of the magnet and reducing the distance between the vessel and magnet. The 
exact magnetic forces are shown as blue arrow overlays within each plot. The case of RM = 1 and 
2 show the arrow magnitudes in linear scale, while the case of RM = 10 shows the arrow 
magnitudes in log scale (an arrow with twice the length will have ten times the magnitude). 
 
Figure 18 shows how the magnetic force ratio does not affect the prototypical behavior. 
When RM = 1, the simulation is exactly equivalent to the cases considered in the main 
chapter. As RM increases, the maximum magnetic force at the bottom edge of the tissue-
vessel system increases. In the case of a magnetic dominated behavior, the magnetic 
force ratio has very little to no effect on the solution. For velocity dominated cases, the 
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vessel still maintains the inlet concentration value but the concentration in the tissue and 
membrane decreases due to increased pull from the magnet. Lastly, in the boundary layer 
formation cases, the vessel wall concentration simply increases. Since the vessel wall 
concentration at a given magnetic-Richardson number increases with the magnetic force 
ratio Rm, the behavior delineation position ( ) will shift left in Figure 11 as the magnetic 
force ratio increases. 
 
2.15.4 Curved Blood Vessels 
Blood vessels within any organism are rarely, if ever, straight. The idealized straight 
blood vessel used throughout the chapter was relaxed and two different curvatures were 
utilized to determine the variance of the characteristic behaviors. The blood vessel length 
in each case was kept constant, and the only geometric parameter that changed was the 
radius of curvature. As can be seen in Figure 19 below, the characteristic behaviors 
retained their defining qualities. The only difference in cross-sectional concentration was 
seen in the boundary layer formation cases where the slight curvature case experienced a 
modest increase in concentration compared to no curvature or large curvature. This was 
because a slight curvature contained a longer segment of blood vessel in which the 
particles are able to form a boundary layer leading to a higher concentration build-up 
over that particular segment. However, this increase in concentration only shifts the 





Figure 19: Curved blood vessels and the three prototypical behaviors. The curvature of the blood 
vessels does not affect the characteristic trend of the behaviors, but it can shift the behavior 
boundary delineation curve slightly. 
 
2.15.5 Particle Agglomeration 
Agglomeration of particles can be considered approximately within our current 
framework. To do so, we thin  of a ‘super-particle’ composed of  ferro-magnetic 
particles stuck together. The magnetic force on such a particle increases by a factor of 
. However, the diameter of the particle goes only as  since it takes  or  
particles to make a twice-as-big super-particle. Thus, the Stokes drag force increases by 
 and so the magnetic-Richardson number increases by  (see equation (27)). For the 
nanoparticles used in the rats of Figure 2b, if we consider a super-particle made up of 125 
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particles, the magnetic-Richardson number increases from 0.14 to 3.5. Since the super-
particle has a larger radius, the blood and membrane diffusivities,  and , will be 
smaller decreasing from  and  (for leaky capillaries with 600 nm 
pores) to  and 0 respectively. The scattering diffusion coefficient, , will stay 
the same, however, since it is only dependent upon the type of blood vessel. This causes 
the mass Péclet number to increase from 1000 to 6000. The Renkin coefficient will 
instead decrease from 0.36 to 0. One can now read-off the behavior of such a particle 
from Figure 9 and Figure 10 as before: clearly, a case that was previously velocity 
dominated could now fall into the boundary layer regime. In reality, during 
agglomeration there will be a statistical distribution of particle sizes, and chains can form 
instead of our simplified ‘super particles’. To analyze such cases correctly requires 
additional research.  
 
2.15.6 Skin Boundary Condition 
In animal and human trials, skin prevents magnetic particles from leaving the tissue. To 
model this case we enforce a boundary condition at the bottom of the tissue closest to the 
magnet that does not allow a flux of magnetic nanoparticles across it. As expected, this 
causes a pile-up of particles just inside the skin nearest the magnet. Depending on the 
width of the tissue section being considered, this build-up can extend into the vessel 
region qualitatively distorting the three prototypical behaviors. Three case studies were 





Figure 20: The effect that the skin boundary condition has upon the three prototypical behaviors 
can be seen by comparing the lower row to the top row of cases. The particles, once pulled 
through the vessel, travel to the skin boundary and then build-up along this interface and can 
extend back into the vessel region. This is most apparent in the magnetic dominated case where 
there is a build-up within the blood vessel membrane due to the presence of the skin boundary 
condition. 
 
For any situation, if the blood vessel is close to the skin, the accumulation of ferrofluid at 
the skin can build up and can extend back through the tissue and into the vessel 
overwhelming any boundary layer that may otherwise have formed at the blood vessel 
wall. The magnetic dominated case saw an increase at the skin boundary, and a slight 
increase in particle concentration in the blood vessel due to the ability of the particles to 
build up at the skin. The velocity dominated case saw only a slight concentration build-up 
near the skin and a negligible change within the blood vessel. This is because particles 
are constantly washed out of the vessel and not captured by the magnetic field thus they 
do not readily arrive at the skin interface. The boundary layer case had a significant 
increase in the particle concentration near the skin and vessel membrane, but very little 
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change within the blood vessel. Particles in this case are pulled through the membrane 
and into the tissue with build-up near the skin only slightly affecting the blood vessel. 
 
2.15.7 Varying of Tissue Diffusivity 
In section Error! Reference source not found., the Renkin tissue coefficient,    
(equation (31)), was always larger than the membrane Renkin coefficient,   (equation 
(29)), so that the limit to particle diffusion out of the vessel was the membrane. This 
behavior is consistent with many tissue-vessel systems but not all [37]. There are 
physiological conditions were the underlying tissue might not allow diffusion of particles 
as easily as a membrane, the Renkin tissue coefficient would then be smaller than the 
membrane Renkin coefficient. Therefore, the effect on particle concentration for 
changing the Renkin tissue coefficient (a fourth non-dimensional number) must be 
examined. Two cases were chosen to explore the effect changing tissue diffusivity has 
upon the steady-state concentration: boundary layer formation and velocity dominated 
behavior. Since the magnetic dominated behavior occurs only at Renkin reduced 
diffusion coefficients that are near unity, it does not make sense to vary the tissue 





Figure 21: The effect on two prototypical behaviors by varying the Renkin reduced diffusion 
coefficient for tissue (   ). The non-dimensional number cases used in section Error! Reference 
source not found. are shown on the top row. The Renkin tissue coefficient is decreased in each 
subsequent row so that the membrane Renkin coefficient is the same as the Renkin tissue 
coefficient in the second row. The last row signifies a Renkin tissue coefficient an order of 
magnitude less than the membrane Renkin coefficient. 
 
The above figure shows cases where the Renkin reduced diffusion coefficient for the 
tissue is changed while the regular (endothelial membrane) Renkin reduced diffusion 
coefficient is held constant at  . The first row ( ) corresponds to the 
typical cases used in this chapter where we have assumed that diffusion in the tissue is 
 greater than the diffusion in the endothelium (diffusion in the tissue is 1/100
th
 that of 
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blood while diffusion in the membrane is 1/1000
th
 that of blood). The second row 
(  ) shows the concentration if the two Renkin values are equal (diffusion in 
the both tissue and membrane is 1/1000
th
 that of blood). Here it is possible to see that the 
tissue space becomes an extension of the membrane space with an equivalent behavior 
(because    ). The third row (  ) shows the solution when the diffusion in 
the tissue is x 10 smaller than the diffusion in the endothelium (diffusion in the tissue is 
1/10000
th
 that of blood while diffusion in the membrane is 1/1000
th
 that of blood). Now 
the tissue space holds the primary concentration of particles. In all cases, the steady state 
vessel wall concentration remains essentially constant as we change the tissue Renkin 
value. This suggests that the relationship between these two Renkin values merely effects 
the distribution of particles between the membrane and the tissue and not the vessel 
concentration. Since the vessel wall concentration is not easily effected, the three 
prototypical behaviors and their delineation boundaries do not change. 
 
2.15.8 Different Particle Hydrodynamic and Magnetic Core Radii 
For simplicity, typically the hydrodynamic and magnetic core radii are assumed to be 
equal. Most often this is not exactly the case and there is a slight mismatch between the 
two values due to particle coatings that are added onto either affix therapeutics or 
immune system evading mechanisms [11], [14]. Then the hydrodynamic radius is slightly 
larger than the magnetic core radius leading to an increase in the Stokes drag force 
compared to the magnetic force. In this case, equation (11) would remain the same and 





where  is the hydrodynamic radius of a particle. Therefore, the non-dimensional 
magnetic-Richardson number changes in addition to a slight change in the Péclet and 
Renkin numbers. Using the same rat example as throughout the chapter, if the 250 nm 
diameter particle had a 300 nm hydrodynamic diameter, the magnetic force acting upon 
this particle would remain constant while the Stokes drag force changes from 0.70 pN to 
0.84 pN. This would cause a slight decrease in the magnetic-Richardson number from 
0.14 to 0.12. Since the particle has a larger radius, the blood and membrane diffusivities, 
 and , will be smaller decreasing from  and  (for leaky 
capillaries with 600 nm pores) to  and  respectively. The scattering 
diffusion coefficient, , will stay the same, however, since it is only dependent upon 
the type of blood vessel. This causes the mass Péclet number to increase from 1000 to 
1200. The Renkin coefficient will instead decrease from 0.36 to 0.28. 
2.15.9 Non-Perpendicular Magnetic Force 
For blood vessels in animal or human vasculature, the alignment of the blood vessels 
obviously varies and the applied magnetic force may not be perpendicular to the blood 
flow. We considered this case in the main text because it is the least complex scenario to 
think about, and because it represents a best case (the magnetic force is lined up to extract 
as many particles as possible). A simple first approximation of the ferrofluid behavior for 
the case when a blood vessel is not aligned perpendicular to the magnet force is to 
separate the magnetic force into the perpendicular ( -direction in Figure 3) and parallel 
( -direction in Figure 3) components. Then the perpendicular magnetic force component 
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can be used as the magnetic force in equation (23), while the parallel component can be 
added to the Sto es drag force to be used as a ‘net’ Sto es drag force in equation (23) to 




It is not enough to compare Stokes drag at the centerline to magnetic forces to conclude 
whether particles can or cannot be magnetically captured against blood flow. Such a 
comparison dramatically under-predicts the ability of magnetic forces to capture particles 
because it does not account for the near-zero velocity of blood near vessel walls nor the 
effects of diffusion. We have carried out a detailed analysis to better understand and 
quantify the behavior of magnetizable particles in vivo. We find that there are three types 
of behaviors (velocity dominated, magnetic dominated, and boundary-layer formation) 
uniquely identified by three essential non-dimensional numbers (the magnetic-
Richardson, mass Péclet, and Renkin numbers). Figure 9, Figure 10, Figure 11, and 
Figure 12 allow magnetic drug delivery researchers to readily determine which behavior 
should occur in their experiments. These three behaviors remain present even if we 
consider additional realistic and complicating features, such as blood flow pulsatility, 
non-uniform magnetic fields, curved blood vessels, and particle agglomeration; although 
these added effects can modestly shift the delineations between the behaviors. Only the 
presence of skin, which creates a new interface where particles can build up, adds a 
qualitatively new behavior and it would require the addition of a fourth non-dimensional 
number to map out its effect. A comprehensive comparison to prior published in-vitro 
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and in vivo experiments shows excellent agreement and explains results that were not 
previously understood. 
 
Contribution to the Field and Clinical Applications 
Previous authors have created models investigating magnetic nanoparticle behavior 
within a single non-permeable blood vessel. These groups have considered either the 
capture efficiency of single particles (non-interacting individual nanoparticles) or the 
concentrations of disperse ferrofluids. However, since only the blood vessel itself is 
modeled, these models do not include particle transport through membranes and into the 
surrounding tissue space. In addition, most models do not include the blood vessel 
velocity profiles and instead simplify this profile to a constant drag force thereby 
neglecting a non-trivial contribution to nanoparticle behavior. Lastly, these models are 
only applicable for specific geometries, magnetic fields, and blood vessel types, and 
therefore do not examine what occurs throughout any region of the body nor any 
experimental condition. 
 
We have created a more realistic and widely applicable FEM model of the blood vessel, 
blood vessel membrane, and outlying tissue section. This model treats nanoparticles as a 
fluid and not individual elements and therefore can handle concentrations specifically as 
they develop large boundary layers between the model domains (vessel, membrane or 
tissue). In addition, the model included blood velocity profiles and diffusion effects 
(either due to Brownian motion or due to blood cell scattering). We wrote equations from 
physical first principles that combined the Navier-Stokes equations, the magneto-static 
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Maxwell equations, Fick's diffusive flux equations, and Einstein's Brownian motion 
approximation. We reduced the number of experimental parameters from 24 by 
simplification and non-dimensionalization to four crucial independent parameters that 
dictate nanoparticle fluid concentration within this system. These independent parameters 
and not the experimental parameters define the ferrofluid concentration. It is possible to 
change a set of experimental parameters (e.g. the particle radius and magnet shape) and 
not change ferrofluid concentration, but it is not possible to change the independent 
parameters and maintain a constant the ferrofluid concentration.  
 
Our collaborators at the California Institute of Technology created a custom-built solver 
to resolve the boundary layers between the vessel, membrane and tissue domains. With 
this solver, we then examined the entire realistic experimental space. From this, we 
determined there were only three fundamental behavior regimes of the ferrofluid. By 
mapping the non-dimensional parameters to the fundamental behaviors, we developed a 
method to predict the nanoparticle behavior for any experimental condition. We then 
verified the mapping by comparing it to available in-vitro and in vivo experimental data. 
 
For a clinical and experimental use, the above model is able to predict the type of 
behavior a researcher will experience. All the details and necessary information has been 
provided in this Chapter. However, for a complete summary and easy reference, the 






Figure 22: The process flow for determining the ferrofluid behavior in and around a blood vessel 
under an external magnetic field. With step 1 the critical parameters are established; step 2 
calculates the required variables from the described formulas; and step 3 predicts the ferrofluid 
 106 
 
behavior based upon the four non-dimensional numbers derived from the calculated variables. All 
units are in standard international (SI) format.  ouble bars (|| ∙ ||) denotes the Euclidean norm of a 
vector.  rac ets within equations ([ ∙ ]) denote a vector or matrix quantity.  denotes the gradient 
operator. 1The magnetic core radius is a radius of the region enclosing the magnetic components 
of the magnetic particle. 2When developing the theoretical model to predict the magnetic field 
and its derivative, it is beneficial to take advantage of any symmetry inherent within the problem. 
In our convention, we align the blood vessel with the x-axis and consider a magnet placed 
symmetrically along the y-axis. 
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Chapter 3: Dynamic Magnetic Shift to Improve Therapeutic Transport 
through Tissue 
This work originally appeared in [274]. 
This work was done in collaboration with colleagues at the National Cancer Institute of 
the National Institutes of Health. Skye Kim, Michael Tangrea, and Mike Emmert-Buck 
collected the samples from the NIH autopsy database. In addition, they fixed, mounted, 
and stained the samples to identify vessel locations. Jaime Rodriguez-Canales, a trained 
pathologist, identified the tumor and normal regions within the liver. These collaborators 
performed the first comparison of normal to tumor tissue, which I further extended with 
image processing. I designed, developed, and examined the magnetic nanoparticle tissue 
transport model and then used it to create the dynamic magnetic shift treatment scheme. 
 
3.1 Introduction 
Given the multitude of potential treatment targets for magnetic drug targeting (MDT), it 
is vital to first choose a desired treatment target before engineering a magnetic drug 
targeting schema. As mentioned in Chapter 1, the initial MDT case was the treatment of 
cranial surface primary tumors [14]. These results have been extended to sensitize tumors 
using thermotherapy [16]. Outside of oncology, advances include using magnetized stem 
cells to treat regions of cardiovascular disease to help restore tissue function [75], [114]–
[116], or to the retina for ocular regeneration [117]. However, a previously unconsidered 




The three-dimensional tumor microenvironment introduces an additional level of 
complexity as the rapid and uncontrolled growth of tumor cells can result in a 
disorganized and only partially functional biological milieu, an environment that favors 
tumor growth over normal physiological processes. One outcome of this process is an 
abnormal vascular system [275]. Unlike the well-structured series of small vessels that 
create a fine meshwork of capillaries in normal tissues to deliver oxygen and nutrients 
within a diffusion-limited distance of cells, tumors often exhibit a complex and 
disordered blood supply resulting in diminished perfusion to some or all parts of the 
tumor microenvironment and reduced delivery of blood borne components, including 
systemically administered therapeutic agents [211], [276]–[280]. 
 
The full complement of reasons for poor chemotherapeutic efficacy in metastases are not 
understood
 
[276], [277]; however, to improve drug delivery functionalized nanoparticles 
are being developed to target cancers and increase local drug concentrations, cellular 
uptake, and clinical effectiveness [45]–[49], [281]–[284]. Unlike small drug molecules 
that equilibrate quickly through tissue space by diffusion alone [37], [38], larger 
functionalized nanoparticles (including targeting antibodies [45]–[49], environmental 
reactive drugs [44], or imaging reagents [285], [286]) are unable to diffuse as easily [37], 
[38]. Several in vivo studies have shown that with targeted carriers, even if the cellular 
uptake is increased, the tumor drug concentration remains unchanged compared to 
untargeted carriers [46], [47], [281]. This poor penetration can reduce the efficacy of 





In order to provide adequate nanoparticle concentrations to breast and other metastatic 
tumors, we are evaluating a new method of normalizing nanotherapy termed dynamic 
magnetic shift (DMS) [185], [287]–[293] (see Figure 23) that is designed to achieve two 
important goals: a) Increase nanoparticle levels in poorly vascularized tumors or tumor 
sub-regions by equalizing the concentration between tumor and normal tissues; and, b) 
Improve tumor nanoparticle levels simultaneously in all tumor foci across a given 
anatomical region, without the need for imaging-based, positional information of lesions. 
To accomplish these objectives, magnetic nanoparticles would be given systemically and 
allowed to distribute throughout the body. A magnetic force would then be applied in one 
direction over a specified anatomical zone of the body to promote movement of the 
therapeutic particles into the tumor space from adjacent, well-vascularized normal tissue 
(an effective external nanoparticle reservoir) and also from sub-regions within the tumor 
that contain high levels of nanoparticles (e.g. internal vessels). The externally applied 
magnetic forces would overcome diffusion limits by physically displacing ferromagnetic 
drug carriers across nano- or micro-meter distances (Figure 23). This displacement can be 
driven in one direction only, but our studies show that it is advantageous to repeat the 
process in at least two directions to more uniformly distribute the nanoparticles due to the 
complex geometries of vessels within tumor foci. Since the nanoparticles have a finite 
circulation time in vivo, there is a balance between magnetically actuating for as long as 
possible in one direction versus successively applying magnetic forces in multiple 
directions to better redistribute drugs into and throughout metastatic tumors. Our finding 
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is that two directions is a practical compromise between shift distance and number of 
shift directions, and we examine that case here. 
 
 
Figure 23: Schematic illustration of magnetic left-then-right shift option to increase nanoparticle 
levels into and throughout liver metastatic tumor foci. Left and right panels: appropriately chosen 
(strong and correctly sized) magnets can create sufficient magnetic gradients on therapeutic 
magnetic nanoparticles to displace them from dense distributions in normal tissue into adjacent 
poorly-vascularized tumor regions. In this example, magnetic shift is shown in just two 
successive directions, but the process can be repeated in multiple spatial planes. Middle panel: 
computer simulations of the resulting therapeutic particle distributions in a 1 mm wide tissue 
region using blood vessel geometry taken from autopsy data (gray markings). The color gradient 
shows the resulting nanoparticle concentration at each tissue location (red is high, white is low). 
Magnetic actuation increases nanoparticle concentration in the tumor area (marked by the black 
circle, also clearly visible by a lack of blood vessels) at 30, 60, 120 and 180 minutes after 
systemic injection. 
 
The natural motion of nanoparticle complexes within a tissue space is diffusion and small 
convective bulk flow. If the convective flow is tiny, than the nanoparticle movement 
through a tissue space or tumor can be described purely by diffusion. Using the particle 
mobility models discussed in section 1.3.1 and a representative size of tumor, it is 





If the particle is small, this distance is large and the particles are able to perfuse through 
the entire tumor. If the particle is large then the diffusive distance is tiny, and the particles 
will not reach far into the tumor. As given by equation (14), the distance traveled by a 
magnetic particle due to a magnetic field is also related to size. The larger the particle the 
further it will travel. Using these two competing effects and models of tissue resistance, it 
is possible to generically predict the regimes in which DMS would provide a significant 
improvement over natural diffusion. Figure 24 gives an overview using these models of 
the potential regions where DMS would provide a significant mobility increase over 
natural diffusion. However, this generic prediction does not incorporate any information 
about the tumor architecture. Incorporating the tissue architecture is the next step to 
determine if DMS would have any impact. 
 
 
Figure 24: A map of when DMS is predicted to be advantageous over diffusion alone for poorly 
perfused liver metastases (for a sample 0.5 mm diameter tumor, therapeutic particles are assumed 
to have a 45 minute in vivo residence time). For two common types of tissue models, a Renkin 
Pore model [37], [38], [197] or a Fiber-Matrix model [37], [38], [202], the coloring shows when 
 MS treatment will improve drug delivery to the tumor.  Here, ‘High  iffusion’ refers to the 
region where diffusion alone should suffice: it is the region where particle diffusion is predicted 
to create a concentration of therapy in all tumor cells that is ≥ 85% of the concentration of therapy 
in the blood stream. ‘Some Advantage’ (yellow) and ‘Most Advantageous’ (red regions) is where 
diffusion will not suffice and DMS has the potential to improve therapy concentration to all cells 
in the tumor by  and  respectively compared to diffusion alone. Thus, DMS will be 
advantageous for mid-range 10 – 500 nm particle sizes, when the particles are big enough so that 
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diffusion alone is no longer effective but small enough so they can be magnetically moved 
through tissue. Particles of this size include heat shock protein cages (  nm) [294], polymeric 
micelles (  nm) [295], colloidal suspensions of albumin-Taxol (Abraxane, 130 nm) [296], and 
functionalized carbon nanotubes (0.1 - 4 μm) [297]. 
 
To evaluate the histological and vascular features of metastatic foci in human subjects 
and their implications for magnetic drug delivery, a series of autopsy cases from women 
who died from metastatic breast cancer were analyzed. Blood vessel density and 
geographic distribution were quantitatively measured and these data used for 
mathematical simulations of the distribution of magnetic particles within tumors with and 
without magnetic actuation, to assess the feasibility of DMS and also to describe and 
understand the critical elements that affect the process. In brief, strong magnets of a 
carefully selected size (20 cm  40 cm) that create substantial magnetic gradients inside 
the body (magnetic fields fall of with distance creating a spatial gradient) were evaluated; 
the magnetic fields, gradients, and forces were computed by standard methods [131], 
[185], [228], [298]; the best available parameters were used for human tissue resistance 
to particle motion [37], [38], [197]; and, DMS parameters (strength and timing for a 2-
direction shift) were varied to evaluate different treatment regimens.  Finally, since one 
of the most common sites for metastasis of breast cancer is the liver and there is clinical 
evidence suggesting that treatment of metastatic hepatic lesions can lead to improvement 
in patient outcome, we focused our attention on hepatic metastasis [299]–[302]. 
 
3.2 Domain Geometry 
Autopsies from eighteen women with metastatic breast cancer who died at the NIH 
Clinical Center were initially evaluated. The liver ( ) and lungs ( ) were the organs 
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most commonly affected in this cohort of patients, although a majority of the women also 
had widespread systemic metastases. The most common causes of death were overall 
tumor burden and respiratory compromise, often associated with infections that were 
secondary to therapy and immune suppression. The chemotherapeutic treatment history 
in the patients varied; however, in all cases the drugs received were standard regimens. 
Grossly, the metastatic tumor foci appeared as firm white nodules, in contrast to the 
adjacent, dusky, liver parenchyma (Figure 25).  
 
 
Figure 25: Photograph of metastatic breast cancer in liver.  The lesions appear grossly as firm, 
white nodules, consistent with a host desmoplastic response and poor vascularization. 
(Note - the image is representative of the pathological descriptions in the autopsy cases in the 
study, but is not an actual image from one of the cases.  Photo provided courtesy of Drs. 
Hanne Jensen and Robert D. Cardiff, Center for Comparative Medicine, University of 
California, Davis.) 
 
3.3 Vessel Measurements – Normal Liver and Metastases 
Ten autopsies were chosen for vessel analysis based on the quality of CD31 immuno-
staining. All ten patients had liver metastases, ranging from micro-metastases that were 
only a few millimeters in diameter, to grossly visible lesions that were a centimeter or 
more across. At the microscopic level, the metastases were comprised of sheets of 
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irregularly shaped tumor cells with pleomorphic nuclei. Foci of chronic inflammation, 
necrosis, and micro-hemorrhage were variably observed in the tumors. 
 
 
Figure 26: Photomicrographs of vessel staining in three cases of metastatic breast cancer in liver. 
Images on the left are immunostained histological sections. On the right are the same sections 
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visualized in black and white to highlight the CD31 stained vasculature. Panels A-F are from 
normal liver and panels G-L are from matched tumors. At low power, the normal sections show a 
fine meshwork of capillaries. In contrast, tumors exhibit vessels that are generally larger in size 
and fewer in number. 
 
Normal liver in the patients contained a fine meshwork of small vessels and capillaries 
interspersed throughout the parenchyma, an architectural pattern consistent with an even 
distribution of blood flow and diffusion-based delivery of oxygen and nutrients to 
hepatocytes and associated support cells. In contrast, the tumor vessels were generally 
larger in diameter but fewer in number than in the adjacent normal liver, with a more 
random distribution and a greater vessel-to-vessel spatial separation. This difference in 
tumor vasculature is evident in the low power histological views shown in Figure 26 and 
was observed in the metastases from nine of the ten patients analyzed. 
 
 
Figure 27: Quantitative measurement of vessels in normal liver and adjacent metastatic breast 
cancer in 10 cases. Panel A: representative whole slide images of a histological liver section 
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containing both normal tissue and tumor. Each rectangle represents a randomly chosen region 
(green = normal, red = tumor; dimensions =  mm; 100X magnification). Panel B: the 
vessels-to-nuclei ratio in tumor regions is lower and more variable than in normal areas. Panel C: 
tumor regions have a lower number of blood vessels per area than in normal. 
 
To quantitatively assess the vasculature patterns of both normal tissue and tumor, twenty 
arbitrary histological regions were chosen for each case: ten that contained normal liver 
(green rectangles) and ten with tumor (red rectangles). As an example, a low power 
microscopic view of one case and geographic regions selected for analysis is shown in 
Figure 27A. Overall, the measurements revealed that tumors contained fewer vessels and 
had more vascular heterogeneity than normal tissue, consistent with the visual 
observations seen in Figure 26. Except for outlier case A98-28 (the only lobular breast 
cancer case in the series, see Discussion section), all tumor cases had fewer vessels than 
normal tissue as measured using vessel count per cell number (Figure 27B) or using 
vessel count per area (Figure 27C). 
 
We next assessed the tumor microenvironment in terms of regions with the fewest 
number of vessels. In other words, we purposefully looked for and measured sub-regions 
of tumors with the lowest vascular density, then compared these sub-regions against 
normal tissue of the same patient by computing the distance to the nearest blood vessel 
for every location within the tissue image. As seen in the panels across the top of Figure 
28, in a normal region the average of the distance from each cell to its nearest blood 
vessel is 5.3 ± 2.7 μm (the maximum is = 67.8 μm; n ≈ 5500). In contrast, in the selected 
tumor region, the average was observed to be 43.8 ± 6.9 μm (the maximum was = 287 
μm; n ≈ 5500). These results indicate that in addition to a lower average vascular density 
than normal tissue, there exist specific sub-regions of tumors that are far away from all 
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vessels, regions that are likely poorly perfused and difficult for systematically 
administered particles to access. 
 
 
Figure 28: Computation of the distance of normal liver cells (panels across top) or tumor cells 
(bottom) to their nearest blood vessel. The black and white images indicate tissue (black) and 
vessel (white) locations. Each normal and tumor region was selected for analysis based on the 
fewest number of vessels observed at low magnification. The three-dimensional relief graphs 
show the distance in microns to the nearest blood vessel for a given tissue location. As the graphs 
increase in height, that tissue location is further from its nearest blood vessel. In all examples, the 
tumor cases have cells located further away from nearest blood vessels (indicated by larger mean 
and max values). 
 
3.4 Governing Equations 
To examine the effect that low vascular density has upon magnetic targeting procedures, 
simulations were constructed using the histology of a representative small metastatic 
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tumor (diameter ≈ 0.5 mm, inset of Figure 29) and the surrounding normal liver 
parenchyma. Using finite element modeling software, the behavior of magnetic 
nanoparticles was examined with and without the application of magnetic actuation 
(Comsol Multiphysics) [261].  All magnetic fields, gradients, resulting forces and particle 
motions, were computed from physical first principles [131], [185], [228], [244], using 
the best available parameters for particle diffusivity and resistance to motion in human 
tissue [37], [38].  
 
Figure 29: Simulation domain showing the larger region (left panel) that encompasses the smaller 
region of interest (right panel). The yellow ellipse represents tumor. 
 
The evolution of particle distributions in media was described by partial differential 
equations (PDEs). Here, for diffusion and magnetic transport in tissue, the appropriate 





 rift  elocity
 
(51) ,  . 
This type of formulation is standard, and the properties of tissue ( , , , 
) were chosen to match the properties of drug-coated 60 nm diameter magnetic 
particles in human tissue [37], [38], [131], [196]. The decay constant, , defines how the 
particle concentration in blood is related to the nanocarrier half-life, .  A fiber 
matrix model with a 1 nm radius fiber volume concentration of CF = 0.3% [37], [38], 
[202], was chosen to evaluate the worst-case situation for DMS where the diffusion 
coefficient of the particles is high thus reducing the benefit of DMS (for this , 
the reduced diffusion coefficient of the Fiber-Matrix model is ) [37], [38], 
[202]. The magnetic field and magnetic gradient around a 20 cm  40 cm magnet (2.5 T 
remnant magnetization) was solved using COMSOL [228], which gave the magnetic 
force at a depth of  11 cm in the body as  fN.  Comparing this force to tissue 
resistance, , where  is the particle radius,  is the fluid 
viscosity and  is the speed at which nanoparticles are transported through the 
region of tissue by the applied magnetic force, yielded a particle magnetic drift velocity 




3.5 Boundary Conditions 
Two sets of boundary conditions are necessary to solve equation (50): one set to describe 
the extravasation from the blood vessels into the tissue (equation (51)), and the second to 
describe the movement of nanoparticles out of the simulated region. 
 
The first set of conditions is determined by the diffusion of particles from the vessels into 
the adjacent tissue governed by the nanoparticle concentration gradient (high in blood, 
low in tissue). Therefore, the movement of particles into the tissue is dependent upon the 
blood plasma concentration. Here we describe the concentration of nanoparticles within 
blood plasma as one that decays over time as described by equation (51). This decay 
models the known physiological plasma concentration of systemically injected 
nanoparticles. From this equation, the half-life ( ) of nanoparticles in the blood 
plasma can be chosen to mimic physiological parameters in humans (here, 
  min was used) [11], [14], [31]. 
 
The second set of boundary conditions defines the free movement, the flux, of 
nanoparticles out of the region of interest (Figure 29). Nanoparticles leave only when the 
magnetic force pulls them out of the simulated region; therefore, the total flux of particles 
out of the tissue is equal to the convective flux created by the magnetic forces as 





 iffusion out of the histolocial region
, therefore 
(53) 




3.6 Simulation Region 
Nanoparticles are swept out of the simulated region then re-enter during treatment. We 
addressed the effects of particle re-entry on the accuracy of our simulation results by 
tripling the simulated region (inset of Figure 29) to 3 mm  1.8 mm, which centered on 
the original region of interest (Figure 29). The increase in size was sufficient to 
accurately track all particles passing through the original region at any time. This did not 
change the results. In other words, all particles near the exterior boundary of the 
expanded region that would either enter or leave (i.e., particles that would not be 
correctly tracked by our simulation) were too far away from the original region to 
contribute to its nanoparticle concentration.  
 
3.7 Simulation Development 
Each case simulated consisted of solving the constitutive equation (50) over the entire 
image and marching it forward through time. Nanoparticles enter the surrounding tissue 
(shown in black in Figure 29 top row) from the identified blood vessels (white regions in 
Figure 29) over time. The amount of nanoparticles moving from the vessels into the 
adjacent tissue is described by equation (51), from which equation (50) generates the 
distribution of particles at the next time instant across the region of interest. This 
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calculation is marched through time for 3 hours, creating a complete solution of the 
nanoparticle distribution for the entire treatment window. 
 
Three treatment scenarios were considered: Case a) No applied magnetic forces (for a 
treatment duration of t = 3 hrs); Case b) A constant unidirectional West magnetic force 
(t = 3 hrs); and Case c) A sequence of magnetic forces chosen by intuition that begins 
with no magnetic force (for t = 45 min) followed by a unidirectional East force (for 
t = 1.5 hrs) which then switches to a unidirectional West force (for t = 45 min). Case c) 
was chosen to test the effects of switching magnetic force directions on both the average 
and maximum over time nanoparticle concentration achieved in the tumor region to see 
whether it could be improved over the results of Case b). Subsequently, we carried out a 
comprehensive search over magnetic force duration and number of pull directions (single 
or bi-directional pull?) to go beyond case c) and to find optimal DMS treatment 
parameters for a 1.5 hour treatment. 
 
Equation (50) describes the basic physics of nanoparticle transport inside the body and 
shows that accumulation or depletion of particles at any location is due to transport by 
diffusion and applied magnetic forces. This type of formulation is standard [196]. 
Parameters are chosen to reflect the tissue properties of the region of interest (e.g. the 
diffusion coefficient can be changed to reflect parameters of normal or tumor tissue), and 
it is this equation that is simulated below. Equation (51) reflects our knowledge about the 
residence time of nanoparticles in vivo and states that the amount of particles that 
extravasate from blood to tissue at a given time is linked to the plasma concentration, 
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which decays exponentially over time due to uptake of the nanoparticles by the 
reticuloendothelial system (RES). 
 
3.7.1 Magnetic Fields, Gradients, and the Resulting Forces on Nanoparticles 
For any electromagnet or permanent magnet, a magnetic field is present surrounding the 
magnet with field lines leaving the north pole and re-entering the south pole [244]. The 
field generated will be stronger closer to the magnet (specifically at the corners) and 
weaker as the distance from the magnet increases [186], [244], [298]. The magnetic field 
falls off very quickly further from the magnet relative to its size (larger magnets will have 
a slower decreasing magnetic field strength [304]) creating a magnetic field gradient, and 
it is this gradient that creates a force that attracts particles towards the magnet.  For a 
 cm magnet with a remnant magnetization of 2.5 T, the field at 11 cm distance 
(along the long axis of the magnet) will be  T, or  A/m. The 
gradient of the magnetic field at that distance will be  A/m
2
. Using 
these values and considering a magnetic nanoparticle with a diameter of 60 nm, the 
magnetic force (see equation (11)) acting on this particle will be 
 Newtons (a femto-Newton is 
10
-15
 Newtons). Considering a Fiber-Matrix model with , as discussed in the 
Materials and Methods section, the reduced diffusion coefficient of the described Fiber-
Matrix model will be . Assuming that the reduced diffusion coefficient 
impacts forced particle movement in a similar manner as diffusion (Einstein's relation 
[37], [38], [197]), the tissue resistance can be expressed as follows 
.  At equilibrium, the magnetic force and the tissue resistances equal, 
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therefore the expected speed of a particle through a tissue space will be 
 μm/s, or  nm/s. 
 
3.7.2 Parameters for Nanoparticle Diffusion and Magnetic Transport through 
Human Tissue 
At present, nanoparticle diffusivity and tissue resistance are not well known or 
characterized, especially within metastatic tumors in humans [37], [38]. However, several 
models can be used to predict the relative movement of nanoparticles through tissue 
based on the size of the particles and relevant tissue parameters. Two traditional models 
(the Renkin Pore model [37], [38], [197] and the Fiber-Matrix model [37], [38], [202]) 
were examined to determine the range of both diffusivity and tissue resistance. 
 
The classical method of describing particle motion through different media is by a 
reduced diffusion coefficient that scales both the blood diffusion coefficient [37], [38] 
and the magnetic drift coefficient (by assuming Einstein's relation [38]). This reduced 
coefficient usually depends upon particle size (it decreases as the size increases) and the 
properties of the tissue (denser tissues increase particle resistance). Conversely, the 
magnetic force increases with particle size – it simply scales with particle volume [185], 
[244]. Thus, there is an optimal particle size for different tissue properties – the particle 
should be big enough so that the magnetic force is substantial, but small enough to 





Figure 30: Optimal particle size for DMS.  Two classical models of tissues (Renkin Pore and 
Fiber-Matrix model) are used to determine the maximum velocity for a given particle size. The 
top panels show the nanoparticle magnetic velocity (by a color scale with black being the fastest 
and white the slowest) for a given particle radius and tissue characteristic (pore size or fiber 
concentration). A cross-section was taken (dashed line) to show the magnetic velocity for either a 
pore radius of 200 nm or a fiber concentration of . A  cm magnet with a 2.5 Tesla 
remnant magnetization held 11 cm away was used to calculate the magnetic velocity of the 
nanoparticles. There is a clear optimal particle size choice, for this tissue density it is 89 nm or 36 
nm according to the Renkin or Fiber-Matrix model respectively. 
 
Using Figure 30 and assuming a physiologically worst-case scenario for DMS of a very 
diffusive metastatic tumor (where the diffusion of nanoparticles is high, reducing the 
potential beneficial impact of the magnetic actuation, see Figure 24), a fiber 
concentration  using the Fiber-Matrix model [37], [38] was chosen that lead to 
an optimal particle diameter of 60 nm and a maximum particle magnetic drift velocity of 
 μm/s.  The associated tissue diffusion coefficient, via the particle's size and 
Einstein’s relation, is  m
2





3.7.3 Physiological Modifications 
The simulation framework presented can be modified and detail can be added to address 
additional questions and to examine different treatment options. Variations in histology, 
changes to nanoparticles, and alterations in magnetic treatment correspond to changing 
the parameters in equation (50) and choosing their variation in time and space. For 
instance, the initial distribution of magnetic particles in blood vessels after systemic 
injection, but not yet in surrounding tissue by subsequent extravasation, diffusion, and 
magnetic forces, is reflected by choosing the initial condition  to match the 
geometric distribution of blood vessels measured from the histology (Figure 26). 
Likewise, computing the magnetic forces and including the migration velocity they cause 
for nanoparticles in each location in the body, including the effect of varying magnetic 
fields during treatment, can be included in . The impact particle and 
physiological parameters have upon specific terms in equation (50), however, is not 
always obvious. For example, varying the particle size will affect not only the diffusion 
coefficient  but also the magnitude of the particle migration velocity, , as 
discussed in the Materials and Methods section. The diffusion coefficient, as is described 
by Brownian motion, decreases as the particle size increases [196]. The magnetic forces 
on particles scales with the volume of the particles but is opposed by the viscous 
resistance to nanoparticle motion offered by blood, interstitial fluid, or tissue, and that 
scales nominally with particle size. However, assuming various tissue models, as particle 
size increases above the geometrical thresholds of the tissue (i.e. above the pore size in a 
Renkin model), the tissue resistance climbs very quickly [37], [38], [197]. The net result 
is that the migration velocity increases with the square of particle diameter for an optimal 
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range and then decreases dramatically [37]. Variations in tissue properties also affect 
both the diffusion and the migration velocity parameters. Nanoparticles have more 
difficulty moving through dense cellular networks than through interstitial fluid [37], 
[38]; thus, tissue morphology effects both the diffusion and magnetic migration of the 
particles. Extravasation modifies how these particles move out from blood into 
surrounding tissue. In summary, although quantifying tissue properties of diffusion, 
migration, and extravasation is challenging and these parameters are often poorly known 
or uncertain, the mathematical model provides the ability to change them in simulations, 
to rapidly see the consequences, and to thus better understand how these tissue properties 
can affect nanoparticle distribution in tissue.  
 
3.8 Magnetic Drug Transport Simulation Results 
To evaluate the utility of externally applied magnetic forces in equilibrating nanoparticle 
levels in tumors, a series of simulations of equations (50) and (51) were performed. The 
rate of nanoparticle extravasation through capillary walls, the decay constant  in 
equation (51), was inferred from the measured half-life ( ) of nanoparticles in 
patients in the clinical trials of Lübbe et al. [11], [14], [31] (For additional details on the 
simulations and mathematics, please see the Supplementary Section.) 
 
Figure 31 and Table 4 compare the time progressed behavior of the magnetic 
nanoparticles for the three treatment scenarios. Figure 31(a) represents the change in 
particle concentration with no applied magnetic forces over 3 hours for a tissue sample 
that includes a small metastasis. Locations with high vascular densities (normal tissue) 
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produced regions with high particle concentrations, while regions with lower vascular 
densities (tumor) experienced lower concentrations. In Figure 31(b), a constant West 
magnetic force was applied for 3 hours. The increase in particle concentration in the 
tumor is especially evident at the end of the second hour (at 120 minutes). Single 
direction shift yielded a  (compared to in blood) time-averaged nanoparticle 
concentration in the tumor, instead of the prior  value – a ×1.6 fold improvement; 
while time-averaged particle concentration in the normal tissue remained almost the same 
as for diffusion only (  instead of ). Thus, magnetic shift in just one direction 
partially re-normalized particle concentration from normal to tumor tissue. Figure 31(c) 
simulated an alternating bi-directional magnetic treatment. This simulation began with no 
magnetic forces (for 45 min), then a unidirectional East magnetic force (for 1.5 hours), 
which then switched to a unidirectional West force (for 45 min). Alternating the direction 
of magnetic forces more effectively normalized particle concentration between normal 
and tumor tissue as the time-averaged concentration of particles in the tumor was , 
which is close to the  concentration in normal tissue, a ×1.99 fold improvement 
compared to no magnetic actuation. The time-averaged metric is appropriate for time-
dependent therapies or phase-specific therapies [305], like paclitaxel [4] and topotecan 
[5], where it is important to ensure that cancer cells experience a higher dosage of therapy 
over a long time window  to continue treating them until they  enter the correct phase of 
their  cell cycle. For phase-nonspecific therapies or dose-dependent  drugs [4], like 
gemcitabine [8] and carboplatin [6], it would suffice to increase the dose in cancer cells 
for just a short time since the drug efficacy is not dependent upon the cancer's cell cycle 
phase. In this phase-nonspecific case, it is more appropriate to consider the time 
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maximum concentration at each tissue location. If such a time-maximum metric is 
considered, then even a single direction shift is sufficient to normalize the maximum-
over-time nanoparticle concentration from normal to tumor regions (see Table 4).  
 
 
Figure 31: Time progression of nanoparticle concentration for the three treatments. The panels 
across the top were from a histological image of normal liver containing a small metastasis 
(marked by the circle). (a) Nanoparticle concentration with no magnetic forces and only diffusive 
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effects. The tumor region had a low nanoparticle concentration even after 180 min. (b) 
Nanoparticle concentration with a constantly applied magnetic force to the left (West). The 
nanoparticles were displaced to the left, increasing the particle concentration in the tumor. (c) 
Nanoparticle concentration with an alternating magnetic force first to the right (East) and then to 
the left (West). Nanoparticles from surrounding normal tissue were effectively brought into the 
tumor region by DMS. 
 
 
Figure 32: Visualization of the time-averaged (for slower acting therapies) and time-maximum 
(for fast acting therapies) concentration of therapy in normal and tumor tissue for the 3 cases from 
Figure 31. The top shows the time-averaged nanoparticle concentrations achieved across the 
tissue section over the 3 hour treatment window using: a) Diffusion only, b) A left magnetic pull 
only, and c) A two-directional magnetic pull. The bottom row represents the maximal 
nanoparticle concentration over time. Note that the tumor in the center of the image receives both 
significantly higher average and time-maximal nanoparticle levels when dynamic magnetic shift 
(DMS) is applied.  
 
Figure 32 plots the results from the simulations, showing the average and maximum 
nanoparticle concentration over time in the tissue for three scenarios: Case a) no applied 
magnetic forces (diffusion only); Case b) West-only magnetic force; and Case c) a 
sequence of alternating magnetic forces (East then West). In Case a), diffusion only with 
no magnetic forces applied, both the time averaged and the time maximum nanoparticle 
concentration in the tumor region was half what it was in the normal tissue (Ave[Normal]a = 
20.4%, Ave[Tumor]a = ; Max[Normal]a = , Max[Tumor]a = ) (Figure 32a). In 
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Case b), a constant unidirectional (West) magnetic force improved the maximum 
nanoparticle concentration over time significantly in the tumor but the average over time 
increased only moderately compared to the surrounding normal tissue (Ave[Normal]b = 
, Ave[Tumor]b = ; Max[Normal]b = , Max[Tumor]b = ) (Figure 32b). 
Finally, Case c), a bidirectional sequence of magnetic forces (East then West), was shown 
to be the most effective and improved both the average and maximum tumor nanoparticle 
concentrations relative to normal tissue (Ave[Normal]c = , Ave[Tumor]c = ; 
Max[Normal]c = , Max[Tumor]c =  in tumor) (Figure 32c).  Overall, Case c) 
increased the Ave[Tumor]  ratio for magnetic actuation vs. diffusion by 1.86 fold, and 
increased the Max[Tumor] ratio by 1.89 fold. In essence, magnetic shift was able to 
normalize the concentration of nanoparticles between normal and tumor cells, both 
according to the time-averaged (flow slow acting therapies) and time-maximum (for fast 




Table 4: Time averaged and time maximum particle concentrations in tumor vs. surrounding 
normal tissue. The time average ‘normal’ and ‘tumor’ values for the three treatment cases were 
computed by taking the average concentration over time within each tissue region (normal or 
tumor). Li ewise, the time maximum ‘normal’ and ‘tumor’ values were computed by ta ing the 
maximum over time at each location, and then spatially averaging that value across the normal 
and tumor regions, respectively. In the table below: time average ‘T:N’ ratio = ‘Tumor Average’ / 
‘Normal Average’, and the  ‘Fold Increase’ = ‘T:N Average (Left Magnet or Shift 2  irections)’ / 
‘T:N Average ( iffusion Only)’, li ewise, the time maximum ratio ‘T:N’ = ‘Tumor Max’ / 
‘Normal Max’, and the ‘Fold Increase’ = ‘T:N Max (Left Magnet or Shift 2  irections)’ / ‘T:N 
Max ( iffusion Only)’. The standard deviations are shown beneath each percentage to quantify 
the spatial variance around the time averaged or time maximum region concentrations. ‘T:N’ 
values close to unity correspond to effective therapy normalization between tumor and normal 
tissue, ‘Fold Increases’ quantify the benefit of  MS.  
 TIME AVERAGE TIME MAX 
CASE Normal Tumor T:N 
Fold 
Increase 







± 3.7 % 
9.9% 
± 4.5 % 
0.49 -- 
28.9% 
± 4.3 % 
15. 8% 





± 3.2 % 
15.8% 
± 3.5 % 
0.81 1.65 27.4% 
± 4.1 % 
27.4% 
± 2.9 % 
1.00 1.81 
c) Shift 2 
Directions 
19.7% 
± 2.8 % 
18.0% 
± 2.6 % 
0.91 1.86 29.0% 
± 3.3 % 
30.1% 
± 2.4 % 
1.04 1.89 
 
The cases above show that DMS can normalize nanoparticle concentrations across 
tumors by effectively transporting particles from well-vascularized normal tissue to 
poorly vascularized tumor regions. In the above example, the bi-directional mode timing 
was chosen based on intuition – it was thought beneficial to wait for some time to allow 
nanoparticles to first accumulate around vessels, and then to pull in the two different 
directions.  
 
Going further, it is possible to examine the cells furthest from the blood vessels and 
compare the drug concentrations that these cells experience versus those that are near the 
vessels. Figure 33 shows the fold increase in the time-average and time-maximum 
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concentration for those cells furthest from the surrounding blood vessels for case b) and 
case c) compared to natural diffusion (case a)). 
 
 
Figure 33: Fold increase for the furthest cells from the vasculature. The fold increase in the time-
averaged and time-maximum drug concentration for case b) and case a) versus natural diffusion 
are shown for the cells furthest from the vasculature. 
 
The cell that are furthest away see an increase in the drug concentration of > 5 times 
higher for time-averaged drug concentrations, and > 3.8 times higher for time-maximum 
drug concentrations. The clinical effect of this drug concentration increase within the 
tumor would have to be determined by animal trials. While this drug concentration 
increase may or may not improve the concentration within the tumors to therapeutic 
levels, DMS introduces the potential to lower systemic dosages. If a patient can currently 
receive therapeutic levels of chemotherapy at dose X, using DMS that dosage could 
potentially be reduced by a factor of 5 to X/5 and retain the same therapeutic effect. This 
systemic reduction in dosage would reduce the side effects experienced by the patient. To 
improve on case c), based on the collected autopsy data, we sought to determine the best 





Metastatic tumors exhibit a diverse set of cellular, pathological, and structural features 
that make them a challenging target for therapeutic intervention [299], [300]. Evaluation 
at the microscopic level shows a variety of histopathologies, both within and among 
different cancer foci. For example: tumor grade, cellularity, degree of inflammation, 
desmoplastic host response, micro-hemorrhages, and necrosis can vary from lesion to 
lesion and even from sub-region to sub-region within a neoplasm. Moreover, the vascular 
characteristics of metastatic tumors differ from normal tissues and among cancer sites, 
both spatially and temporally [211]. Tumor vessels are often dilated, saccular, tortuous, 
and disorganized in their patterns of interconnection, producing a geometric resistance to 
blood flow and a decrease in perfusion [278]. The dysfunctional vasculature is evident at 
the gross pathological level as a striking feature of metastatic lesions is their firm, white 
appearance, suggesting that blood perfusion is less than that of most normal organs 
(Figure 25). 
 
The chaotic nature of the vasculature and the subsequent increase in interstitial fluid 
pressure can result in uneven, fluctuating blood flow in tumors and prevent exposure to 
conventional nanotherapies that rely on the blood supply for diffusion-based distribution 
throughout the body, since the highest concentration of systemically delivered 
therapeutics are achieved at sites closest to the blood vessel and the concentration falls as 
the distance increases. As an example of this phenomenon, a study of local concentration 
of 5FU in liver metastases models as compared to adjacent normal tissue revealed limited 
5FU penetration in areas of poor blood flow [276]. Inadequate tumor perfusion can also 
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result in hypoxia, postulated to be a central feature of cancer that is important to the 
physiological functioning and survival of the tumor cells and associated host cells. 
Historically, hypovascular tumor foci have been indirectly observed by their resistance to 
ionizing radiotherapy that relies on tissue oxygen content at the time of treatment [277]. 
More recently, hypoxic regions have been described to produce genomically unstable, 
clinically aggressive tumor cells that thrive in these regional microenvironments [280]. 
Thus, poorly vascularized tumors or tumor sub-regions can be clinically problematic 
based on both the inability to achieve therapeutically effective drug levels as well as the 
hypoxic microenvironment that is favorable to tumor cell growth and progression. 
 
In the present study, we found that metastatic breast tumors in liver consistently had a 
lower number of blood vessels on average across the lesions than adjacent normal liver 
tissue (see Figure 26). Moreover, specific tumor sub-regions contained little or no 
vasculature, with vessel-to-tumor cell distances as large as 287 μm (see Figure 27). The 
one exception to this pattern was the outlier case A98-28. Interestingly, A98-28 is a liver 
metastasis of lobular carcinoma, the only non-ductal cancer that was included in the 
study. Detailed histopathological inspection of this tumor revealed large, poorly 
differentiated cells that did not grow in solid sheets, but rather in clusters that invaded the 
liver through the sinusoidal system, expanding it rather than replacing the normal tissue. 
The endothelium of the expanded sinusoids continues to express CD31; however, the 
majority of the CD31 positive cells are not blood vessels. Thus while case A98-28 
appears well-perfused, it may in fact be the least vascularized tumor in the series due to 




To date, magnetic drug delivery has been used for focusing anti-neoplastic agents to 
primary, superficial tumors and has been evaluated in phase I clinical trials by placing a 
strong permanent magnet (0.8 Tesla) near the tumor [14], [31], [209]. While this 
approach is promising to treat single inoperable tumors in known, near-skin surface 
locations, it does not solve the larger clinical problem of increasing therapeutic levels in 
widespread metastatic disease, including lesions that are not near the skin surface. For 
nano-therapy, this is especially problematic since nanocarriers will diffuse substantially 
less effectively than small drug molecules. Simulations of the effect magnetic gradients 
have upon nanoparticle movement in tissue revealed it is possible to use DMS to 
transport nanoparticles from vessel reservoirs in normal tissue to avascular tumor areas. 
Both single and two directional dynamic shift were able to better distribute nanoparticles 
over the tissue space, with the bi-directional approach achieving a more even 
concentration throughout the tumor, showing the promise of using magnetic actuation for 
reaching into regions of the body inaccessible to pure diffusive movement of 
nanocarriers. Of particular note, the DMS method described and simulated here can be 
applied simultaneously to all metastatic foci in a given anatomical region of the body, as 
the magnets used would create sufficient gradients and forces on nanoparticles across all 
target locations, without the use of radiological imaging to identify lesions. This is 
important in breast cancer and other common epithelial tumors where many hundreds of 
metastatic sites typically exist in patients with advanced disease, ranging in size from 
grossly visible tumors to small, micro-metastatic foci (as an example in liver, see Figure 
25). A one-by-one approach to visualize each tumor by radiological imaging and then 
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using magnetic control to target them individually would be impractical; however, DMS 
does not require such imaging and can be applied simultaneously to all lesions within a 
defined anatomical zone. 
 
While there are other organs that will contain metastatic sites, we began with the 
treatment of the liver. Liver was a good candidate for DMS since it has large vessel gaps, 
is relatively homogenous in nature, and is the body’s natural filtration system. DMS was 
capable of improving the nanoparticle concentration in the furthest cells by a factor of 5. 
This could further be improved if the micro-tumor is larger or denser and particles are 
unable to reach the isolated cells by natural diffusion.  
 
DMS appears to be a promising solution to the problem of low blood supply in tumors. 
However, there are specific caveats that must be considered regarding this approach and 
the results described above. First, we used vascular density as a surrogate marker of 
perfusion and this assumption may not be accurate – in other words, the decrease in 
vessel number in metastatic lesions and the focal sub-regions with few or no vessels are 
consistent with decreased perfusion, but it is also possible that the unique nature of the 
tumor microenvironment, or other factors we have not yet considered, can compensate 
for the disordered vasculature and so perhaps therapeutic levels of drugs or nanoparticles 
may reach most or all tumor cells by diffusion alone. Ultimately, measurement of actual 
drug levels in clinical cancer samples will be necessary to gauge the effect of the 
abnormal tumor vasculature on drug concentration close to and distant from vessels and 




The second caveat is that the liver tissue utilized as a ‘normal control’ in our study may 
not be an appropriate metric for evaluating tumor vessels. Liver is richly vascularized 
with vessels and sinusoids in order to support the extensive metabolic functions of 
hepatocytes and has a high degree of vascular input and output. The fact that metastases 
have fewer vessels than adjacent liver tissue does not necessarily indicate the tumor 
vasculature is incapable of providing therapeutic nanoparticle levels to cancer cells.   
 
The third caveat is that applying a magnetic force and moving the particles through the 
tissue space might cause damage to the tissue itself as the particles force their way 
through the extracellular space. This damage might be detrimental if it affects healthy 
tissue causing inflammation and loss of proper tissue function. On the other hand, this 
effect might be beneficial if it affects tumorous tissue as it could damage the tumor 
extracellular spaces, widening the gaps between densely populated cells, allowing more 
drug to perfuse through the micro-tumors. 
 
Finally, the use of external magnets as a nanoparticle delivery system requires particles of 
large enough size to generate sufficient force to displace them in tissue – the larger the 
particle, the larger the force. However, as the size of the particle increases, the 
diffusability (  in the differential equation described in the Results section above) will 
decrease due to mechanical constraints in the microenvironment. These constraints 
include: physical barriers of cell-to-cell adhesion; the composition and density of stromal 
constituents; and, the nature of the tumor cell-stromal interactions. Overall, the balance of 
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magnetic force vs. tissue resistance favors medium sized particles (  nm, but 
 nm). Magnetic forces increase with particle volume (radius cubed) while the tissue 
resistance initially increases slowly with particle size, until the particle size nears a 
defining characteristic of the tissue (i.e. pore radius for the Renkin Pore model) making 
the resistance grow exponentially thereafter [37], [38]. In normal, highly organized and 
tightly compartmentalized tissues, the characteristics that define a tissue will favor 
smaller particles (i.e. small pore radii ~ 10 nm). But within the disorganized and 
haphazard structure of the tumor microenvironment, the tissues can be described to have 
much larger pore sizes that allow relatively unimpeded movement of even large sized 
nanoparticles (~ 200 nm) through substantial areas of tumor space.  
 
Clearly though, all of these critical aspects of magnetic drug delivery will need to be 
carefully evaluated both in future simulations and in model systems designed to test and 
optimize the method in the laboratory. The goal of this chapter was to present the 
motivation and initial proof-of-concept for DMS based on autopsy studies of vasculature 
in human metastases and using mathematical modeling that has been validated against 
both in-vitro and in vivo experiments in prior studies. 
 
3.10 Conclusion 
In summary, DMS simulations based on quantitative analysis of the tumor vasculature in 
women who died of metastatic breast cancer indicate that improved nanoparticle 
concentrations can be achieved using magnetic gradients generated by one or two 
externally held strong magnets. Depending on the desired therapy, slow or fast acting, we 
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showed a DMS strategy for improving the nanoparticle normalization throughout the 
entire tumor space within the treated anatomical region. The next steps of this effort are 
to optimize DMS for future patients within unknown microtumor architecture. 
 
Contribution to the Field and Clinical Applications 
Metastasis is often a terminal diagnosis for cancer patients and current chemotherapy or 
radiotherapies have a limited beneficial impact on the patients' quality of life. Due to the 
physiological differences between primary tumors and metastatic sites, chemotherapy, 
which works well for primary tumors, often fails to effectively treat metastases due to the 
physical differences and cellular resistance of chemotherapeutics. To improve upon small 
drug molecules, researchers have developed various nanotherapeutics designed to target 
cancer cells more specifically and improve cellular uptake of these compounds. However, 
these nanotherapeutics often have a decreased and limited mobility in tissues due to their 
larger size created by the addition of targeting moieties or engineered coatings. Most 
targeted nanotherapeutics designed for metastatic cancers have a very promising outlook, 
but have in a clinical setting failed to live up to expectations. The discrepancy between 
expected therapeutic benefit and actual clinical results is an open question but a 
suggested factor includes limited drug perfusion into metastatic sites either from 
increased affinity of nanotherapeutics to peripheral metastatic cells or the decreased 
diffusional mobility of these large nanotherapeutics. We aimed to address this limited 
mobility by examining the physiology of the tissue microenvironment and then 
overcoming the limit of diffusional movement by pulling the ferrofluid using external 




Previous modeling has been conducted for non-magnetic particles diffusing into tumor 
spheroids or into various tissues cavities. However, there has been a lack of modeling for 
magnetic nanoparticles under an applied magnetic field in different tissues using 
anatomical data (i.e. actual blood vessel distributions). Our collaborators at the National 
Cancer Institute gathered images of unique liver histological sections obtained from NIH 
patients who died from metastatic breast cancer. We analyzed the vessel distribution in 
normal and metastatic cancer tissue. We presented a relationship between the blood 
vessel distribution and the tissue type (normal versus cancerous). We used these blood 
vessel distributions, available analytical particle diffusion models within tissues, and 
simulations of magnetic forces to determine in which tissues and particle sizes the use of 
magnetic forces could provide a clinical benefit. We developed an FEM model that 
incorporates the particle diffusion, magnetic forces, and particle half-life in the 
circulatory system, and is uniquely initialized with blood vessel distribution data of 
isolated breast cancer liver metastases in surrounding tissue (the exact situation in which 
we are trying to improve treatment). We created an open-loop control treatment scheme, 
which is designed to increase particle concentration at the metastatic sites that 





Chapter 4: Optimizing Dynamic Magnetic Shift for Future Patients 
Portions of this work originally appeared in [240]. 
This work utilized the same database of samples originally gathered by our collaborators 
at the National Cancer Institute (Skye Kim, Michael Tangrea, Mike Emmert-Buck, and 
Jaime Rodriguez-Canales). A finite element solver was developed by our collaborators at 
the California Institute of Technology (Aditya Viswanathan and Oscar Bruno). I 
developed the optimization scheme and performed the optimization upon the samples. 
 
4.1 Introduction 
Chapter 3 developed a novel model of the transport of ferrofluid within a tissue 
architecture. The model began from physical first principles of nanoparticle diffusion and 
magnetically induced velocities (equations (52) and (53)). Particle parameters were 
estimated from available theoretical models that predict the diffusive and mobility 
parameters within various tissues (see section 1.3.1). Then histological samples of breast 
cancer liver metastases were cultivated from a NIH autopsy database. These images 
became the basis for the tissue architectures used within the transport model. These 
histologically derived images provided a physiological relevance of the desired disease 
target, metastatic breast cancer. 
 
Using the developed model, blood vessel distribution statistics were calculated and 
simple diffusion simulations conducted (column (a) of Figure 31 and Figure 32). 
Supporting previously observed results [211], [279], the regions where particles were 
unable to effectively reach by diffusion were small microtumors. As has been suggested 
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[211], [279], the adequate treatment of these microtumors is difficult and inadequate 
treatment leads to cancer reoccurrence. 
 
To treat these small microtumors, the novel treatment scheme of DMS was introduced to 
assist diffusive transport by pulling magnetic nanoparticles through these avascular 
microtumors. The developed model was then used to investigate the potential impact 
DMS would have in treating these avascular microtumors. Using two treatment schemes, 
the benefit on the micro-environment of metastatic breast cancer within the liver by using 
DMS was quantified (see Table 4). However, while the benefit was significant in 
Chapter 3 (  improvement over diffusion), the question remained if the proposed 
treatment strategies used were the best strategies available. In addition, if there are many 
variations of microtumors throughout the entire liver, what treatment strategy would 
provide the best results for the whole liver? What combination of magnetic fields 
overtime would be the best to pull the ferrofluid throughout the liver to achieve 
therapeutic treatment goals for any given patient with any given microtumor distribution? 
 
Chapter 4 takes the next logical step and examines the optimal parameters necessary to 
deliver the ferrofluid throughout the liver architecture by applying a magnetic force to the 
nanoparticles. As with most optimization problems, the most challenging aspect to 
determining the optimal results is properly formulating the optimization problem [306]. 
For optimizing DMS, choices have to be made about which magnetic fields and in which 
directions these fields should be applied. In addition, what is the proper metric to measure 




From our initial simulations in Chapter 3, DMS saw substantial improvement by applying 
the magnetic field in two directions versus a single direction, but not for three directions 
over two. This allowed us to focus the optimization problem on pulling the magnetic 
nanoparticles only in two opposite directions (left and right). Combined with a fixed total 
treatment time (1.5 hours, as determined by the nanoparticle circulation half-life of 45 
minutes), the only choice needed to be optimized is the amount of time the particles are 
pulled in any given direction (as a function of the total treatment time). 
 
Considering the wide range of metrics available (a sample of which are shown in Table 
4), it was necessary to develop robust metrics that capture the treatment potential of a 
given scheme. In addition, it is impractical that a clinician would know the precise 
location of all microtumors within a patient’s liver and even if these positions were 
known, it would be impractical for a clinician to spot treat each site. Therefore, the 
metrics used to find the optimal treatment could not rely upon knowledge of the exact 
microtumor locations. Lastly, the therapeutic treatment goals were defined for two 
classes of chemotherapeutic agents: 1) those drugs that only act during a specific phase of 
the cell cycle and must therefore be available to the cells for as long as possible [4], [5], 
[305]; and 2) those drugs that are insensitive to the current phase of the cell cycle [4], [6], 
[8]. All of these requirements led to the development of two distinct metrics to quantify 
the benefit a specific treatment scheme has upon the tissue architecture. These metrics are 





To determine the optimal treatment scheme, four requirements are needed: a tissue 
transport model; a defined optimization space; a chosen set of metrics; and an 
optimization technique. Each of these elements will be discussed in the following section. 
Sacrificing time, physical storage space, and computer memory for simplicity allowed a 
simple exhaustive search technique to be used to find the optimal treatment parameters, 
simplifying the fourth requirement.  
 
4.2.1 Tissue Transport Model 
The tissue transport model of the ferrofluid is almost identical to the one developed in 
Chapter 3, section 3.7.2. Equations (52) and (53) were used to describe the time 
dependent transport behavior through a prescribed tissue space. The diffusive and 
magnetic velocity parameters used in Chapter 3 were again used for determining the 
optimal treatment scheme. Repeated again for clarity, these are a particle size of   
nm, a diffusion coefficient of  m
2
/s, and a magnetic drift velocity of 
µm/s. The same half-life of 45 min was used but the treatment time was 
reduced to 1.5 hours. This treatment time was reduced for two reasons: 1) after a time 
period of twice the half-life has passed, the majority of available nanoparticles have 
extravasated out of the blood vessels and into the tissue; 2) patients are unwilling to 
submit to treatment for a prolonged period of time and even a treatment period of an hour 




Lastly, the most important aspect of the tissue transport model comes from the 
physiologically relevant tissue architectures used to initialize the model. For examining 
an optimal treatment scheme, it is important to utilize a variety of similar microtumors 
from various patients. To this end, 142 samples from 16 patients were extracted from the 
library of whole organ histological slices. These samples had small microtumors centered 
within larger liver sections. A representative section is shown in Figure 34. 
 
 
Figure 34: Representative section collected for the sample set used to find the optimal treatment 
scheme. Here there is a microtumor located at the center of the section denoted by the yellow 
circle. The un-shaded middle section is the region of interest and the metrics are calculated only 
over that specified un-shaded region. The lightly shaded buffer regions on all borders are 
necessary to properly account for nanoparticle movement into and out of the region of interest 
(see section 3.5). 
 
To ensure that the physiological characteristics of these microtumors were similar, 
statistics of the blood vessel distribution were examined. Only two samples from the 
larger group were rejected because they contained very high concentrations of blood 
vessels within the treatment region (microtumor). This is exactly not the desired 
treatment case because these samples would receive high concentrations of nanoparticles 
regardless if a magnetic field was applied. The remaining samples comprised the sample 
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set of cases. This sample set was then used as the basis for determining the optimal 
treatment scheme. 
 
4.2.2 Treatment Vectors 
As discussed in section 4.1, only two magnetic field directions were examined. For 
further simplification, only two treatment vectors were considered. These are as follows: 
(54) 
1)  iffusion
2) Pull to the left




2) Pull to the right
3) Pull to the left
 . 
There are many other combinations of treatment vectors possible with the constraint of 
only pulling in two directions, however, to maintain simplicity to decrease simulation 
time and physical storage, these two vectors were chosen. Treatment vector  begins by 
allowing the particles to diffuse a certain amount of time, followed by pulling the 
particles to the left for a period, and then the remaining portion to pull to the right. 
Treatment vector  allows the particles to diffuse, and then pulls to the right, followed 
by a pull to the left. Since the total time amount of time spent in each stage (diffusion, left 
or right pulling) must be equal to the total treatment time of 1.5 hours, it is sufficient to 
express the treatment scheme as a function of only two time periods. The two ‘active’ 
stages where magnetic forces are applied were chosen to describe a treatment scheme. 
Therefore, it is possible to plot any given metric within the following shape, shown in 





Figure 35: Optimization space as a function of the two defining time periods. The -axis defines 
both the initial pull direction and the duration of the first active period. A negative -value would 
correspond to a  treatment scheme, while a positive -value would correspond to a  
treatment scheme. The -axis corresponds to the second active period’s duration. If in the second 
quadrant, the second active direction would be to the right. If in the first quadrant, the second 
active direction would be to the left. All values have been given as a fraction of the total 
treatment window. Regions near the origin consist mainly of treatment schemes that primarily 
allow the particles to diffuse for the majority of the treatment window. Regions near the 
extremities of the triangle rely on constant manipulation of the particles by applied magnetic 
fields. 
 
By plotting the metrics from the various treatment schemes onto Figure 35, the optimal 
scheme can be determined. In addition, these types of plots will easily allow 
identification of any symmetry between the two treatment vectors. Ideally if the sample 
set has sufficient randomness, the plot should exhibit symmetry across the -axis. This 
can easily explained because the samples do not have a biologically predetermined 
coordinate system. Moving the particles left through a sample is equivalent to moving the 
particles right through a sample if a patient is reversed within the machine. Therefore, 




4.2.3 Metric Calculations 
Beyond considering a single sample tumor, magnetic sweep sequences were optimized 
based on autopsy data across multiple tumors and patients. During sweep, there is a 
fundamental tradeoff; since the nanoparticles have a finite circulation time in vivo, there 
is a balance between magnetically pulling in one direction for as long as possible to 
sweep therapy as far as possible versus applying magnetic pulls in multiple different 
directions to bring drugs into poorly vascularized tumors from a variety of adjacent 
locations. A third pull direction did not add much value, so the timing of sweep was 
optimized only in two opposite directions. Vessel distribution autopsy data is only 
available for deceased patients, so there is a need to choose treatment for future patients 
based on autopsies of similar past patients. Hence, bidirectional sweep is optimized based 
on one set of samples (group A) and then tested on a second set of samples (group B). 
 
The optimization metric has to be chosen with care. The goal of sweep is to normalize the 
distribution of therapy, to avoid therapy cold spots at thousands of metastatic tumors. 
Moreover, for a single small tissue area (for example, the 1.5 mm wide sample shown in 
Figure 34), a trained pathologist can identify the micro-tumor location and its extent (the 
yellow circle). However, it is not feasible for a pathologist to visually identify thousands 
of tumors per liver autopsy, and to do so over many patients. There is also a need to 
continue to consider both slow-acting and fast-acting therapies, for which, respectively, 
time-averaged and time-maximum particle concentrations are more appropriate. Thus, 




Spatial average of the time averaged concentration
Spatial variance of the time averaged concentration
 
(57) 
Spatial average of the time maximum concentration
Spatial variance of the time maximum concentration
 
 where the numerator is the spatial average of the nanoparticle concentration across the 
entire tissue slice, for either the time average or the time maximum. The denominator of 
the metrics penalizes high spatial variance across tissue; if the spatial standard deviation 
is high (if the tissue has regions of both high and low particle concentration, an undesired 
situation since now some tumor regions remain untreated), then the denominator is high 
and the metric is low. Together, the numerator and denominator try to ensure a nonzero 
and uniform concentration of therapy across the entire tissue. In particular, if sweep-
timing parameters can be chosen to create a uniform high nanoparticle concentration, 
then this metric will tend to infinity and sweep will have completely eliminated the 
problem that poorly vascularized tumors lack therapy. 
 
4.3 Results 
4.3.1 Exhaustive Search 
The bidirectional sweep optimization considered 70 tissue samples in group A and 
another 70 for group B. Two parameters were optimized across group A: the duration of 
the first pull and the duration of the second pull. Since the treatment time was kept 
constant at 1.5 hours, this also defined the waiting period at the start by  hrs
. Each of the two pull durations was varied across 25 values yielding 
625 simulations per tissue slice, and thus a total of 87,500 simulations. It took 7 days to 
complete the simulations on a Core i7 2.6 GHz computer running Windows 7 with 32 GB 
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of RAM. Figure 36 shows the fold increases in the two metrics  and  
versus the diffusion-only case for group A. 
 
In the top panels of Figure 36, the optimal strategies for slow- and fast-acting drugs are 
marked by the blue stars. To increase the degree of normalization for slow-acting 
therapies ( ), it was best to shift in one direction for ~ 45% of the time, and then 
shift in the opposite direction for the remaining ~ 55% of the time. This procedure 
corresponded to shifting in one direction until just before the half-life of the nanoparticles 
was reached, and it made no difference if the shift was to the right or left first. By 
comparison, in order to increase the degree of normalization for fast-acting therapies 
( ), it was best to shift the nanoparticles in only one direction (either only left or 
only right) for the entire duration of the 1.5 hour treatment. This procedure ensured that 
every region of tissue saw as many new nanoparticles as possible. Bringing the particles 
back in the opposite direction did not improve the maximum over time. Thus, depending 
on whether a fast- or slow-acting therapy was considered, a different sweep strategy was 
optimal. 
 
The optimums of Figure 36ab were then tested on group B. Panels Figure 36cd show the 
histograms of  and  for diffusion alone versus optimal bidirectional 
sweep. As can be seen, the group A sweep optima effectively shift the mean of the 





Figure 36: Sweep optimized over group A (first row) was then applied to group B (second row). 
a,b) Degree of nanoparticle normalization (  (56) and  (57)) averaged over 
group A, as a function of pull left and right durations. Dark colors corresponded to high average 
concentrations and low spatial variances across group A tissue samples. Low values correspond 
to low concentrations or therapy hot and cold spots. In the triangles, the first pull duration is 
varied along the horizontal axis, the second along the vertical axis, with any remaining time spent 
waiting at the start of the treatment. For example, the location (+ 0.50, - 0.20) represents a  
(27 minute) waiting time, followed by a  (45 min) pull to the right, then a final  (18 min) 
pull left. Pure diffusion (no pulling) corresponds to the center white vertical axes above D. 
Optimal strategies are marked by the blue stars. c,d) Dotted black lines shows the histogram of 
metrics  and  across group B samples for diffusion only. When the optimal 
sweep sequences of group A are applied to group B samples, these metrics shift to higher values 
as shown by the solid blue histograms in panels c and d. The optimal sweep sequences are 
summarized within the red box at the top right of each panel: in both cases it is optimal to begin 
pulling immediately (“no wait”) and the pull directions and optimal durations are shown by the 
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green arrows and text. In group c) the suboptimal and optimal means are 5.1 and 7.1 with a 
 (ANOVA). In group d) the suboptimal and optimal means are 6.3 and 8.7 with a 
 (ANOVA). 
 
The following Figure 37 shows the optimal results for all 140 cases. In addition, since the 
improvement over passive diffusion is the standard, the fold increase over diffusion is 
shown. As is evident by the minimal differences between Figure 36 and Figure 37, the 
optimal solution has not changed with the addition of twice the number of samples. They 
are again represented as blue stars and correspond to 
 for  and  for . 
 
 
Figure 37: Treatment metrics for 140 cases for  mm2/s, and  m/s. 
Here the treatment metrics are shown as a fold increase over the diffusion only case. Therefore, 
larger values correspond to regions where DMS improves the drug concentrations within the 
micro-tumors. The optimal treatment schemes are shown as blue stars. They represent 




4.3.2 k-Fold Cross Validation 
The separation of the samples into two groups, the treatment group and the training 
group, can be extended to better predict the treatment potential of future patients. This 
process termed k-fold cross validation is a well-defined statistical technique to determine 
the applicability a sample set has to future sets [307]. Similar to Figure 36, k-fold cross 
validation begins by randomly separating the samples into  groups of roughly equal size, 
usually  is small and around 10. One of these  groups is then used as the treatment set 
while the rest are used together as the training set. The optimal treatment strategy is 
determined from the training set and then applied to the treatment set. In this way, the 
bias of knowing the details of the treatment sets is removed from determining the optimal 
treatment strategy.  
 
 
Figure 38: Treatment metrics of -fold cross validation for 10 groups. The blue circles dictate the 
average treatment metric for the th group. The standard deviation is illustrated by the associated 
error bars. The red line is the metric value associated with diffusion only movement. The average 





This process is then repeated for each  group. The metrics achieved from the treatment 
sets are then averaged and are a reasonable approximation of the potential treatment gain 
for future samples. Figure 38 shows the results of a  cross validation. The average 
treatment metric for each  group are shown in blue with associated standard deviations. 
The red line denotes the diffusion only case. For each  group, the treatment strategy as 
determined by the training set produced on average better than diffusion treatment for the 
treatment groups. The average improvement to diffusion by using an optimized DMS 




Figure 36 shows the optimum of the two treatment vectors,  and , for a given set of 
physical parameters as described in section 4.2.1. The next logical step is to examine the 
robustness of these optimums as the physical parameters relax. How do the optimums 
change if the nanoparticle diffusivity and mobility are an order of magnitude less? This 
could occur if the tissue architecture resists particle motion more than the models 
(sections 1.3.1 and 3.7.2) predict. 
 
This complication was investigated by performing the same optimization procedure upon 
the sample set for varying Renkin reduced diffusion coefficients. As in equation (26), the 
Renkin reduced diffusion coefficient will change both the diffusion coefficient and 




(58)        
 iffusion
 rift  elocity
 
 
where the new addition is the coefficient         describing the unknown resistive tissue 
effects. This coefficient was varied over two orders of magnitude:         to . 
In addition, the coefficient was adjusted to emulate the case where the particles are in 
blood, i.e. the tissue has no resistance to particle motion        . The results are 
shown in Figure 39. These consist of three additional cases investigated and each pair of 
triangular plots below represents 625 simulations. These simulations quadrupled the 
required amount of physical storage space and simulation time compared to those 
investigated in Section 4.3.1. An exhaustive search of all possible         would be 





Figure 39: Robustness of optimization for various Renkin reduced diffusion coefficients. The 
optimal results are shown for various Reduced Renkin coefficients          and for the ratios of  
 and  to diffusion. The second column represents the results as seen previously 
Figure 36. The first column represents the particles when they are within blood and not hindered 
by tissue. The third and fourth columns are with an increased tissue resistance increasing by an 
order of magnitude each time. Each triangle is shown on their own color scale as denoted beneath 
it where red is high and white is low values. In the gray panels beneath the triangular images, the 
metrics from each case taken at the previous optimum,  and 
, are shown. This allows one to compare the optimums for every case to the previously 
obtained optimum. 
 
The first row in Figure 39 shows the ratios to diffusion of the time-averaged metric, 
, for varying          coefficients, while the second row shows the time-
maximum metrics, . As          decreases, the optimal movement becomes 
biased to pulling the magnetic field in only one direction. At        , the optimal 
choice is similar to that for        , which is pulling in both directions for roughly 
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equal amounts of time. At         the optimal choice is close to pulling in only one 
direction while at        , the optimal choice is to move the particles to the left the 
entire time. This transition to a single pull describes a bias that few samples have upon 
the optimal solutions.  
 
Going further, it is possible to compare the magnitude of the metrics at the local and 
previous optimum locations. This is accomplished by examining the maximum value 
seen on the color scale (corresponding to the current optimum) compared to the value 
shown in the gray bar (compared to the prior cases’ optimum). As          decreases the 
difference between these two values widens suggesting that the prior optimum scheme is 
not as effective. Lastly, it is important to note that the benefit achieved from DMS 
decreases dramatically as the particles are unable to move. This makes intuitive sense 
because as the particles are unable to move due to an applied field, they behave more like 
they would under diffusion only conditions. Table 5 shows the -fold cross validation 
results for the cases in Figure 37 at their local optimums. 
 
While Figure 39 describes the optimal behavior as tissue resistance is changed, it does 
not detail what would happen if the particles could be moved within a tissue. Even if the 
tissue resistance forces increase by orders of magnitude, it might be feasible for certain 
circumstances to apply significantly more magnetic force to counteract this increase in 




The following Figure 40 details the optimal results of DMS for decreasing diffusion 
coefficients while keeping the magnetic velocity constant. This corresponds to a case 
where the particles have a lower than expected diffusional movement but maintain their 
magnetic velocities. Again, these are an additional three cases and each pair of triangular 




Figure 40: Optimal DMS treatment schemes as the diffusion coefficient decreases and the 
magnetic velocity remains constant for two treatment metrics. The second column represents the 
results as seen previously Figure 36. The first column represents the particles when they are 
within blood and not hindered by tissue. The third and fourth columns are with an increased 
tissue resistance increasing by an order of magnitude each time. Each triangle is shown on their 
own color scale as denoted beneath it where red is high and white is low values. In the gray 
panels beneath the triangular images, the metrics from each case taken at the previous optimum, 
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 and , are shown. This allows one to compare the 
optimums for every case to the previously obtained optimum. 
 
For both the  and  metric ratios, Figure 40 shows that the optimal 
treatment scheme barely changes. This is evident by the difference seen in the maximum 
value of the color scale (corresponding to the current optimum) compared to the value 
shown in the gray bar (compared to the prior cases’ optimum). This suggests that the 
optimal treatment schemes are robust when the magnetic velocities remain constant even 
when the diffusion coefficient decreases. As the diffusion coefficient decreased, the 
optimum scheme did spread to include more possibilities of magnetic movement as 
shown by a less confining region of high metric values along the exteriors of the 
triangular plots. This suggests that while there are defined optimums, constantly moving 
the particles by magnetic fields produces a near optimum solution. 
 
In addition, as the diffusion coefficient decreases, the benefit achieved from DMS 
increases dramatically. When the diffusion coefficient is 100 times smaller than expected, 
the benefit from DMS is double that of diffusion only. This increase in DMS benefit as 
the diffusion coefficient decreases and the magnetic velocity remains constant shows that 
the DMS strategy can provide real benefit to those regions where magnetic forces have a 
significant impact on particle movement. 
 
The results from -fold cross validation for the robust investigation cases are shown in 
Table 5 below. This -fold cross validation was performed using the local optimums for 
each case. As mentioned previously in Section 4.3.2, -fold cross validation provides an 
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appropriate measure of the ability of a given optimal treatment scheme to treat future 
patients. 








Fold Increase over 
Diffusion 
           [mm
2/s]   
6.6 1.59 1.54  1.094 1.078 
1 1.34 1.30  1.34 1.30 
0.1 1.028 1.033  1.79 1.92 
0.01 1.0006 1.0007  1.94 2.13 
 
4.4 Conclusion 
Chapter 3 introduced a novel model of ferrofluid transport within tissue architectures. 
The model began from physical first principles of nanoparticle diffusion and 
magnetically induced velocities. Well-developed theoretical models were used to predict 
the particle mobility parameters within a tissue. To obtain accurate and anatomically 
relevant tissue geometries, histological samples of breast cancer liver metastases were 
cultivated from a NIH autopsy database. These images became the basis for the tissue 
architectures used within the transport model. Using this image database, the chosen 
disease target of hepatic metastatic breast cancer was accurately modeled. 
 
The ferrofluid mobility model through hepatic metastatic breast cancer identified the 
crucial lack of perfusion through microtumors. A proposed treatment strategy of dynamic 
 162 
 
magnetic shift was introduced to simultaneously improve the perfusion of ferrofluid 
throughout the multitude of microtumors. Even with a naïve DMS treatment strategy, 
ferrofluid concentrations within microtumors were significantly increased versus passive 
diffusion. The next step was to determine the optimal treatment strategy for a multitude 
of microtumor samples in order to treat future patients within unknown microtumor 
architectures. 
 
In order to determine the optimal treatment strategy for future patients with unknown 
microtumors, a dataset of available microtumor architectures was culled from the image 
dataset previously obtained. In addition, two metrics to quantify the benefit DMS 
provides to the treatment of the microtumors. These metrics describe the benefit of two 
classes of therapies: 1) cell-cycle sensitive therapies ( ); or 2) cell-cycle non-
sensitive therapies ( ). Then with the micotumor sample dataset, two DMS 
schemes (1: diffusion, left, and then right movement, or 2: diffusion, right and then left 
movement) were exhaustively searched to determine the optimum treatment.  
 
Using the exhaustive search method with appropriate ferrofluid mobility parameters 
(  mm
2
/s,  m/s), the optimal treatment strategy to treat the 
microtumor data set was determined for two treatment metrics. Two treatment vectors 
were investigated over the prescribed treatment window of an hour and a half. In total for 
the typical nanoparticle parameters associated with 60 nm particles, 87,500 simulations 
were conducted using the tissue mobility models. These simulations identified the 
optimal treatment scheme to maximize the two treatment metrics. These are shown in 
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Figure 36 and Figure 37. To extend this DMS scheme to future patients where the 
microtumor architecture may not be known, a -fold cross validation was performed on 
the data set. The results from this cross-validation are shown in Figure 38. The potential 
benefit of DMS to future patients would be an improvement of 34% and 30% for 
 and  therapies respectively. 
 
Then extending upon this optimization technique, the particle parameters were relaxed. 
As the exact mobility parameters of the ferrofluid are difficult to determine for a given 
tissue, it was important to investigate the dependence of the optimum as the mobility is 
changed. An appropriate Renkin reduced diffusion coefficient,        , was used to adjust 
the particle parameters within a range of the upper limit (mobility within blood) to a 
reduction by two orders of magnitude. With small decreases in the particle mobility, the 
optimum solutions remain in a similar region, see Figure 39. However, as the particle 
mobility decreases to two orders of magnitude, the optimum solutions start to favor a 
single direction of magnetic shift suggesting that individual samples bias the DMS 
treatment. In addition, as both the particle diffusive and magnetic mobility decrease so 
does the treatment potential of DMS. 
 
Lastly, the DMS treatment optimum for cases where the magnetic velocity remains 
constant as the diffusion decreases was examined. All of these additional investigations 
increased the total simulation count to 612,500 simulations. The treatment schemes 
associated with the optimums, as the diffusion coefficient was reduced, were retained 
(see Figure 40). As the diffusion coefficient decreased, the optimum scheme did spread to 
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include more possibilities of magnetic movement as shown by a less confining region of 
high metric values. This suggests that near optimum results can be obtained by constantly 
moving the magnetic nanoparticles. In addition, as the diffusion decreased, DMS 
provided an increasing improvement over the diffusion only scenarios. 
 
Contribution to the Field and Clinical Applications 
Prior techniques to deliver therapeutics to metastatic and primary tumors rely upon active 
affinity moieties such as Herceptin [45], [47], [276]. However, these methods have 
significantly decreased perfusion rates when they encounter solid tumors. The reduction 
in perfusion into small metastatic micro-tumors leads to cancer reoccurrence. To 
potentially improve the treatment of these micro-tumors, a treatment strategy utilizing 
magnetic materials and external magnetic fields to improve perfusion was developed. 
DMS is a novel technique and could potentially improve treatment of these metastatic 
sites over normal diffusive behavior. This Chapter went further and investigated the 
optimal strategies needed to use DMS within a clinical setting. As DMS itself is novel, 
the optimal DMS treatment strategy has never before been investigated. 
 
The optimal treatment schemes determined from this Chapter have been investigated for 
their potential future treatment of patient microtumors. The optimal behaviors suggest 
that there are cases when DMS is not clinically relevant or appropriate due to the low 
achievable benefit. This low benefit occurs when magnetic forces are unable to move 
nanoparticles sufficiently. However, there are also many circumstances were DMS would 




To appropriately use these optimized treatment schemes in the clinic, experiments in 
excised animal tissue sections (currently under way) and in live animals (planned) must 
be accomplished. Although it was consistently found, across more than a hundred micro-
tumors, that liver metastases are poorly vascularized compared to normal tissue, the 
autopsy and simulation studies were carried out on a relatively small cohort (16 breast 
cancer patients). More data is needed to determine effective control strategies for 
different scenarios so that the optimal method can be chosen according to patient profiles 




Chapter 5: Conclusions 
5.1 Looking Back 
This thesis was aimed at understanding the magnetic nanoparticle behavior within blood 
vessels and tissues so that we could intelligently design the magnetic fields to place the 
nanoparticles where we want them. We developed a method to design appropriate 
magnetic fields to illicit nanoparticle boundary layer formation behavior within blood 
vessels and surrounding tissue. Using these concentrated nanoparticles at blood vessels as 
a reservoir, we showed how nanoparticles could be moved through bulk tissue. Finally, 
we explored the idea of utilizing this nanoparticle tissue transport to treat metastatic 
breast cancer liver metastases. 
 
While magnetic drug targeting is not unique, the field had only a cursory understanding 
of the interaction between magnetic fields and the particles within biological structures. 
This thesis added the first in-depth analysis of how magnetic nanoparticles are 
transported within a biological environment. This transport is complex, and as noted 
earlier in sections 2.1 and 2.13.4, a simple analysis is not sufficient to predict how the 
nanoparticles will behave. This thesis showed that examining only the magnetic forces 
versus blood flow velocities led to an incorrect assessment of nanoparticle targeting 
ability. It is therefore necessary to include diffusion and profiles of the blood flow. 
 
With these additions, the model correctly predicted experimental behavior. It offers a 
framework to begin to understand nanoparticle transport in a generic biological system. 
In practice when examining a specific treatment case, all of the biological factors unique 
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to the treatment scenario should be included within the analysis. Failure to include these 
factors might lead to a misunderstanding of the ability to magnetically target drugs. Many 
potential factors could be included, but the specific treatment case will dictate those that 
are important.  
 
Generally, the two most important considerations are the extravasation ability of the 
nanoparticles and the diffusion coefficients of the tissue. How and by what method the 
nanoparticles extravasate from the target vessels needs to be understood so that it can be 
incorporated within the model. For example, if the particles are being targeted within 
large healthy intact vessels (e.g. aorta), extravasation will not occur. This may or may not 
matter for the specific treatment scenario. Similarly, the diffusivity and mobility through 
a specific tissue should be folded into the model. Nanoparticle mobility determines not 
only the particle behavior but also the treatment potential. Unfortunately, most of the 
mobility information of nanoparticles through specific tissues is not known and is quite 
complex. Nanoparticle mobility is dictated by particle size, tissue architecture, 
nanoparticle coating, tissue composition, cellular endocytosis and affinity, and potentially 
magnetic forces. 
 
While other organs will show metastatic sites, we began with the liver as a first step and 
proof of principle. Since we examined the specific treatment case of the liver with breast 
cancer metastases, we were able to address these two main considerations. Extravasation 
within the liver is not an issue because the vasculature within the liver is primarily 
sinusoidal capillaries with larger holes (> 20 micron gaps) capable of allowing the 
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transport of cells [37]. This makes liver a perfect candidate to investigate magnetic drug 
targeting, as there are no limitations to particles leaving the vasculature. In addition, since 
the liver is the body’s filtration system, most substances are transported to this organ 
ma ing the particles’ biodistribution favorable. 
 
The second issue of particle mobility through the liver is more nuanced. Most organs 
have a well-ordered superstructure that lends directionality to the organ. For example, the 
lung is a highly ordered and well-defined structure with tightly controlled vessels for 
transporting oxygen and blood. While the liver has a structure, it is one of the more 
homogeneous organs within the body. This allowed us to approximate nanoparticle 
diffusion as an isotropic diffusion coefficient dependent upon the collagen content (see 
section 1.3.1). 
 
These two factors are an example of how to apply the unique biological characteristics to 
the analysis but they are not the only specifications to consider. Other applicable factors 
include the blood vessel composition (the number and type of layers), and the ways in 
which the nanoparticles interact with the tissue itself. If extravasation does not occur, it 
could be important to understand in which vessel layers the particles accumulate. It is 
conceivable that without extravasation the particles would concentrate within the 
basement membrane of vessels next to the smooth muscle layers of vessels. In addition, 
for a given tissue the particles could potentially be endocytosed and degraded based upon 
the type of particle surface coating. The attached drugs, therefore, may not reach their 
desired target. Therefore, it is important to consider and understand the specific drug 
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type, drug-nanoparticle interaction, and the exact way in which cells within the tissue 
might affect this interaction. 
 
There are a whole host of possible modifications to the generic model we have 
developed. Some of these modifications can be directly implemented, others require 
significant model adjustments, and the rest require an entirely new model. A subset of 
these modifications and possible changes to the model are discussed next. 
 
Particle Coatings 
Nanoparticles are designed with a myriad of coatings for specific purposes [68]–[71], 
[308], [309]. These coatings vary from polyethylene glycol (PEG) significant for its 
nonantigenic properties, dextran for biocompatibility, polyvinyl alcohol for preventing 
agglomeration, to polyacrylic acid for its increase in bioadhesion [309]. These coatings 
have a varied impact on their environment from how they change the nanoparticles’ size 
to how they change the interaction of the nanoparticles with surrounding cells, 
extracellular matrix proteins, and plasma proteins. The change in the particles’ size has 
been considered in section 2.15.8 and can easily be added into the model.  
 
However, the change in particle “adhesive” properties has not been included in the 
model. One such adhesive property is the interaction of the antibody-functionalized 
particles to their associated antigen. Adhesive properties take two forms: 1) adhesiveness 
with the passive extracellular matrix, and 2) adhesiveness with cells due to surface 
protein interactions. The first effect could be accounted for by dramatically decreasing 
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the diffusion coefficient within the tissue. The second effect could be included in a 
simplified manner by adding a reaction term that removes nanoparticles as they come in 
contact with the cells (applicable if the cells endocytosis and degrade the particles). If 
more complexity is needed, then the model should be adjusted to keep track of individual 
cells and the amount of surface receptors on each cell that has interacted with a given 
nanoparticle. 
 
Implanted Magnetic Devices 
Implantable magnetic devices are being investigated for a variety of applications from the 
treatment of cardiovascular disease [97], [310] to ocular regeneration [117], [142]. While 
the principal of implantable magnetic devices is the same as an externally applied 
magnetic field, the local behaviors of the magnetic nanoparticles would change. The 
externally applied magnetic fields always concentrate the particles towards the direction 
of the magnet. However, due to biological barriers (such as the skin), the particles are not 
in direct contact with the magnet. Implantable devices typically have direct contact or 
nearly direct contact (separated by a permeable tissue layer) with the magnetic 
nanoparticles. To incorporate implanted magnetic devices to the model, a non-uniform 
magnetic field would have to be included that attracts magnetic particles to a solid object. 
This is a difficult modification to the model and should be done on a case-by-case basis. 
 
Damage to Vessels and Tissues 
Since magnetic particles are forcibly dragged through tissues and membranes by 
magnetic forces, there is a potential that the particles could cause damage to the 
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biological environment. This damage is a significant effect that is not considered in this 
model due to the lack of knowledge of how variously-sized particles at various forces 
will interact with the tissue environment. It is conceivable that small particles would 
damage their environment less than their larger counterparts because the magnetic forces 
and tissue resistance forces acting upon the larger particles is greater. However, this has 
not been characterized and is not known. There are various possible effects caused by 
damage to the tissue. Damage to membranes or biological barriers would not only allow 
more nanoparticles to traverse across the membrane, but also could potentially allow 
various plasma components to leak across the membrane. This could be potentially 
harmful as there are several plasma components that are purposefully separated from the 
tissue. For example, when blood plasma is exposed to sub-endothelial cells that express 
the blood clotting protein tissue factor, blood coagulation occurs [311]. These effects 
could be significant and should be investigated in future studies. 
 
There are two ways to incorporate tissue damage into the model. A simplified approach 
would consist of introducing a time-dependent diffusion coefficient and mobility term. 
This would approximate the increase in mobility and natural diffusion as holes are 
created over time within membranes or tissues. A more complex scheme would require 
monitoring the specific holes and pathways created by pulling particles through 
biological barriers. Then created holes would have a higher diffusion and mobility 




Concentration of Nanoparticles needed for Therapeutic Levels 
There have only been a few clinical trials involving magnetic drug targeting in animals 
and even fewer in humans. The needed concentrations of magnetic nanoparticles to 
produce therapeutic levels of conjugated drugs are unknown. The drug elution profiles as 
they are released from the nanoparticles have been measured for in vitro conditions but 
have not been investigated in vivo. For example, it is not yet known how the forced 
movement of magnetic particles across a membrane will affect the association of 
conjugated drugs. Therefore, it might be necessary for the concentration of magnetic 
nanoparticles targeted within a tissue to be greater than is estimated from simple bound 
drug amounts.  
 
In addition, endocytosis of the nanoparticles could reduce the available drug bound to the 
nanoparticle. Most drugs are not designed to withstand nor target the lysosomes within a 
cell and therefore would degrade once the particle-drug complexes are engulfed by a cell. 
These modifications to the model can be addressed by measuring and simulating the drug 
concentration as it elutes from the particles, diffuses through the tissue, and metabolized 
by the cells. To incorporate the removal of nanoparticle-drug complexes by the cells, a 
reaction term can be included that will decrease the available nanoparticle concentration 
over time. Both of these modifications are complex, but they are possible within the 




Unique Tissue Architecture Characteristics 
Tissues architectures have various biological components and structures. Even when 
considering normal versus tumor tissue, these structures could have varying diffusion 
coefficients depending on tissue density. These variations between tissue types can be 
included by adding a spatially varying diffusion coefficient. While it is possible to add 
into the model, the diffusion and mobility of particles through the environment is not 
known. These values must be measured from animal experiments. Additionally, 
increased interstitial pressure within the tumor can be incorporated by adding a 
directional velocity to the particles. This velocity term would be centered at the tumor 
site and exert a force outwards from the tumor decreasing further away from the tumor. 
The pressure exerted can be measured and approximate velocities can be calculated from 
[37], [38]. 
 
The tissue mobility model is developed in only two dimensions, but a tissue is a complex 
three-dimensional system. Therefore, by simplifying the model to two dimensions, the 
mobility of the particles is underestimated. To incorporate three dimensions into the 
model would require new tissue architectures measured from the histological samples. 
 
5.2 Future Experiments 
Since validation of the model relied upon prior experimental studies that were good but 
not ideal for validation purposes, it would be beneficial to have an experiment designed 
specifically for this purpose. Two crucial in vivo experiments are needed to validate the 




The first in vivo experiment consists of visualizing and quantifying the nanoparticle 
concentration flowing within a capillary and its surrounding tissue under a measured 
magnetic field. Knowing specifically how the nanoparticles are able to extravasate 
through capillaries and into the surrounding tissue space is crucial to validating the 
vessel-membrane-tissue model. Starting with capillaries simplifies the model by reducing 
the number of membrane components (there are no smooth muscle layers within 
capillaries). The most important measurement is how the particles build up along the 
vessel wall and within the tissue. Possible methods of measuring this concentration are 
with fluorescence, ultrasound, or magnetic particle imaging. The magnetic field strength 
and particle size should be changed to create various boundary layers. The varied 
boundary layers can be compared against the predicted boundary layers allowing for the 
validation of the transition region between velocity dominated and boundary layer 
formation cases. While live tissue is more realistic than ex vivo samples, it is more 
difficult to accurately control the experimental parameters. Therefore, initial 
experimental studies might have to be performed with ex vivo samples. Christoph 
Alexiou is already beginning experiments of this type [312]. 
 
The second recommended in vivo experiment is measuring the ability of magnetic fields 
to shift systemic magnetic nanoparticles millimeter distances through live tissue. This 
would validate the tissue transport model for hepatic metastatic breast cancer. These 
experiments are relatively simple but require significant preparation. Ideally, 
nanoparticles would be injected systemically into both healthy and diseased animals. The 
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particles would circulate through the animal and collect at the liver. A magnet held near 
the liver would be applied to a subset of these animals for a given treatment time. 
Afterwards histological sections of all sets of animals (normal versus diseased, with and 
without magnetic fields), would be taken of the liver. Then by visually inspecting these 
histological samples, the distribution of the magnetic nanoparticles throughout the tissue 
would be known and could be compared against the models for tissue movement. This 
comparison is crucial to knowing if and how the magnetic nanoparticles are able to be 
pulled into the diseased tissue within the liver. These experiments are currently under 
way as a collaboration between the University of Maryland and the National Cancer 
Institute.  
 
Although not crucial, it would be beneficial to the model to be able to measure the natural 
diffusion of nanoparticles and the induced magnetic mobility of nanoparticles within 
various tissues for various particle types. This experiment can be performed using ex vivo 
samples. However, caution should be taken to ensure that the tissue is physiologically 
relevant. Tissues that have been frozen, while easy to procure, contain damaged 
extracellular matrixes due to ice crystal formation. Therefore, only fresh tissue should be 
used, but if they are not recently excised and kept cold before usage, there could be 
significant tissue digestion that occurs due to tissue death. This effort is currently under 
way at the University of Maryland. We are gathering information about the ability of 
nanoparticles to move through bulk tissue while maintaining physiologically relevant 
conditions. These mobility and diffusion parameters can then feed into the model to 
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